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Abbreviations
ALAT alanine aminotransferase
ASAT aspartate aminotransferase
BP blood pressure
BPDS bathophenanthrolinedisulfonic acid
CAD coronary artery disease
CI confidence interval
CDNB 1 -chloro-2,4-dinitrobenzene
CVD cardiovascular disease
CYP cytochrome P450 monooxygenase
CYS cysteine
CysGly cysteinylglycine
DBP diastolic blood pressure
EDTA ethylenediaminetetra-acetic acid
ELISA enzyme linked immunosorbent assay
EPHX epoxide hydrolase
FRAP ferric reducing ability of plasma
fThiol free thiol
GA gestational age
GPX glutathione peroxidase
GSH glutathione
GSSG glutathione disulphide
GST glutathione S-transferase
GSTA glutathione S-transferase Alpha
GSTM glutathione S-transferase Mu
GSTP glutathione S-transferase Pi
GSTT glutathione S-transferase Theta
G6PDH glucose-6-phosphate dehydrogenase
Hcy homocysteine
HELLP haemolysis, elevated liver enzymes and low platelets
Hp haptoglobin
H2O2 hydrogen peroxide
ISSHP international society for the study of hypertension in pregnancy
IU international unit
IVS intervillous space
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kD kiloDalton
LDH lactic dehydrogenase
LDL low density lipoprotein
MDA malondialdehyde
mmHg millimeter mercury (1 mmHg = 133.322 Pa)
n number of subjects / observations
NEM N-ethylmaleimide
NO nitric oxide
OR odds ratio
oThiol oxidised thiol
O2- superoxide radical
PACs polycyclic aromatic hydrocarbons
PBS phosphate buffered saline
PBST phosphate buffered saline supplemented with 0.05% (v/v) Tween20
PCA perchloric acid
PCR polymerase chain reaction
PGH prostaglandin H
PO2 partial oxygen pressure
PGI2 prostacycline
RFLP restriction fragment length polymorphism
ROS reactive oxygen species
rs Spearman's rank correlation coefficient
rThiol free-to-oxidised ratio of thiol
SeGPX selenium dependent glutathione peroxidase
SBDF 7-fluorobenzofurazane-4-sulfonic acid
SOD superoxide dismutase
TBARS thiobarbituric acid reactive substances
TGPX total glutathione peroxidase
TXA2 tromboxane
UGT UDP-glucuronosyltransferase
v/v volume per volume
w/v weigth per volume
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Part I
General Introduction
Chapter 1
Objectives and outline of the thesis.
Chapter 1
Despite many years of intensive research, preeclampsia is still a common complication of 
pregnancy with high maternal as well as foetal morbidity and mortality. The haemolysis, 
elevated liver enzymes and low platelets (HELLP) syndrome often complicates preeclampsia, 
although HELLP may also occur solely. Recently, the hypothesis of maladaptation of 
throphoblast invasion in early pregnancy resulting in poor placental function has been 
postulated as a key factor in the aetiology of preeclampsia. Placental oxidative stress may lead 
to oxidative stress in maternal circulation. Part 1 of this thesis provides a general overview of 
the concept of oxidative stress, biotransformation and the implication of oxidative pressure 
and antioxidant defence in normal pregnancy and preeclampsia.
In the last decade many studies on the pathophysiology of severe preeclampsia and HELLP 
syndrome have been performed in a co-operation between the departments of 
Gastroenterology and Obstetrics & Gynaecology. This has resulted in the insight that 
oxidative stress and its detoxification by glutathione and related enzymes play an important 
role in the pathogenesis of these disorders. In the second part of this thesis the role of these 
enzymes in physiological pregnancy and during embryonic development is described. The 
main objective, however, is to study the specific role of aminothiols in preeclampsia.
Besides their role in protein synthesis, aminothiols such as cysteine, homocysteine and 
glutathione are important elements in the defence against oxidative and chemical stress. When 
oxidative stress occurs, aminothiols are oxidised to scavenge all kinds of free radicals or 
reactive oxygen species in order to maintain the intracellular redox-balance, which is 
important for normal functioning of numerous cellular processes. The third part of this thesis 
describes the role of aminothiols in oxidative stress during preeclampsia.
Maternal oxidative stress is an important feature of preeclampsia. Several proteins are able to 
"capture" molecules that induce oxidative stress or produce reactive oxygen species. 
Therefore, we were also interested in the role of polymorphisms in the genes encoding for 
such proteins as outlined in the fourth part of this thesis.
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Objectives and Outline
The main objectives of this study were:
1) To investigate the importance of the glutathione / glutathione biotransformation system in 
male fertility and physiological pregnancy.
2) To investigate the role of the aminothiol redox-balance in women with severe 
preeclampsia.
3) To investigate the association between polymorphisms in oxidative stress related genes and 
the pathogenesis of severe preeclampsia.
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Chapter 2
The concept of detoxification and oxidative stress.
Chapter 2
2.1 . B iotransform ation
During life, numerous harmful compounds, including carcinogens and reactive oxygen 
species (ROS) are introduced to organisms at several different ways, including nutritional 
intake, inhalation of polluted air or generation by UV-radiation (1). In addition, organisms 
itself may produce toxic compounds, such as free radicals and ROS, by metabolic processes 
that may lead to oxidative stress. Since many of these compounds are associated with disease 
in humans, both non-enzymatic as well as enzymatic defence mechanisms are present (2). The 
major defence against xenobiotic compounds and their breakdown products is provided by the 
two-stage mechanism of phase I and phase II biotransformation reactions (Figure 2.1). Phase I 
reactions involve oxidation, reduction, hydrolysis or dealkylation of many compounds and is 
mainly catalysed by a variety of cytochromes P450 monooxygenases (CYP) and two epoxide 
hydrolases (EPHX) (3). The purpose of this initial reaction is to create or liberate free 
hydroxyl- or amino-moieties, which can readily be conjugated resulting in hydrophilic 
molecules by phase II reactions. These phase II reactions are largely catalysed by the 
glutathione S-transferase (GST) and UDP-glucuronosyltransferase (UGT) families, which 
conjugate glutathione (GSH) and UDP-glucuronic acid, respectively. Many other Phase II 
enzymes including sulfotransferases and acetyltransferases may play an important role. After 
phase II reaction, the end products are less biologically active and more water-soluble, 
thereby facilitating their excretion via urine or bile.
CYP
EPXH GST y-GT 
RX -------- ► R’X + GSH — -----► GSR’ — ^ -----► Excretion
HX Glu
Phase I Phase II Phase III
Figure 2.1 Schematic overview of phase I and phase II biotransformation:
In phase I toxic compounds (RX) are activated by e.g. cytochromes (CYP). In phase II GSH is 
conjugated to the reactive intermediate by GST after which the conjugates can be secreted via bile or 
urine (phase III).
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2.1.1 Glutathione S-transferase
One of the most important protective systems, at least in a quantitative sense, is the 
glutathione dependent GST enzyme system (1;4). In eukaryotes the family of GSTs 
compromises two different multigene superfamilies. One family consists of membrane-bound 
transferases, whereas the other family is soluble, also referred to as cytosolic GSTs. So far, 
seven classes of the cytosolic GST family have been characterised, which were designated 
Alpha, Pi, Mu, Theta, Sigma, Zeta and Kappa (4). In humans the first four classes of GSTs 
are primarily expressed (1). The genetic origins of these four classes are located on 
chromosomes 6, 11, 1 and 22, respectively. Generally, GSTs that share over 40% homology 
belong to the same class, whereas those with less than 30% homology are assigned to 
different classes. For both GSTMu and GSTTheta a null-genotype, corresponding with no 
detectable expression of GST enzyme activity, can be found in approximately 54% and 18% 
of the North-West European population, respectively (5). However, the presence of both 
polymorphisms differs markedly between human races (1).
Each class of GSTs is composed of homo- or heterodimeric enzymes with subunits of 
approximately 25 kDaltons (kD) molecular mass (ranging from 23 to 28 kD). This different 
subunit composition results in substrate specificity for each GST isoform, although substrate 
overlap exists. Additionally, expression of GST isoforms is tissue specific and a diverse 
expression pattern of GST isoforms is seen, which results in specific protection for each 
tissue. Generally, GSTAlpha is the main isoform in liver, kidney and adrenal gland (6-8), 
GSTPi is predominantly expressed in placenta, oesophagus, stomach, lung and heart (7;9;10), 
whereas in bladder GSTMu is the main isoform (11). During embryonic and foetal 
development GST isoforms are also expressed. However, amounts of specific isoenzymes 
may differ between foetal and adult tissues (12;13), indicating that some foetal tissues exert 
different functions in comparison with those in adults. For instance, foetal liver primarily 
expresses GSTPi, whereas in adult liver GSTAlpha is the predominant form in even higher 
amounts than that of GSTPi in foetal liver. Such findings demonstrate the hepatic change of 
erythrocyte synthesis during antenatal development to its main task as detoxification organ in 
adult live. Furthermore, expression of GSTPi in foetal lung decreases with gestational age
(14). Since, induction of GST expression may be an adaptive response to chemical or 
oxidative stress (1), presence of GST isoforms may be a reflection of a specific toxic 
environment.
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Besides catalysing the conjugation of GSH to reactive intermediates in phase II reactions, 
which is the most important function, the family of GSTs has several other functions. By its 
peroxidase activity GSTs play an important role in the reduction of reactive oxygen species 
(ROS), as outlined in Figure 2.2. Furthermore, GSTs are capable in the non-catalytic binding 
and transport of several exogenous and endogenous compounds including bilirubin, genotoxic 
electrophiles etc. However, this function is relatively unknown as compared to the transferase 
and peroxidase activities (1).
Figure 2.2 Reduction of reactive oxygen species by glutathione and related enzymes:
Hydrogen peroxide (H2O2) or organic hydroperoxides (ROOH) can be reduced enzymatically by 
glutathione peroxidase as well as non-enzymatically by direct oxidation of glutathione (GSH), resulting 
in H2O or corresponding alcohols (ROH). The inactive, oxidised form of glutathione (GSSG) is reduced 
by glutathione reductase thereby consuming nicotinamide-adenine-dinucleotide phosphate (NADPH). 
Superoxide anion may be converted to H2O2 by oxidation of GSH.
2.1.2. Glutathione
Glutathione is a water-soluble antioxidant, which has as main functions to serve as co-factor 
in phase II conjugation reaction by GSTs and to protect cells from oxidative damage induced 
by ROS. In the latter reaction GSH itself may directly scavenge ROS or indirectly by action 
of glutathione peroxidase (GPX). Besides these two functions glutathione has a myriad of 
other functions, of which maintenance of -SH groups in the reduced state, storage and 
transport of amino acids in particular cysteine, and formation of leukotriene C4 and 
derivatives are the most important ones (15;16).
Synthesis of glutathione takes place in two consecutive steps that are catalysed by y- 
glutamylcysteine and glutathione synthetase, respectively (Figure 2.3) (15;17). In the first and 
rate-limiting step cysteine is covalently bound to glutamate and subsequently glutathione is 
formed by the subsequent addition of glycine. In the first reaction a very stable y-glutamyl 
bond, instead of the normal peptide bond, is formed. This y-glutamyl bond cannot be cleaved
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by the abundantly present peptidases, but only by y-glutamyl transpeptidase. Regulation of 
glutathione synthesis takes place at the first reaction in two different ways: a) by feedback 
inhibition of glutathione and b) the availability of free cysteine.
Glutathione is widely distributed in human tissues and is present in high intracellular 
amounts. Therefore, GSH is the most prevalent cellular thiol and accounts for over 90% of 
non-protein sulphur (17). In blood, GSH levels in erythrocytes are high (~1000 ¡^mol/L) (18), 
whereas in human plasma they are relatively low (<20^mol/L) (19).
Glutamate Cysteine Glycine
I
SH
Figure 2.3 Synthesis of glutathione:
The initial rate-limiting step is catalysed by y-glutamylcysteine synthethase, which couples cysteine 
and glutamate, subsequently followed by the addition of glycine catalysed by glutathione synthetase, 
resulting in glutathione. The first reaction is feedback inhibited by glutathione.
GSH can be excreted from tissues as glutathione S-conjugate or as glutathione disulphide 
(GSSG) (20) by multidrug resistance proteins (21) or by other ATP-dependent transporters 
(22;23). Excessive amounts of GSSG may be produced during periods of oxidative stress and
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in the absence of sufficient reducing equivalents some of the GSSG may be excreted to 
preserve cellular thiol balance. Therefore, the rate of GSSG transport may represent 
intracellular oxidative status (23).
2.2  O xidative stress
Oxidative stress is defined as disturbance in the balance between antioxidants and 
(pro)oxidants in favour of the latter. Oxidative stress occurs when free radical generation 
exceeds the capacity of antioxidant defences due to an inadequate dietary intake of 
antioxidants or by an increase of cellular oxidants, which can be defined as substances with 
one or more unpaired electrons (24). The amount of oxidants may increase due to exposure to 
free radical generating toxins such as those from cigarette smoke (2) or radiation (25). A 
small part (1 -  3%) of the inhaled oxygen is converted into ROS, including the superoxide 
radical (O2-) and hydrogen peroxide (H2O2). Some of it is deliberately produced to inactivate 
viruses or to kill bacteria or fungi (2). However, most intracellularly generated ROS are 
unavoidable by-products of oxidative metabolic pathways (25). Unless properly scavenged, 
ROS may lead to lipid peroxidation, which represents an important manifestation of oxidative 
stress (24). Lipid peroxidation is initiated when a free radical interacts with polyunsaturated 
fatty acids of cell membranes and may finally result in a chain-reaction forming lipid 
hydroperoxides (26). Therefore, ROS may induce damage to DNA, proteins, carbohydrates or 
even disturb cell membrane integrity (2;27;28), which might result in impairment of 
enzymatic properties as well as cell membrane functioning.
On the other hand, oxidative stress induces the expression of redox-sensitive transcription 
factors like activating protein-1, hypoxia inducible factor-1a and nuclear factor-KB (29;30), 
which results in the expression of several genes including those of the GST family (31). Thus 
oxidative stress indirectly initiates antioxidant defence. Biological antioxidants can be defined 
as compounds that protect biological systems against the harmful effects of processes or 
reactions that can cause excessive oxidation (32). This antioxidant defence comprises 
enzymatic as well as non-enzymatic systems.
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2.2.1 Glutathione peroxidase and other enzymatic antioxidants 
First line defence against ROS is provided by the glutathione peroxidases (GPXs), which 
catalyse the reduction of organic hydroperoxides or hydrogen peroxide into their 
corresponding alcohols or H2O by the oxidation of glutathione (Figure 2.2). Like the family of 
GSTs, GPXs consist of a multigene family of six members (4). Most members require 
selenium for catalysis (SeGPX) and are characterised by a covalently bound selenocysteine in 
its active centre. At least four members are described: a. the classical cellular/cytosolic GPX 
(GPX1), b. gastrointestinal GPX (GPX2), c. extracellular/plasma GPX (GPX3) and d. 
phospholipid hydroperoxide GPX (GPX4). SeGPXs are capable to reduce organic 
hydroperoxides as well as H2O2. The second type of GPXs are selenium independent and 
probably mainly consist of GSTs (4). This GPX is only reactive towards organic 
hydroperoxides. GPXs are ubiquitously expressed including placental and decidual tissue 
(33;34), but most abundantly in erythrocytes, kidney and liver (4).
Two other enzymes play a major role in defence against the superoxide anion. Superoxide 
dismutase (SOD) converts superoxide anion to H2O2 and oxygen. Since H2O2 is highly 
reactive and can easily cross the cell membrane, SOD works in parallel with the H2O2- 
removing enzymes GPX and catalase, both quickly reducing H2O2 to H2O and oxygen (2). 
Both enzymes are expressed at different locations, GPX is mainly present in cytosol, whereas 
catalase is localised in the matrix of peroxisomes. Therefore, both enzymes have their own 
specific function and complement each other (24).
2.2.2. Non-enzymatic antioxidants
A relatively large number of compounds are capable to prevent lipid peroxidation or metal- 
catalysed radical reactions and thus possess antioxidant capacity (32). In general, non- 
enzymatic antioxidants can be grouped in lipid-soluble and water-soluble antioxidants.
The major lipid-soluble antioxidants are the family of tocopherols including a-tocopherol, or 
vitamin E. All tocopherols are effective inhibitors of the propagation step of lipid 
peroxidation by reacting with one ore two peroxyl radicals. Carotenoids, precursors of e.g. 
vitamin A, show a similar antioxidant capacity as tocopherols, thus quenching at least two 
peroxyl radicals, by their conjugated double-bond systems. The main function of ubiquinone, 
one of the quinones, is to reduce the a-tocopherol radical. However, it may also directly act 
on either peroxyl or alkoxyl radicals. Although bilirubin is a product of heme-metabolism, it
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is also an important lipid-soluble antioxidant, which has similar properties as a-tocopherol
(32).
Major water-soluble antioxidants include glutathione, ascorbic acid (vitamin C), uric acid, 
metal-binding and heme-binding proteins. Ascorbic acid acts synergistically with a- 
tocopherols, since it is capable to quickly regenerate a-tocopherol by reduction of the a- 
tocopherol radical (2;32). Though uric acid is a waste product like bilirubin, at physiological 
concentrations it shows a strong antioxidant capacity towards water-soluble oxidants. 
Furthermore, metal-binding (transferrin) as well as heme-binding proteins (haptoglobin) 
prevent metal-initiated oxidation by binding to transition metals like iron (32).
2.2.3. Oxidative stress during pregnancy
Increased lipid peroxidation is a normal phenomenon of pregnancy (35). Several studies have 
reported higher blood levels with an increase throughout pregnancy of lipid peroxidation 
markers, such as thiobarbituric acid reactive substances (TBARS), lipid hydroperoxides and 
conjugated dienes in pregnant women as compared with those in non-pregnant controls 
(26;36;37). However, not all studies report increasing TBARS levels during gestation (38). 
Elevated levels of oxidative damage products normalise within days after delivery (26).
In order to maintain a physiological metabolism, the progressive increase of oxidants has to 
be counterbalanced by a parallel increase of total antioxidant capacity (39). Two major 
enzymatic antioxidant enzymes, SOD and GPX, were shown to be progressively increased 
during pregnancy (37;38). Also levels of the non-enzymatic antioxidant, a-tocopherol, which 
is tightly bound to ß-lipoproteins, increase during pregnancy (37;40). In contrast with other 
antioxidants, the level of vitamin A is slightly lower during pregnancy (40). Both lipid 
peroxidation products and antioxidants systems normalise after delivery (26;37;40).
Thus during uncomplicated pregnancy the transiently increased lipid peroxidation is followed 
by a parallel increase of antioxidant capacity. However, when not properly counteracted this 
could lead to several complications of pregnancy, including hypertensive disorders of 
pregnancy such as preeclampsia (17;18;24;35).
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2.3 . P reeclam psia
Preeclampsia complicates approximately 5% of all pregnancies (41) with poor maternal as 
well as foetal outcome (42). It is accompanied by high maternal and foetal morbidity and 
mortality (41;43). According to the definition of the International Society of the Study of 
Hypertension in Pregnancy preeclampsia is classically defined as pregnancy-induced 
hypertension with proteinuria (diastolic blood pressure (DBP) >90mmHg (Korotkoff V), 
measured on two or more consecutive recordings more than 4 hours apart and an urinary 
protein excretion of >300 mg/24 hours) (43). Severe preeclampsia is defined as a DBP above 
110mmHg or preeclampsia accompanied with complications such as HELLP (haemolysis, 
elevated liver enzymes, low platelets) syndrome. HELLP is biochemically defined by lactic 
dehydrogenase > 600 IU/L, both aspartate and alanine aminotransferase > 70 IU/L, and a 
platelet count < 100x109/L (44). Preeclampsia is a multi-system disorder in which many 
organs may be affected including the kidney and the liver.
Although the definite aetiology of preeclampsia is not yet elucidated, several underlying 
pathogenetic mechanisms are clear. A central pathological feature of preeclampsia is 
dysfunction of the endothelium layer lining the vascular walls, which normally maintains 
vascular integrity (42). This results in several pathophysiological features including an 
activated clotting cascade, and high levels of endothelin, von Willebrand factor and 
fibronectin, (41). Furthermore, related to endothelium dysfunction increased oxidative stress 
is present, which also shifts the balance between prostacycline (PGI2) and tromboxane 
(TXA2) in favour of increased vasoconstriction and trombocyte aggregation (43;45). 
Preeclampsia has a familial occurrence (41;43). Offspring of mothers with preeclampsia, 
sisters of women who had preeclampsia or being pregnant from a partner who fathered a 
preeclamptic pregnancy (42) are all risk factors to develop preeclampsia. Therefore it is likely 
that a genetic predisposition is involved, which could be from both maternal and paternal 
origin (41-43;45-48). However, instead of originating from a single "preeclampsia-gene" it is 
rather a complex of several genetic polymorphisms contributing to the development of 
preeclampsia (42). Furthermore, the fact that a) preeclampsia predominantly affects first 
pregnancies, b) long-term exposure to seminal fluid diminishes preeclampsia risk, whereas c) 
change of partner increases the risk to develop preeclampsia, may indicate that an inadequate 
immunological response plays a role in the pathogenesis of preeclampsia (41;43;45;49). 
Additionally, preeclampsia can only occur in the presence of placental tissue, which is partly
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from paternal origin. Hydatidiform moles, i.e. a pregnancy with only placental tissue and 
absence of a foetus, are at higher risk (43) and symptoms and lesions of preeclampsia resolve 
after delivery of the placenta (41;49;50). Therefore, it is proposed that preeclampsia originates 
from a disturbed placental development and/or function.
2.3.1 Hypothesis o f pathogenesis o f preeclampsia
Adequate maternal-foetal exchange is a key requirement for a successful pregnancy (51). The 
current concept of the pathogenesis involves the early development of the placental unit 
(Figure 2.4). Until approximately the 10th week of gestation maternal blood flow is absent 
from the precursors of the intervillous space (IVS) due to the presence of aggregates of 
cytotrophoblastic cells derived from the developing placenta. Therefore, a capillary 
circulation or simple diffusion performs the exchange of oxygen, nutrients and waste products 
between the developing embryo and mother (51). Around the 10th week of gestation the 
arterial plugs loosen and gradually disappear and maternal blood is able to enter the IVS. As a 
result of this maternal blood flow the oxygen tension (pO2) rises, with subsequent generation 
of ROS and oxidative stress (51). This transient burst of oxidant stress may trigger differential 
pathways that develop a full maternal circulation to the placenta and can be counterbalanced 
by the induction of several antioxidant systems (51) or exaggerated by chemical stress 
induced by e.g. medication, environmental factors or metabolic disorders. One of the 
responses during a physiologically normal pregnancy is the invasion of syncitiotrophoblasts 
into the spiral arteries, resulting in an increased diameter. During this process the endothelium 
of the vascular wall and the musculature are destroyed by interstitial trophoblasts, converting 
them into flaccid sinusoidal sacs lined by endovascular trophoblasts (41;52). These changes 
are necessary to have a sufficient placental blood flow in the intervillous space to provide the 
developing foetus with adequate amounts of oxygen and nutrients.
At this regulatory point oxidative stress is controlled by maternal antioxidant capacity, which 
is determined by genetic predisposition, nutritional intake as well as by the expression of 
antioxidants by trophoblasts, which is influenced by both maternal and paternal genotype. 
When antioxidant capacity is not sufficient or when fluctuations of pO2 or too high levels of 
pO2 cause an extensive temporal oxidative stress that may overwhelm the antioxidant 
capacity, trophoblast degeneration may occur resulting in trophoblast malfunction and 
decreased invasive capacity. This may initiate diminished remodelling of the spiral arteries 
and lead to poor placental perfusion, which most probably occurs in women who develop
26
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preeclampsia. Poor placental perfusion may lead to chronic oxidative stress in the placental 
unit, which has damaging effects on DNA and cell structure integrity.
Figure 2.4. Proposed pathogenesis of preeclampsia (adapted from Jauniaux et al. (51):
In short; after unplugging spiral arteries the continuous blood flow in the intervillous space (IVS) 
results in a rise of oxygen tension and transient oxidative stress. If not properly counterbalanced by 
antioxidants or when exaggerated by chemical stress, this may lead to trophoblast degeneration, 
resulting in maladaptation of trophoblast invasion. As a consequence of poor placental circulation, 
chronic placental stress may evolve, which finally may affect maternal endothelium in the systemic 
circulation.
27
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Although, increasing enzyme activity of GPX and other antioxidants are found in placental 
tissue to prevent oxidative damage (33;51), the amount of oxidative products may exceed the 
placental antioxidant capacity. Eventually, the overproduction of lipid peroxides may also 
affect maternal circulation due to leakage of ROS to maternal vascular system and may finally 
result in the clinical symptoms of preeclampsia and HELLP syndrome.
2.3.2. Oxidative stress in preeclampsia
In line with the role of placental oxidative stress in the pathogenesis of preeclampsia, 
numerous independent markers of oxidative stress indicate the presence of placental oxidative 
stress in women with preeclampsia. However, the problem with the measurement of oxidative 
damage is that these products can easily be formed in vitro and therefore no golden standard 
to measure oxidative stress is present, which may explain the contradictory findings as 
reported in literature (35). Several studies reported higher placental levels of lipid 
peroxidation (53-55), whereas recently also higher levels of oxidative protein damage (56) or 
ROS (57) were described in women with preeclampsia as compared with those in 
uncomplicated pregnancies. However, Poranen et al. (58) described lower levels of 
conjugated dienes, which are formed in the process of lipid peroxidation, in placental tissue of 
women with preeclampsia. In the same study elevated levels of thiobarbituric acid reactive 
substances, which include malondialdehyde (MDA) and a higher peroxidation potential were 
described in placentas of women with preeclampsia as compared to those in normal pregnant 
women (58).
In most of these studies it was also shown that placental antioxidant capacity was decreased in 
placental tissue of women with preeclampsia (53;54;56). In preeclampsia the expression of 
the important enzymatic antioxidants Cu-Zn SOD and GPX is down regulated in placental 
tissue as demonstrated by lower mRNA levels (53;59). Furthermore, also protein levels of 
these specific enzymatic antioxidants as well as those of G6PDH are lower in women with 
preeclampsia (35;58;59), whereas the level of GSTPi, the major GST isoform in placenta, is 
lower in placental tissue of women with preeclampsia (9). Additionally, levels of the non- 
enzymatic antioxidant vitamin E were found to be lower (59).
In contrast with the studies that show decreased placental antioxidant capacity some studies 
describe that glutathione levels (33;55), GPX enzyme activity (33), and catalase enzyme 
activity (59) are higher in placentas from women with severe preeclampsia. It is postulated
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that the increase of these specific antioxidant systems is necessary to cope with increased 
oxidative stress.
In conclusion, the elevation of lipid peroxidation markers and the down-regulation of the 
antioxidant system as often noticed provide a clear indication for the presence of placental 
oxidative stress in women with preeclampsia.
Reports of oxidative stress in maternal circulation have been variable, however, most of them 
indicate higher oxidative damage and lower antioxidant capacity (35;54) or an increase of 
superoxide generation from circulating neutrophils (24;60). Furthermore, some studies 
showed an elevated oxidant potential of preeclamptic blood by measurement of increased 
oxidation of vitamin C (61) and the increased generation of superoxyde or peroxynitrite 
(24;35;62). Increased serum levels of MDA, a major breakdown product of lipid peroxides, 
was one of the first markers showing elevated lipid peroxidation in women with preeclampsia
(50). Numerous other studies have confirmed that MDA levels or the concentrations of 
TBARS, which mainly consists of MDA, are higher in women with preeclampsia as 
compared to normotensive pregnant women (29;35;38;63-67). However, one study could not 
demonstrate a difference in MDA levels, although the ratio of MDA over total antioxidant 
capacity was much higher in women with preeclampsia versus uncomplicated pregnancies, 
indicating increased oxidative stress (68). A consequence of lipid peroxidation is the 
formation of conjugated dienes, which involves bond migration in the unsaturated fatty acid 
hydrocarbon chain (50), thereby being specific markers of lipid peroxidation. Levels of 
conjugated dienes are elevated in plasma and platelets of women with preeclampsia 
(50;63;69). Free radical attack of arachidonic acid results in the generation of stable products 
the so-called iso-prostanes. Results on measurement of iso-prostanes levels seem to be 
ambiguous. In plasma of women with preeclampsia higher levels of 8-isoprostane were 
detected (70), whereas in urine no differences were found (71). This controversy might be 
explained by an impaired renal clearance in preeclampsia (70). Since extra-cellular low- 
density lipoproteins (LDL) may be exposed to cell-derived oxidants and may be less protected 
by antioxidants, they are prone to oxidative attack. In several disorders associated with 
oxidative stress including preeclampsia, increased levels of antibodies against an epitope on 
the oxidised form of LDL are found (35;72).
Besides damage to lipids, oxidative stress may have noxious effects to carbohydrates, amino 
acids, proteins, RNA, DNA and other molecules. Proteins may be modified by direct 
oxidative attack or by lipid peroxidation products, affecting their amino acid side chains
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resulting in the formation of additional carbonyl groups. In plasma of women with 
preeclampsia higher protein carbonyl levels were found (73). Free radicals may also react 
with the free sulfhydryl group of aminothiols, such as cysteine, homocysteine, 
cysteinylglycine and glutathione, resulting in the formation of (mixed) disulphides. A 
relatively higher increase of the oxidised thiol level as compared with the rise of the 
corresponding free thiol level in whole blood results in a lower free-to-oxidised ratio and may 
be a direct measure of oxidative stress. The free-to-oxidised ratios for cysteine, 
cysteinylglycine, and homocysteine were found to be lower in women with preeclampsia. (74, 
this thesis).
Besides the elevation of oxidative damage products, the decrease of specific antioxidants or 
the total antioxidant capacity are other indirect indications for oxidative stress in 
preeclampsia. However, measurement of total antioxidant capacity may be confusing, since 
depending on the method used -SH containing antioxidants are not measured (56) or uric 
acid, a breakdown product of purines that is elevated in women with preeclampsia, is also 
measured (58;75). The elevation of uric acid levels in preeclampsia may reflect an adaptive 
mechanism in the defence against oxidative stress, be an indication for the increased 
destruction of tissue, or point at an altered metabolism or clearance of purines (76). Overall 
total antioxidant capacities were reported to be lower in women with preeclampsia (39;68). 
Results on vitamin E levels in preeclampsia are ambiguous; some papers report lower levels 
(39;64), whereas others demonstrate increased levels (75) or no differences (35;61) between 
preeclamptic and uncomplicated pregnancies. Since vitamin E is transported by ß- 
lipoproteins, the discrepancy is most likely explained by the presence of hyperlipoproteinemia 
in preeclampsia and absence of correlation of vitamin E with lipoprotein levels (35). The 
same contradiction is found for vitamin C, which is reported to have a synergistic effect on 
the activity of vitamin E. Some studies found lower levels in preeclampsia (39;61), whereas in 
others studies unchanged levels were reported (66;75).
Other important non-enzymatic antioxidants comprise the thiol-containing peptides, 
especially glutathione. Total thiol content in blood was reported to be lower (66;77). Studies 
on glutathione show inconsistent results. Levels in plasma are lower in women with 
preeclampsia (60;78), whereas free levels of glutathione were shown to be lower in women 
with HELLP (18).
In preeclampsia the presence and activity of enzymatic oxidants have hardly been studied. In 
studies with a small number of subjects, SOD activity was found to be lower in preeclampsia
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(38;62;66), whereas GPX activity was found to be slightly lower (38), or remained unchanged
(66). However, in a recent larger study SOD was lower in preeclampsia, whereas GPX 
activity was higher (67). In the same study catalase enzyme activity was found lower in 
preeclampsia (67), whereas others have reported unchanged enzyme activity (38).
In addition, the antioxidant therapies applied by Chappell et al. (79) and Gülmezoglu et al.
(80) indirectly support the concept of oxidative stress in the pathogenesis of preeclampsia. In 
both studies supplementation with high doses of vitamin E and vitamin C was given, which 
reduced the risk of preeclampsia in the study of Chappell et al, whereas no effect was found in 
that of Gülmezoglu et al. However, treatment protocol was different, Gülmezoglu et al. 
started the vitamin treatment at onset of severe preeclampsia, whereas Chappell et al. 
supplemented a high risk population starting in early pregnancy (16 -  22 weeks) until 
delivery. This indicates that early intervention might be essential. Since placental oxidative 
stress arises after unplugging of the spiral arteries at approximately the 10th week of gestation 
(Figure 2.4) and lipid peroxidation progressively increases with gestational age, even in 
uncomplicated pregnancy, the positive effect of vitamin intervention might indicate that 
oxidative stress is an early factor in the pathogenesis of preeclampsia.
2.3.3 Pathophysiological consequences o f oxidative stress in preeclampsia. 
Oxidative stress may alter vascular function by direct action on endothelial cells or through 
vasoactive pathways including nitric oxide (NO) synthase, prostaglandin H (PGH) synthase 
and endothelin (24). Lipid peroxides may interact with endothelial cells or alter their function
(81) and may have a contractile effect on the vascular system by the formation of increased 
levels of oxidised LDL, which may inhibit endothelial-dependent relaxation (24;50). The 
levels of NO synthase and nitric oxide are increased in women with preeclampsia. Although 
NO is a potent vasorelaxant; it may rapidly react with superoxide yielding peroxynitrite, 
which a) reduces the availability of NO and thus prevents its action as a vasorelaxant, b) is 
involved in necrosis and apoptosis, and c) may directly damage endothelial cells due to its 
pro-oxidant capacity (24;62). Additionally, peroxynitrite along with lipid peroxides may 
increase phospholipase A2 activity, which activates prostaglandin synthase resulting in 
overproduction of prostacyclin (24;62). However, high levels of lipid peroxides inhibit PGH 
synthase. Normally prostacyclin is a vasorelaxant, however, it also binds to the tromboxane
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receptor causing a vasoconstrictive response (24). Furthermore, both cell damage and oxygen 
radicals stimulate the release of endothelin, a potent vasoconstrictor, into the circulation.
The above-mentioned effects of ROS, lipid peroxides and other radicals may explain the 
characteristics of preeclampsia, since vasoconstriction results in hypertension, whereas 
damage of the endothelium, including that lining the renal glomular capillaries, may result in 
proteinuria (35).
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A bstract
Objective: To study the levels of glutathione, glutathione S-transferase A1-1 and glutathione 
S-tranferase P1-1 in seminal fluid of fertile and subfertile men.
Design: Retrospective case-control study.
Setting: The Departments of Gastroenterology, Obstetrics / Gynaecology, and Epidemiology / 
Biostatistics of the University Medical Center Nijmegen, The Netherlands.
Patients: Twenty-five subfertile males visiting the fertility clinic and twenty-five fertile males 
from midwife practices were recruited.
Main outcome measures: Plasma levels of glutathione, glutathione S-transferase A1-1 and 
P1-1 in relation to seminal characteristics.
Results: Glutathione, glutathione S-transferase A1-1 as well as glutathione S-transferase P1-1 
were found in considerable amounts in seminal fluid of subfertile and fertile men. No 
differences between groups were found for glutathione S-transferase A1-1 and P1-1. Also no 
associations with sperm count, motility or morphology could be detected. Fertile men had 
significantly higher glutathione levels as compared with subfertile males. Associations of 
glutathione with sperm motility quality (rs = 0.321) and abnormal sperm morphology (rs =- 
0.496) were found.
Conclusions: Presence of glutathione S-transferase A1-1 and P1-1 in seminal fluid suggest a 
role in the protection against (oxidative) damage of spermatozoa, whereas glutathione may 
play a role in male fertility.
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In troduction
Human spermatozoa are capable of generating reactive oxygen species and this activity is 
accelerated in cases of defective sperm function (1). Because of the presence of extraordinary 
high levels of polyunsaturated fatty acids in the plasma membrane of spermatozoa, human 
spermatozoa are highly susceptible to oxidative stress, which may lead to peroxidative 
damage of the cell membrane, resulting in more permeable membranes (2). This may have a 
negative effect on sperm quality, motility, and fertilization and may result in defective sperm 
function and conception, or even infertility (3). Protection against reactive oxygen species and 
prevention of other damage is of critical importance and can be provided by both enzymatic 
or non-enzymatic antioxidants (2;4-7). However, due to the high density of mitochondria, 
which may leak oxygen radicals in the cytoplasm, the ability of spermatozoa to scavenge 
oxidants in the small midpiece is limited. Therefore, antioxidant capacity has to be present in 
the seminal fluid as well. In spermatozoa and in seminal fluid the presence of considerable 
amounts of the antioxidants a-tocopherol, uric acid, and vitamin C, as well as the enzymes 
superoxide dismutase, glutathione peroxidase and catalase have been described (3;5).
An important endogenous antioxidant in humans is the tripeptide glutathione, which plays a 
central role in the defence against oxidative damage and toxins, where it serves as co-factor 
for glutathione peroxidases and glutathione S-transferases. The family of human cytosolic 
glutathione S-transferases consists of four main classes, Alpha, Pi, Mu and Theta, each 
subdivided in one or more different isoforms (8). Due to the existence of many different 
isoenzymes broad substrate specificity is achieved.
It was already shown that glutathione and glutathione S-transferases play an important role in 
reproduction (9). However, data on glutathione and glutathione S-transferases in human 
seminal fluid are limited (5). Therefore, we investigated the amounts of glutathione, 
glutathione S-transferase P1-1, and glutathione S-transferase A1-1 in seminal fluid of both 
fertile and subfertile males.
43
Chapter 3
M ateria ls and M ethods
Patient material
The local Institutional Review Board approved the experimental protocol. Fertile subjects 
were recruited from midwife practices. They had no history of fertility problems and their 
partners had a spontaneously pregnancy at the time of participation. Subfertile males were 
recruited at the fertility clinic of the University Medical Center Nijmegen, The Netherlands, 
from couples who failed to conceive after one year of regular unprotected intercourse with the 
same partner and who had a sperm count of 5 -  20 million per milliliter. After informed 
consent was given semen samples were collected standardised by masturbation after a sexual 
abstinence of at least 48 hours. Semen samples were collected for a large study on zinc and 
folic acid deficiency in male factor subfertility (10). Subgroups of fertile (n=25) and subfertile 
(n=25) men were randomly selected from this study. Semen samples were characterised by 
the semen parameters: sperm count, percentage of motile spermatozoa, quality of sperm 
motility (on a scale of 1-6) and percentage of spermatozoa with abnormal morphology, as 
described earlier by Menkveld et al. (11). The semen characteristics of both fertile and 
subfertile males are summarised in Table 3.1. Seminal plasma was prepared by centrifugation 
of the ejaculate (1,500xg, 10 min and 4°C) and was stored at -30°C until use.
Table 3.1. Age and Semen Characteristics of the Study Groups.
Fertile males 
(n=25)
Subfertile males 
(n=25) P-Value
Age (years) 34 (27 -  42) 33 (27 -  41) NS
Sperm count (x106/mL) 75 (35 -  175) 5 (0.1 -  13) 0.0001
Quality of sperm motility * 4/5 (3 -  5/6) 3 (2 -  4) 0.0001
Motile spermatozoa (%) 60 (30 -  70) 20 (1 -  60) 0.0001
Abnormal Morphology (%) 63 (35 -  90) 81 (54 -  98) 0.0001
* Quality of sperm motility is given on a scale of 1 -6.
Data are presented as median (range). Abbreviation: NS = not significant
Assays
Levels of glutathione S-transferase A1-1 (GSTA1-1) and glutathione S-transferase P1-1 
(GSTP1-1) in seminal plasma were determined by ELISA as previously described for blood 
plasma (12;13). In short; polystyrene microtiter plates (Microlon®-600 High Binding
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Capacity, Greiner, Alphen a/d Rijn, The Netherlands) were coated overnight with purified 
monoclonal antibody against GSTA1-1 (14) or GSTP1-1 (15). Plates were washed 5 times 
with phosphate-buffered saline supplemented with 0.05% (v/v) Tween 20 detergent (PBST). 
100 jL  of standard solutions (0.8 -  20 jg/L for GSTA1-1 and 0.4 -  100 jg/L for GSTP1-1) 
and seminal plasma samples (diluted up to 1:200) were added to the wells and incubated 
overnight. After washing with PBST, plates were incubated with rabbit anti-glutathione S- 
transferase A1-1 or anti-glutathione S-transferase P1-1 antiserum. Plates were washed again 
and incubated with horseradish peroxidase-labeled swine anti-rabbit antiserum (DAKO, 
Glostrup, Denmark). After a final wash, plates were stained with o-phenylenediamine/H202 
(Sigma Chemicals, Zwijndrecht, The Netherlands). The detection limits are 0.04 jg/L and 0.4 
jg/L for GSTA1-1 and GSTP1-1, respectively.
For determination of glutathione concentrations, 100 jL  of 12% perchloric acid (Merck, 
Darmstadt, Germany) was added to 20 jL  seminal plasma to precipitate all proteins in the 
sample. After centrifugation (13,000xg, 10 min and 4°C) clear supernatants were stored at -  
30°C until analysis. Glutathione concentrations were determined after conjugation to 7- 
fluorobenzofurazane-4-sulfonic acid (SBDF; Fluka Chemie AG, Bornem, The Netherlands) 
using a high performance liquid chromatography (HPLC) method, essentially as described 
previously (16). In short; 100 jL  sample was reduced for 30 min at room temperature with 10 
jL  10% (w/v) tris-2-carboxyethyl-phosphine (Fluka Chemie AG). Subsequently, samples 
were neutralised with 75 jL  2M NaOH. 100 jL  of the neutralised sample was derivatised 
with SBDF, thereafter, 60 jL  derivatization buffer (50 jL  borate buffer (125 mmol/L 
K2B4O7'4H2O (Fluka Chemie AG) with 4 mmol/L EDTA, pH 9.5), 5 jL  SBDF (4 mg/mL 
borate buffer) and 5 jL  1.55 M NaOH) was added. Subsequently, samples were incubated for 
1 hour at 60°C. Samples were cooled and 20 jL  was injected into the HPLC system.
Statistics
Differences between fertile and subfertile males were analysed by a Wilcoxon-Mann-Whitney 
test. Data from the fertile and subfertile group were pooled for the calculation of associations 
between GSTA1-1, GSTP1-1 and glutathione with spermatozoa count, percentage of motile 
spermatozoa, quality of sperm motility and morphology, which were computed by Spearman's 
rank correlation test. All statistical tests were performed with the Astute Statistical Add-In for 
Microsoft Excel 5 version 1.50.
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R esults
In most seminal plasma samples of both fertile and subfertile males considerable amounts of 
glutathione, glutathione S-transferase A1-1 and glutathione S-transferase P1-1 could be 
detected (Table 3.2). Median levels of glutathione were significantly higher in fertile males as 
compared with subfertile males (1.2 (0 -  3.9) versus 1.8 (0.1 -  7.7) ¡^mol/L, respectively, 
P=0.02). No statistical differences between subfertile and fertile males were found for 
GSTA1-1 and GSTP1-1 concentrations. In the pooled data, values of glutathione showed 80­
fold variation, whereas those of GSTA1-1 and GSTP1-1 both showed approximately 20-fold 
variation. Median GSTP1-1 concentration was approximately 6 times higher than that of 
GSTA1-1.
Table 3.2. Levels of glutathione, glutathione S-transferase A1-1 and P1-1 in Human Seminal 
Plasma
Fertile males Subfertile males Total study group
Glutathione 1.8 (0.1 -  7.7) 1.2 (0 -  3.9)* 1.5 (0 -  7.7)
GSTA1-1 238(34 -  660) 143 (34 -  674) 176 (34 -  674)
GSTP1-1 1174 (430 -  2622) 981 (265 -  4837) 1104 (265 -  4837)
Data are presented as median (range) and expressed as |jmol/L (glutathione) and ng/ml (GSTA1-1 
and GSTP1-1).
Statistics: * P=0.02 fertile versus subfertile males
Neither glutathione S-transferase A1-1 nor glutathione S-transferase P1-1 concentrations were 
correlated with glutathione levels, sperm count, percentage of motile spermatozoa, motility 
quality, or abnormal morphology. Glutathione concentrations in seminal plasma were 
significantly correlated with semen morphology and motility quality (rs = -0.496, P<0.001 and 
rs = 0.321, P=0.02, respectively).
D iscussion
Due to the generation of oxygen free radicals by spermatozoa both seminal plasma as well as 
spermatozoa itself should be capable of scavenging these reactive oxygen species (ROS) for
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protection against oxidative damage. Lipid peroxidation in the cell membranes of 
spermatozoa, generated by ROS, may result in impairment of function (5). The presence of 
enzymatic (superoxide dismutase, catalase, glutathione peroxidase) and non-enzymatic 
antioxidants (vitamin C, vitamin E, urate, albumin, taurine, hypotaurine, and glutathione) 
(2;4-7;17;18) or total antioxidant capacity (19) in seminal plasma or spermatozoa have been 
previously studied .
Previous reports on glutathione in seminal plasma are in line with the results of our study. 
Ochsendorf et al. (5) reported median (range) levels of 0.6 (0.3 -  1.1) and 0.7 (0.2 -  2.4) 
¡^ M in oligozoospermia and normozoospermia, respectively, whereas in the study of Yeung et 
al. (17) amounts of glutathione were below the limit of detection (<2.5 ¡^ M) in seminal plasma 
samples. However, in contrast with the studies of both Ochsendorf et al. and Yeung et al. we 
established significantly lower glutathione concentrations in seminal plasma of subfertile 
males compared with those of fertile males. In addition, we showed that higher glutathione 
levels in seminal plasma were associated with a higher motility quality index and that lower 
glutathione levels were associated with a higher degree of spermatozoa with abnormal 
morphology. This emphasizes the previous findings by Lenzi et al., who showed that 
glutathione therapy improved semen quality (20). Therefore, our results provide evidence that 
the levels of glutathione in seminal plasma seems to play a role in fertilty, since glutathione 
may protect against oxidative damage of the cellular membranes of spermatozoa.
So far, no attention was given in literature to the presence of glutathione S-transferase 
isoenzymes in seminal plasma. We now demonstrate that, besides their co-factor glutathione, 
glutathione S-transferase A1-1 and glutathione S-transferase P1-1 are present in considerable 
amounts in seminal plasma of all subjects investigated. However, a broad inter-individual 
variation was seen. Exposure to pesticides or the recent use of antibiotics were associated 
with male factor subfertily (10), whereas the importance of glutathione for semen quality was 
noticed (20). Therefore, we also expected to find differences in seminal plasma concentrations 
of GSTA1-1 and GSTP1-1 between fertile and subfertile men, or associations of these GSTs 
with semen quality factors. Although both GSTA1-1 and GSTP1-1 tended to be lower in 
subfertile versus fertile men, no statistical significant differences were found, which is most 
probably due to high inter-individual variation and the multifactorial cause of subfertility
(10). In addition, no of the associations between GSTA1-1 or GSTP1-1 and semen quality 
factors could be found. These results indicate that GSTA1-1 and GSTP1-1 may have no 
dominant protective function in seminal plasma. The protective effect of glutathione may, 
therefore, not mainly originate from its co-operation with GSTA-1-1 or GSTP1-1, but may be
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explained by its direct scavenging of ROS, by its contribution to glutathione peroxidases, or 
by a combination of these functions.
In conclusion, glutathione S-transferase A1-1, glutathione S-transferse P1-1 and their co­
factor glutathione are present in considerable amounts in most seminal plasmas of both fertile 
and subfertile men. Glutathione might play a role in fertility, since glutathione concentrations 
in seminal plasma were higher in fertile than in subfertile males. Furthermore, higher levels of 
glutathione seem to improve or protect the quality of sperm motility and morphology of 
spermatozoa, independently from glutathione S-transferase levels.
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Developmental aspects of glutathione and glutathione S-transferases.
Paragraph 4.1
Glutathione S-transferases and thiol concentrations in embryonic 
and early foetal tissues.
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Chapter 4, paragraph 4.1
Abstract
Background: Glutathione S-transferases (GSTs) are important in intracellular binding and 
transport of numerous compounds and play a central role in human detoxification. Human 
GSTs mainly consist of class Pi (GSTP), Mu (GSTM), Alpha (GSTA), and Theta (GSTT) 
enzymes, each subdivided into one or more isoenzymes. They catalyse the conjugation of 
glutathione to toxic compounds resulting in more water soluble and less biologically active 
products that can easily be excreted from the body. The reactive -SH  group in glutathione 
(GSH) is provided by cysteine, which is an important amino acid in glutathione synthesis. 
Methods: In this study we investigated GST expression, enzyme activity, and levels of 
cysteine and glutathione in cytosolic fractions of organs from an embryo and a foetus at 8 and 
13 weeks of gestational age, respectively.
Results: GSTP1 was predominantly present in all tissue samples of both the embryo and 
foetus. GSTA (GSTA1 + GSTA2) levels were moderate as compared to GSTP1 levels, 
whereas GSTM1 was present in only low amounts. GSTT1 could not be detected in any of the 
tissue samples. GST enzyme activity was highest in organs directly exposed to amniotic fluid. 
In all embryonic and foetal organs considerable amounts of glutathione and cysteine could be 
detected, with higher GSH concentration in organs where lower cysteine concentrations were 
demonstrated.
Conclusions: These results suggest that in embryonic and early foetal development cysteine, 
glutathione, and glutathione S-transferases are present in high amounts and that GSTP1 is the 
most important GST isoform at these developmental stages.
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Introduction
The family of glutathione S-transferases (GSTs) consists of homo- or heterodimeric cystolic 
proteins composed of subunits with an estimated molecular mass of approximately 25 
kilodaltons (range 23-28 kilodaltons). Today four main subclasses of GST isoforms have been 
recognised in humans: Alpha, Mu, Pi, and Theta (GSTA, GSTM, GSTP, and GSTT), each 
divided into one or more distinct isoforms with different reactivity towards specific 
substrates. Therefore, a diverse expression pattern of GSTs isoforms is seen in the various 
adult tissues. GSTAlpha is mainly expressed in liver but it is also present in kidney, testis, 
adrenal gland, and small intestine (1) whereas GSTPi is mainly expressed in lung, placenta, 
breast, and urinary bladder. GSTM1 and GSTT1 are found in relatively low levels in many 
organs. GSTs catalyse the conjugation of glutathione with a wide variety of xenobiotics such 
as carcinogens and pharmacologically active agents as well as reactive oxygen species. This 
conjugation may result in the formation of more soluble and less biologically active 
compounds, which can easily be excreted in urine (1-5) . The characteristic feature of the 
tripeptide glutathione (y-glutamyl-cysteinylglycine) is the presence of the reactive sulfhydryl 
(-SH) group donated by cysteine, which dictates the chemistry of glutathione. Besides its role 
in detoxification, glutathione is important in storage and transport of amino acids (5).
Embryonic and foetal growth and development depend on a constant flow of nutrients from 
the mother (6 ). During the first weeks of development the embryo exchanges nutrients and 
waste products by diffusion, followed by exchange via the placental intervillous space. 
Despite the large detoxification capacity of the placenta (7;8), almost every drug present in 
the maternal circulation is able to pass the placental barrier and may reach the foetal organs
(9). Therefore, cysteine and glutathione may have a function in foetal detoxification in 
combination with GSTs, which may be vital to scavenge toxic compounds passing the 
placental barrier. Levels of cysteine, glutathione, and distribution of GST isoforms in 
combination with GST enzyme activity have been extensively studied in adult tissues. 
However, little is known about embryonic or foetal tissues, which is subject of this descriptive 
study.
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Materials and Methods
Tissue samples
The Institutional Review Board approved the study protocol. After informed consent was 
obtained stomach, small intestine, liver, kidney, adrenal gland, lung, heart, and testis were 
excised on ice from a male extra-uterine located embryo with gestational age of 8  weeks and a 
crown-rump length of 31 mm (10). Another male foetus with a crown-rump length of 85 mm 
was removed from an uterus and placed on ice, together with samples of decidual and 
placental tissue, from a patient undergoing hysterectomy for cervical cancer. From this foetus 
with a gestational age of 13 weeks oesophagus, stomach, small intestine, liver, spleen, kidney, 
adrenal gland, lung, heart, bladder, testis, brain, and brain stem were excised on ice. 
Gestational ages of both embryo and foetus had been confirmed by ultrasound examination. 
All tissue samples were frozen in liquid nitrogen and stored at -80°C until analysis.
Tissue homogenates were prepared on ice by adding 4 volumes of ice-cold homogenisation 
buffer (0.25 M saccharose, 20 mM Tris/HCl buffer pH 7.4, and 1 mM dithiothreitol). After 5 
strokes using a glass-glass potter tube, homogenates were centrifuged for 1  hour at 1 0 0 ,0 0 0 xg 
and 4 °C. Immediately after centrifugation cytosols were stored in aliquots at -80°C until 
analysis. Protein was determined using the method of Lowry et al. (11) using bovine serum 
albumin as a standard.
Quantification o f glutathione S-transferase isoforms:
Levels of the GST isoforms were determined as described before (12). Samples of the embryo 
and foetus were run in parallel on different blots. In short, cytosolic samples were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis ( 1 2 % acryl-/bisacrylamide w/v, 
37.5:1, Bio-Rad Laboratories, Veenendaal, The Netherlands) and separated under 
standardised conditions. Subsequently, proteins were transferred to nitrocellulose membranes 
(Protran®; Schleicher and Schuell, 's Hertogenbosch, The Netherlands) using a semidry 
blotting system (Novablot II, Pharmacia, Uppsala, Sweden). After blocking with 1% gelatine 
(w/v) in PBS-T, western blots were incubated with monoclonal antibodies (ascites diluted 
1:5,000) against human GST class Alpha (both Ai and A2) (13) GSTMi (14), GSTPi (15) and 
GSTTi (16) as described in detail before. After three wash cycles with PBS-T, specific 
binding of monoclonal antibodies to the isoforms was detected by incubation with peroxidase-
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conjugated rabbit anti-mouse immunoglobulin (Dakopatts, Glostrup, Denmark) followed by 
subsequential development of the peroxidase label with 0.1% 3,3’ diaminobenzidine in PBS 
(Sigma Chemicals, Zwijndrecht, The Netherlands) containing 0.01% hydrogen peroxide 
(Merck, Darmstadt, Germany), 0.34 g/L imidazole (Merck) and 0.26 g/L cobalt-chloride.6H20 
(ICN Biomedicals B.V., Zoetermeer, The Netherlands). Staining intensity on the 
immunoblots was quantified using a laser densitometer (Ultroscan XL, LKB, Bromma, 
Sweden). Quantification of GST isoforms in the cytosolic fractions was performed with 
known amounts of purified GSTs, which were run in parallel with the samples. The detection 
limit of each GST isoform was approximately 50 nmol/mg protein (12), whereas the within- 
assay and day-to-day variation were 10 and 15%, respectively.
Determination o f glutathione S-transferase enzyme activity
Glutathione S-transferase enzyme activity was determined in duplicate according to Habig et 
al. (17). In short, 10 ^L of each cytosolic fraction was added to 2.0 mL 0.1 M potassium 
phosphate buffer pH 6.5 containing 1.0 mM 1-chloro-2,4-dinitrobenzene (CDNB; Sigma 
Chemicals) and 5.0 mM glutathione (Sigma Chemicals) at 25 °C in a disposable cuvette. The 
change in absorbance at 340 nm was followed for 3 mins using a Lambda 12 spectrofotometer 
(Perkin Elmer, Nieuwerkerk a/d IJssel, The Netherlands).
Analysis o f thiols
For the analysis of cysteine, homocysteine, cysteinylglycine and glutathione 10 ^L 10% (w/v) 
tris (2-carboxyethyl) phosphine (Fluka Chemie AG, Bornem, The Netherlands) was added to 
100 ¡^ L of each sample. After reduction for 30 min at room temperature, samples were 
neutralised by adding 75 ^L 2 M NaOH. Subsequently, 100 ^L of the neutralised sample was 
derivatised with 7-fluorobenzofurazane-4-sulfonic acid (SBDF; Fluka Chemie AG) for 1 hour 
at 60°C by adding 60 ^L of derivatizaton buffer containing 50 ^L borate buffer (125 mmol/L 
K2 B4 O7 '4H2O and 4 mmol/L EDTA, pH 9.5), 5 ^L SBDF (4 mg/mL borate buffer), and 5 ^L 
NaOH (1.55 M)). Thiols were separated using high performance liquid chromatography as 
described previously (18). Thiol concentrations were determined using a calibration curve for 
all thiols which was run in parallel with the samples.
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Statistics:
To determine associations between glutathione levels, cysteine levels, glutathione S- 
transferase isoforms, and glutathione S-transferase enzyme activity the Spearman Rank 
coefficient of correlation was calculated using Astute for Microsoft Excel 5.0. An association 
was considered significant if a P-value of 0.05 was reached.
Results
Table 4.1 shows the concentrations in embryonic and foetal tissue of glutathione S-transferase 
Alpha (Ax + A2 : GSTA), Pi (GSTP1 ), Mu (GSTM1 ), and Theta (GSTT1 ). In addition GST 
enzyme activity with CDNB is presented. Due to insufficient amount of material from some 
organs full analyses of all parameters was not possible.
In the embryo of 8  weeks gestation, GSTP1 was the predominantly expressed GST isoform in 
all but one tissue sample. Only kidney mainly expressed GSTA instead of GSTP1. Overall, 
GST was composed of 23% GSTA, 73% GSTP1, and 4% GSTM1. Highest GSTP1 levels were 
seen in lung and stomach, but only in kidney GSTP1 expression was much lower as compared 
to the other organs. The highest expression of GSTA was found in liver, intermediate levels 
were detected in testis, kidney, small intestine and stomach, whereas low levels were found in 
lung and adrenal gland. In heart no GSTA could be demonstrated. The level of GSTM1  
expression was comparable in all tissues studied. In none of the organs GSTT1 could be 
detected, which was supported by the GSTT1 null genotype found by PCR analysis (19). All 
organs showed considerable GST activities towards CDNB, with highest enzyme activity in 
stomach and small intestine.
In the foetus of 13 weeks gestation, GSTP1 was also predominantly expressed in all organs, 
with the highest levels in small intestine, kidney and lung. Most other tissues had high GSTP1  
expression levels, except for spleen, which showed a relatively low level. Overall, GST was 
composed of 26% GSTA, 69% GSTP1, and 5% GSTM1. Highest expression of GSTA was 
seen in liver, small intestine and adrenal gland. Oesophagus showed a moderate expression of 
GSTA, whereas low expression was seen in spleen and lung. No GSTA could be detected in
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brain. GSTMi was mainly present in kidney and in tissues exposed to the amniotic fluid being 
the oesophagus, small intestine and lung.
Table 4.1. Glutathione S-transferase isoform levels and enzyme activity in embryonic and foetal 
organs.
GSTAlpha GSTPi GSTMi GSTT 1 GST- Activity
Embryo (8 wks)
Stomach 1072 8622 325 -- 723
Small intestine 2946 7253 353 -- 635
Liver 3717 6874 674 -- 386
Kidney 2085 531 340 -- 511
Adrenal gland 114 4946 117 -- 389
Lung 165 8812 264 -- 547
Heart -- 6617 341 -- 334
Testis 2961 4210 324 -- 432
Mean 1868 5983 342 -- 495
Foetus (13wks)
Oesophagus 853 6735 764 -- 314
Stomach 2036 4233 433 -- NA
Small intestine 4813 9688 728 -- 882
Liver 4916 7596 398 -- 545
Spleen 263 1159 192 -- 61
Kidney 2144 9670 743 -- 496
Adrenal gland 4519 6159 155 -- 515
Lung 209 9562 907 -- 472
Heart 1897 5420 83 -- 289
Bladder 1265 5622 551 -- 323
Testis NA NA 234 -- NA
Brain -- 4075 412 -- 228
Brainstem 3080 5705 276 -- 144
Mean 2363 6302 444 -- 388
Placenta -- 8059 98 -- 212
Decidua 896 8121 280 1793 268
GST protein levels and enzyme activity are expressed as ng/mg cytosolic protein and nmol/min.mg 
cytosolic protein, respectively.
Abbrev iations -- = Not Detectable, NA = Not Analysed.
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In all other tissues a moderate expression was found with exception of heart, where only faint 
expression of GSTM1 was seen. GSTT1 was not detectable in all foetal organs examined, but 
was found in considerable amounts in decidua. PCR analysis revealed that this foetus also 
bore the GSTT1 null genotype. GST enzyme activity was highest in small intestine, and lower 
levels were seen in liver, adrenal gland, kidney and lung. In the other tissues moderate 
enzyme activities were found, except for spleen where enzyme activity was just measurable.
Both the embryo and foetus showed considerable and similar amounts of acid soluble 
glutathione and cysteine in all organs examined, whereas the levels of cysteinylglycine and 
homocysteine were much lower (Table 4.2). Overall, thiols were composed of 14% cysteine, 
85% glutathione, <1% cysteinylglycine, and <1% homocysteine. Surprisingly, glutathione 
levels in liver tissues are very low, whereas the amount of cysteine is high compared to the 
other organs. In the embryo highest cysteine levels were found in liver and testis, while low 
amounts were shown in kidney and lung compared with the other organs. Glutathione 
concentrations were highest in stomach, lung, heart and kidney compared to the other organs, 
whereas in liver almost no glutathione could be detected. Foetal liver and small intestine 
showed the highest amount of cysteine in comparison with the other foetal tissues. In 
oesophagus and spleen almost no cysteine was detectable. High glutathione was found in 
adrenal gland, heart, brain, and brainstem. Liver, testis and spleen showed the lowest 
glutathione levels.
Expression of GST isoforms in placental and decidual tissue, which was obtained in parallel 
with the foetus, was comparable to that in the foetal organs. Both placenta and decidua mainly 
expressed GSTP1. A relatively high level of GSTT1 was found in decidua, whereas GSTA in 
decidua and GSTM1 in placenta and in decidua were only expressed at relatively low levels. 
GST enzyme activity was similar in placenta and decidua, however activities were lower in 
comparison with that of most foetal organs. In both placenta and decidua thiol levels were 
similar to the levels in most foetal tissues, except for cysteine in decidua where a high level 
was found.
Significant correlations between GST enzyme activity and expression of GSTA (rs=0.61, 
P<0.05), GSTP1 (rs=0.48, P=0.03), and the sum of all GST isoforms (rs=0.59, P=0.005) were 
found in the foetus, whereas in the embryo no such correlations could be found. A significant
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inversed-correlation between cysteine and glutathione was found in the embryo (rs=-0.74, 
P=0.04).
Table 4.2. C ysto lic  th io l concentra tions in em bryon ic and foeta l organs.
Cysteine Homocysteine Cysteinylglycine Glutathione
Embryo (8wks)
Stomach 3.6 0.1 0.1 89.7
Small intestine 4.4 <0.1 1.0 54.3
Liver 30.7 <0.1 0.1 2.0
Kidney 2.5 0.1 0.4 64.5
Adrenal gland 5.9 0.4 1.3 38.7
Lung 2.4 <0.1 0.8 68.0
Heart 5.0 0.2 0.9 77.8
Testis 16.2 0.1 0.1 36.7
Mean 8.8 0.2 0.6 54.0
Foetus (13wks)
Oesophagus 0.8 0.2 0.2 62.8
Stomach 6.7 <0.1 0.1 35.5
Small intestine 15.8 0.3 0.8 50.1
Liver 40.1 0.1 0.1 26.2
Spleen 1.4 <0.1 0.1 30.8
Kidney 8.4 0.1 0.9 57.7
Adrenal gland 5.5 0.3 0.6 105.2
Bladder 5.8 <0.1 0.3 46.2
Lung 6.6 <0.1 0.4 66.9
Heart 10.5 0.2 0.8 81.2
Testis 5.3 0.1 0.4 24.0
Brain 7.2 0.2 0.8 80.1
Brainstem 4.9 0.1 0.3 81.3
Mean 9.2 0.2 0.4 57.5
Placenta 5.8 <0.1 0.1 32.8
Decidua 19.5 0.4 0.2 33.0
Data are expressed in nmol/mg cytosolic protein.
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Discussion
So far, thiol levels and the expression and enzyme activity of glutathione S-transferases in 
foetuses with comparable gestational ages have been described in several studies (Table 4.3). 
Although only data of one embryo and one early foetus are presented here, in contrast to 
earlier studies on development of GSTs, we now present quantitative data on a wide variety of 
tissues, which allows a direct comparison between organs. All tissues examined express 
considerable amounts of cysteine, glutathione, glutathione S-transferases P1, A1 + A2  and M1, 
and show a substantial GST enzyme activity, though in variable range. It was striking, 
therefore, that GSTT1 was not detectable at all in the embryonic and foetal tissues examined, 
but was only demonstrated in decidual tissue of the 13 weeks' pregnancy. Of the GSTTlocus 
a null genotype exists, which has a frequency of 10 to 30% in a normal West-European 
population (20). Both embryo and foetus were of the GSTT1 null genotype and are therefore 
unable to express GSTT1.
Table 4.3. Overview o f foetal G lutath ione S-transferase iso form s and enzyme a c tiv ity  in 
literature.
GSTAlpha GSTP 1 GSTM 1 GST-activity Reference
Liver + ++ -- 260 22
+ ++ -- /+- 23
Spleen + ++ --/+- 23
Kidney + ++ +- 21
-- ++ -- / +- 23
Lung +- ++ + 21
180 25
Brain -- + 43
GST enzyme activity is expressed in nmol/min.mg cytosolic protein.
++: Strong expression, + = normal expression, +- = faint expression, -- = no expression.
Generally, GSTP1 is the predominantly expressed GST isoenzyme in embryonic and early 
foetal organs, whereas expression of GSTA and GSTM1 is moderately and low, respectively. 
These results are in line with those previously reported (21) also indicating that GSTP1 is the 
most important glutathione S-transferase during foetal development.
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In liver a relatively high expression of GSTMi was found, in contrast to results by others 
(22;23), where no or only faint GSTM1 expression could be detected in foetuses of 10 -  20 
weeks of gestation using starch gel electrophoresis. In accordance with these studies we also 
found high levels of GSTA and GSTP1. Also a higher GST enzyme activity was found in both 
the embryo and foetus compared to others (2 2 ), which might be explained by the high 
expression levels of GSTM1. In adult liver GSTA is predominantly expressed (Table 4.4), 
whereas GSTP1 is only seen in bile duct epithelium and blood vessels (24). However, in 
embryonic liver GSTP1 is the most expressed GST isoenzyme. This indicates that expression 
of GSTM1 and GSTA increase during human development, whereas the expression of GSTP1  
decreases, as reported by others (21). These changes in expression levels of GST isoforms 
might also explain the higher GST enzyme activity in adult liver as reported previously (24). 
The different GST isoenzymes expressed in the developing liver and the lower GST enzyme 
activity as compared to adult liver are in agreement with the different functions of embryonic, 
foetal and adult liver. In the developing liver synthesis of erythrocytes is the main function, 
whereas biotransformation of toxic compounds is one of the primary functions of the adult 
liver.
Table 4.4. Glutathione S-transferase isoforms and enzyme activity in adult tissue in literature.
GSTA GSTP 1 GSTMi GST-activity Reference
Oesophagus 456 8511 518 482 32
Stomach 2480 3384 263 331 32
Liver 21840 420 +/- 900 24
Kidney 5750 610 60 610 29
2000 2500 1000 26
347 31
Adrenal gland 3700 2400 1400 26
Lung 300 4500 30 26
53 28
Heart -- 4700 300 26
Bladder -- 1324 2404 176 33
Testis ++ --/+- ++ 2050 44
Brain 200 9800 2100 26
GST isoforms and enzyme activity are expressed in ng/mg cytosolic protein and nmol/min.mg 
cytosolic protein, respectively.
++: Strong expression, + = moderate expression, +- = faint expression, -- = no expression.
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In lung a similar expression of GST isoforms as found by us is described earlier (21); levels 
of GSTP1 were high in early gestation, but decreased during gestation, whereas GSTM1 and 
GSTA were expressed moderate and weak, respectively. During gestation, GST enzyme 
activity decreases in parallel with GSTP1 expression (25). The GST enzyme activity remained 
low in samples obtained more than a year after birth. In adult tissue GSTP1 still is by far the 
most predominant GST isoform (26;27), however the levels are approximately two times 
lower than in foetal tissue. GST enzyme activities were found to be much lower in adult than 
in foetal lung tissue (28;3). When fully functional, the placenta, which has a large 
detoxification capacity (8;7), removes toxic metabolites from foetal circulation. Amniotic 
fluid may also contain toxic metabolites, therefore, tissues exposed to the amniotic fluid like 
those of lung and the gastrointestinal tract might need adaptation to such environment. The 
high level of GSTP1 and high enzyme activity of lung tissue in early gestation both as 
compared with other tissues as well as adult levels, may be such an adaptation.
With exception of the low GSTP1 expression in the embryo, the expression pattern of GST 
isoforms in kidney as reported here were in line with those reported earlier (2 1 ) being high, 
moderate, and faint expression of GSTP1, GSTA and GSTM1, respectively. In contrast to the 
results of others (23), who found that GSTA was absent in foetal kidney, we measured a 
moderate expression of this GST subclass. In foetal kidney, levels of GST isoforms and 
enzyme activity are similar to those found in adult tissue, where the predominantly expressed 
GST isoform is GSTA (26;29-31). This similarity might indicate that GST subclass 
development is an early event of pregnancy.
Very similar results were found in literature for the expression and activity of GST isoforms 
in adult tissue of brain (26), oesophagus and stomach (32) compared with embryonic and 
foetal tissues as reported here. In contrast, values in adult bladder do differ considerably than 
compared to corresponding foetal values (33). These discrepancies and similarities between 
adult and foetal GST capacity may indicate the different development patterns for the various 
foetal organs.
Mean concentrations of cysteine and glutathione are comparable between the embryo and the 
foetus studied. The inverse association between glutathione and cysteine levels in the embryo 
may point to the importance of availability of free cysteine in the synthesis of glutathione or 
the storage function of glutathione (5). Nutritional cysteine is the only -SH containing amino 
acid available for glutathione synthesis in the development due to absence of the
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cystathionine pathway in early gestation (34), which trans sulfurâtes methionine through 
homocysteine into cysteine in adults. Cysteine levels in embryonic and foetal liver were 
higher than those of glutathione, which is in contrast with the levels in most other organs and 
with the situation in adult liver, where glutathione levels are much higher. This may be 
explained by functional differences. One of the main functions of adult liver is its role in 
detoxification, whereas in early gestation liver has mainly a hemopoetic function. It was 
previously reported (35) that only a small fraction of the detected -SH residues in foetal liver 
corresponded to glutathione. Most -SH residues originated from cysteine, which was present 
in higher amounts than glutathione. However, the authors suggested artefacts during sample 
preparation and handling explaining these results, since glutathione can easily be metabolised 
to cysteine after foetal death, due to the presence of high foetal y-glutamyltranspeptidase 
enzyme activity, but they do not rule out the possibility of high cysteine in foetal liver.
As compared to adults, glutathione levels in embryonic and foetal lung and bladder was 
approximately six (36) and two times (37-39) higher, respectively. The results in lung can be 
explained, since glutathione levels might be coupled to the expression of GST isoenzymes 
and enzyme activity, which are very high during early gestation and decrease to a level which 
is two times lower in adults (25;26). This change in expression of glutathione, glutathione S- 
transferase P1 expression, and glutathione S-transferase enzyme activity during gestation 
might be explained by the development of the placenta. In early gestation the placenta is not 
fully developed and subsequently adaptations must be made to prevent damage by toxic 
products, which are preferably excreted to the amniotic fluid. Therefore, tissues exposed to 
the amniotic fluid probably have higher concentrations of glutathione, GSTs and a higher 
enzyme activity. When the placental detoxification starts to function and is able to remove 
waste products from the foetal circulation, this adaptation is not necessary anymore and 
consequently levels of glutathione S-transferase and the enzyme activity may be reduced.
Although placenta and decidua are partly and totally, respectively, from maternal origin both 
tissues probably play an important role in foetal detoxification and protection during growth 
and development. GST enzyme activity in placenta and decidua is comparable to previous 
published values in early pregnancy (40) and term placenta and decidua (7;41;42). However, 
the expression of all GST isoforms found here was much higher compared with the levels 
reported in term placenta and decidua (8 ), which may point to another function of the placenta 
in early gestation as compared with third trimester placenta.
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In placental and decidual tissue similar levels of glutathione were found. Although the 
placental glutathione levels and GST enzyme activity are similar in our study as compared to 
third trimester values, the glutathione level in term decidua seems to be much higher as 
reported earlier (7). Knapen et al. reported a level in decidua, which is approximately 5 times 
higher than in placenta. These results might indicate that decidual GSTs found in early 
gestation have other functions or is not as important as in third trimester pregnancy.
In conclusion, we have shown that early in embryonic and foetal development cysteine, 
glutathione, GST isoforms, and GST enzyme activity are expressed in considerable amounts 
in most tissues examined. In contrast to adult tissue, GSTP1 is the predominant GST isoform 
in embryonic and foetal organs, whereas moderate levels of GSTA and GSTM1 were found in 
comparison with adults, which might point to different functions of GSTs as compared to 
adult tissues.
References
(1) Beckett GJ, Hayes JD. Glutathione S-transferases: Biomedical applications. Adv Clin Chem 
1993; 30:281-389.
(2) Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST* 
and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit 
Rev Biochem Mol Biol 1995; 30:445-600.
(3) Mukhtar H, Zoetemelk CEM, Baars AJ, Wijnen JT, Blankenstein-Wijnen LMM, Meera Khan 
P. Glutathione S-transferase activity in human fetal and adult tissues. Pharmacology 1981; 
22:322-329.
(4) Knapen MFCM, Zusterzeel PLM, Peters WHM, Steegers EAP. Glutathione and glutathione- 
related enzymes in reproduction. A review. Eur J Obstet Gynecol Reprod Biol 1999; 82:171­
184.
(5) Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related 
disease. Nutr Revs 1996; 54:1-30.
(6) Ronzoni S, Marconi AM, Cetin I, Paolini CL, Teng C, Pardi G, Battaglia FC. Umbilical amino 
acid uptake at increasing maternal amino acid concentrations: effect of a maternal amino acid 
infusate. Am J Obstet Gynecol 1999; 181:477-483.
66
Embryonic and foetal thiols and glutathione S-transferases.
(7) Knapen MFCM, Peters WHM, Mulder TPJ, Merkus HMWM, Jansen JBMJ, Steegers EAP. 
Glutathione and glutathione-related enzymes in decidua and placenta of controls and women 
with pre-eclampsia. Placenta 1999; 20:541-546.
(8) Zusterzeel PLM, Peters WHM, De Bruyn MAH, Knapen MFCM, Merkus HMWM, Steegers 
EAP. Glutathione S-transferase isoenzymes in decidua and placenta of preeclamptic 
pregnancies. Obstet Gynecol 1999; 94:1033-1038.
(9) Krauer B, Dayer P. Fetal drug metabolism and its possible clinical implications. Clin 
Pharmacokinet 1991; 21:70-80.
(10) Van Lieshout EMM, Knapen MFCM, Lange WHP, Steegers EAP, Peters WHM. Localization 
of glutathione S-transferase Alpha and Pi in human embryonic tissue at 8 weeks' gestational 
age. Hum Reprod 1998; 13:1380-1386.
(11) Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol 
reagent. J Biol Chem 1951; 193:265-275.
(12) Van Lieshout EMM, Peters WHM. Age and gender dependent levels of glutathione and 
glutathione S-transferases in human lymphocytes. Carcinogenesis 1998; 19:1875-1875.
(13) Peters WHM, Boon CEW, Roelofs HMJ. Expression of drug-metabolizing enzymes and p-170 
glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 1992; 103:448­
455.
(14) Peters WHM, Kock L, Nagengast FM, Roelofs HMJ. Immunodetection with a monoclonal 
antibody of glutathione S-transferase Mu in patients with and without carcinomas. Biochem 
Pharmacol 1990; 39:591-597.
(15) Peters WHM, Nagengast FM, Wobbes T. Glutathione S-transferases in normal and cancerous 
human colon tissue. Carcinogenesis 1989; 10:2371-2174.
(16) Juronen E, Tasa G, Uusküla M, Pooga M, Mikelsaar AV. Production and characterization of 
monoclonal antibodies against class Theta glutathione D-transferase T1-1. Hybrydoma 1996; 
15:77-82.
(17) Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in 
mercapturic acid formation. J Biol Chem 1974; 249:7130-7139.
(18) Raijmakers MTM, Zusterzeel PLM, Steegers EAP, Hectors MPC, Demacker PNM, Peters 
WHM. Plasma thiol status in preeclampsia. Obstet Gynecol 2000; 95:180-184.
(19) Pemble S, Schroeder KR, SpencerSR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. 
Human glutathione S-transferase theta (GSTT1) cDNA cloning and the characterization of a 
genetic polymorphism. Biochem J 1994; 300:271-276.
(20) Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM. Glutathione S-transferase GSTM1 and 
GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch 
Toxicol 1996; 71:123-126.
67
Chapter 4, paragraph 4.1
(21) Beckett GJ, Howie AF, Hume R, Matharoo B, Hiley C, Jones P, Strange RC. Human 
glutathione S-transferases: radioimmunoassay studies on the expression of alpha-, mu- and pi- 
class isoenzymes in developing lung and kidney. Biochim Biophys Acta 1990; 1036:176-182.
(22) Strange RC, Faulder CG, Davis BA, Hume R, Brown JA, Cotton W, Hopkinson DA.The 
human glutathione S-transferases: studies on the tissue distribution and genetic variation of the 
GST1, GST2 and GST3 isozymes. Ann Hum Genet 1984; 48:11-20.
(23) Strange RC, Davis BA, Faulder CG, Cotton W, Bain AD, Hopkinson DA, Hume R. The 
human glutathione S-transferases: developmental aspects of the GST1, GST2, and GST3 loci. 
Biochem Genet 1985; 23:1011-1028.
(24) Mulder TPJ, Roelofs HMJ, Peters WHM, Wagenmans MJM, Sier CFM, Verspaget HW. 
Glutathione S-transferases in liver metastases of colorectal cancer. A comparison with normal 
and primary carcinomas. Carcinogenesis 1994; 15:2149-2153.
(25) Fryer AA, Hume R, Strange RC. The development of glutathione S-transferase and 
glutathione peroxidase activities in human lung. Biochim Biophys Acta 1986; 883: 448-453.
(26) Rowe JD, Nieves E, Listowsky I. Subunit diversity and tissue distribution of human 
glutathione S- transferases: interpretations based on electrospray ionization-MS and peptide 
sequence-specific antisera. Biochem J 1997; 325:481-486.
(27) Anttila S, Hirvonen A, Vainio H, Husgafvel-Pursiainen K, Hayes JD, Ketterer B. 
Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res 
1993; 53:5643-5648.
(28) Clapper ML, Hoffman SJ, Carp N, Watts P, Seestaller LM, Weese JL, Tew KD. Contribution 
of patient history to the glutathione S-transferase activity of human lung, breast and colon 
tissue. Carcinogenesis 1991; 12:1957-1961.
(29) Howie AF, Forrester LM, Glancey MJ, Schlager JJ, Powis G, Beckett GJ, Hayes JD, Wolf 
CR. Glutathione S-transferase and glutathione peroxidase expression in normal and tumour 
human tissues. Carcinogenesis 1990; 11:451-458.
(30) Rodilla V, Benzie AA, Veitch JM, Murray GI, Rowe JD, Hawksworth GM. Glutathione S- 
transferases in human renal cortex and neoplastic tissue: enzymatic activity, isoenzyme profile 
and immunohistochemical localization. Xenobiotica 1998; 28:443-456.
(31) Eickelmann P, Ebert T, Warskulat U, Schulz WA, Sies H. Expression of NAD(P)H:quinone 
oxidoreductase and glutathione S- transferases alpha and pi in human renal cell carcinoma and 
in kidney cancer-derived cell lines. Carcinogenesis 1994; 15:219-225.
(32) Peters WHM, Roelofs HJM, Hectors MPC, Nagengast FM, Jansen JBMJ. Glutathione and 
glutathione S-transferases in Barett' s epithelium. Br J Cancer 199367:1413-1417.
(33) Berendsen CL, Peters WHM, Scheffer PG, Bouman AA, Boven E, Newling DW. Glutathione 
S-transferase activity and subunit composition in transitional cell cancer and mucosa of the 
human bladder. Urology 1997; 49: 644-651.
68
Embryonic and foetal thiols and glutathione S-transferases.
(34) Viña J, Vento M, Garcia Sala F, Puertes IR, Gasco E, Sastre J, Asensi M, Pallardo FV. L- 
cysteine and glutathione metabolism are impaired in premature infants due to cystathionase 
deficiency. Am J Clin Nutr 1995; 61:1067-1069.
(35) Rollins D, Larsson A, Steen B, Krishnaswamy K, Hagenfeldt L, Moldeus P, Rane A. 
Glutathione and gamma-glutamyl cycle enzymes in human fetal liver. J Pharmacol Exp Ther 
1981; 217:697-700.
(36) Cook JA, Pass HI, Iype SN, Friedman N, DeGraff W, Russo A, Mitchell JB. Cellular 
glutathione and thiol measurements from surgically resected human lung tumor and normal 
lung tissue. Cancer Res 1991; 51:4287-4294.
(37) Pendyala L, Velagapudi S, TothK, Zdanowicz J, Glaves D, Slocum H, Perez R, Huben R, 
Creaven PJ, Raghavan D. Translational studies of glutathione in bladder cancer cell lines and 
human specimens. Clin.Cancer Res 1997; 3:793-798.
(38) Singh SV, Xu BH, Tkalcevic GT, Gupta V, Roberts B, Ruiz P. Glutathione-linked 
detoxification pathway in normal and malignant human bladder tissue. Cancer Lett 1994; 
77:15-24.
(39) Giralt M, Lafuente A, Pujol F, Mallol J. Enhanced glutathione S-transferase activity and 
glutathione content in human bladder cancer. Followup study: influence of smoking. J Urol 
1993; 149:1452-1454.
(40) Di Ilio C, Polidoro G, Arduini A, Muccini A, Federici G. Glutathione peroxidase, glutathione 
reductase, glutathione S- transferase, and gamma-glutamyltranspeptidase activities in the 
human early pregnancy placenta. Biochem Med 1983; 29:143-148.
(41) Polidoro G, Di Ilio C, Del Boccio G, Zulli P, Federici G. Glutathione S-transferase activity in 
human placenta. Biochem Pharmacol 1980; 29:1677-1680.
(42) Mutlu-Turkoglu U, Ademoglu E, Ibrahimoglu L, Aykac-Toker G, Uysal M. Imbalance 
between lipid peroxidation and antioxidant status in preeclampsia. Gynecol Obstet Invest 
1998; 46:37-40.
(43) Carder PJ, Hume R, Fryer AA, Strange RC, Lauder J, Bell JE. Glutathione S-transferase in 
human brain. Neuropathol Appl Neurobiol 1990; 16:293-303.
(44) Institoris E, Eid H, Bodrogi I, Bak M. Glutathione related enzymes in human testicular germ 
cell tumors and normal testes. Anticancer Res 1995; 15:1371-1374.
69
Paragraph 4.2
Distribution of components of the glutathione detoxification system 
across the human placenta after uncomplicated vaginal deliveries.
Maarten T.M. Raijmakers, Sophia W.M. Bruggeman, Eric A.P. Steegers, 
Wilbert H.M. Peters.
Placenta 2002; 23:490-496
Chapter 4, paragraph 4.2
Abstract
The function of the glutathione-related detoxification system plays an important role to ensure 
an uncomplicated pregnancy outcome. This study was performed to investigate whether the 
components of the glutathione-related detoxification system are equally distributed among the 
different cotelydons in the human placenta. We measured glutathione, cysteine, glutathione S- 
transferase (GST) isoenzyme levels (GSTA1+A2, GSTP1, GSTM1 and GSTT1), enzyme 
activities of glutathione S-transferase and glutathione peroxidases, protein carbonyl levels, 
and antioxidant capacities at twelve different standardised positions in six placentas from 
healthy women after uncomplicated pregnancy and vaginal delivery. Data were statistically 
evaluated with a Friedman two-way ANOVA with Bonferroni correction. "Foetal"-side values 
were not significantly different from those at the "maternal"-side. Except for GSTA1+A2, no 
significant differences were found between different sampling sites indicating that the 
distribution of all parameters measured was homogenous throughout the placenta. Since 
levels of GSTA1+A2 were minor compared to those of GSTP1 and GSTT1, the clinical 
relevance of this heterogeneity may be limited. These results implicate that the location of 
sampling is not important as long as biopsies are taken from physiological cotelydons.
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Introduction
An optimal maternal-foetal exchange is necessary for a successful pregnancy. Knowledge of 
placental function and anatomy provides insight into normal as well as pathologic pregnancy. 
Several complications of pregnancy including intra uterine growth restriction and 
preeclampsia ( 1 ) seem to be related to poor trophoblast invasion and/or a placental 
insufficiency, which may result in placental ischaemia and oxidative stress (2,3). However, it 
is not yet understood how a reduction in placental perfusion triggers the characteristic 
widespread maternal oxidative stress and endothelial dysfunction responsible for the 
development of severe preeclampsia.
In the defence against oxidative stress, glutathione peroxidases (GPXs) play an important role 
(4,5). They catalyse the reduction of hydrogen peroxide (H2 O2) and organic hydroperoxides, 
thereby simultaneously oxidising glutathione (GSH) (6 ). Two major types of GPX have been 
described: a selenium dependent GPX (SeGPX), which is reactive to both organic 
hydroperoxides and H2 O2, whereas the other group is selenium independent and probably 
mainly consists of glutathione S-transferases (GSTs). This second group of GPXs shows only 
reactivity towards organic hydroperoxides (4,5).
However, the main function of GSTs is the conjugation of GSH to a wide variety of substrates 
making these compounds less biologically active and more water soluble, thus facilitating 
their excretion via urine or bile (7). Human cytosolic GSTs are encoded by at least four 
related gene families constituting of class Alpha, Pi, Mu and Theta. These classes 
comprehend several hetero- or homodimeric isoforms (7). They display strong substrate 
specificity though some substrate overlap may occur. Expression of particular isoenzymes is 
tissue specific and might reflect the presence of certain substrates, representing an adaptive 
mechanism.
In addition to its role in GST and GPX enzyme activity GSH, a tripeptide possessing a 
reactive sulfhydryl group provided by cysteine, has several other functions such as storage 
and transport of cysteine, maintenance of proteins and thiols in a reduced form, and direct 
protection against reactive oxygen species (ROS) (8 ). An overview of glutathione and related 
enzyme system in reproduction is given by Knapen et al. (5).
Placental detoxification seems to play an important role during pregnancy, which was shown 
by the presence of large amounts of GSH, GST isoenzymes and GST and GPX enzyme
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activity (5,9-11). Furthermore, recent data suggest that increased placental oxidative stress, 
measured by elevated levels of protein carbonyls and a lower antioxidant capacity might play 
a role in the development of pregnancy complications like preeclampsia (12). In many studies 
on placental tissue, including those on placental detoxification systems, no details are given 
on the exact site of sampling and whether the parameters under study are equally distributed 
throughout the placenta. The transverse flow of foetal blood flow in a cotyledon towards 
maternal flow in the intervillous space could lead to oxygen tension differences and local 
oxidative stress. Therefore, the expression and function of the above mentioned enzyme 
system could be different in "maternal"- versus "foetal"-side of the placenta. The objective of 
our study was to investigate the distribution of several components of the glutathione related 
detoxification system as well as of markers for oxidative damage and non-enzymatic 
antioxidant capacity across the human placenta after uncomplicated vaginal delivery.
Materials and methods
Tissue samples
The Institutional Review Board of the University Medical Centre Nijmegen approved the 
study protocol. Immediately after delivery, six placentas were collected from healthy women 
with uncomplicated pregnancy outcome. From each placenta six standardised biopsies 
throughout the whole thickness of the placenta were taken and each divided into two samples 
originating from "maternal"- and "foetal"-side of the placenta, as indicated in Figure 4.1. 
Therefore, in total 12 samples of each placenta were analysed. Biopsies were directly frozen 
in liquid nitrogen and samples were stored at -80°C until analysis.
Before analysis, homogenates (20% w/v) were prepared by adding 4 volumes of 
homogenising buffer (0.25 M saccharose, 20 mM Tris/HCl buffer pH 7.4, and 1 mM 
dithiothreitol) to the samples and tissue was homogenised by 5 to 10 strokes at 2500 rpm with 
a motor-driven glass/teflon homogenizer (B. Braun Melsungen AG, Germany). Subsequently, 
homogenates were centrifuged for 75 min at 150,000xg and 4°C (Optima L-70K, Beckmann 
Instruments, Palo Alto, CA, USA) after which supernatant (cytosolic fraction) was stored in 
small aliquots at -30°C or -80°C for the appropriate analysis. Total protein content was
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determined according to the method of Lowry et al. (13) using bovine serum albumin as a 
standard.
Maternal surface
Figure 4.1. A schematic illustration of the human placenta and the regions of which samples 
were obtained. Each placenta was placed on a clean towel in a similar way; with the umbilical cord 
placed downwards and located on upper part of the placenta. Subsequently, six transversal biopsies 
were taken at the indicated places and each was sliced into two pieces of equal size as indicated, 
resulting in twelve biopsies.
Measurement o f non-protein bound glutathione and cysteine 
For the measurement of non-protein bound levels of cysteine (CYS) and GSH, proteins were 
precipitated immediately after ultracentrifugation by adding 1 0 0 ^L 1 2 % perchloric acid to 
10^L cytosol, followed by subsequent mixing and centrifugation for 15 min at 16,000xg and 
4°C. Clear supernatants were stored at -80°C. Concentrations of CYS and GSH were 
determined using the method described earlier (14) using calibration curves for each thiol, 
which were run in parallel with the samples. Cysteine and glutathione concentrations were 
expressed in nmol/mg cytosolic protein.
Quantification o f glutathione S-transferase isoenzymes
Levels of the GST isoenzymes were determined as described before (14) using specific 
antibodies against GST Alpha (GSTA1+A2), Pi (GSTP1), Mu (GSTM1) and Theta (GSTT1). 
For each isoenzyme, the 12 samples from each placenta were quantificated in the same run. 
Amounts of each GST isoenzyme were expressed in ng/mg cytosolic protein. The limit of 
detection of the immunoblot method is approximately 1 0  ng/mg protein.
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Determination o f glutathione S-transferase enzyme activity
Total cytosolic glutathione S-transferase (GST) activity was measured by a 
spectrophotometric assay according to Habig et al. (15), using 1-chloro-2,4-dinitrobenzene 
(CDNB) as a substrate. GST activity was expressed in nmol/min.mg cytosolic protein.
Analysis o f glutathione peroxidase enzyme activity
To measure both selenium dependent (SeGPX) and total glutathione peroxidase (TGPX) 
enzyme activity, the method according to Howie et al. (16) was followed. Cumene 
hydroperoxide and H2 O2  were used as substrates for determination of TGPX and SeGPX 
activities, respectively. Enzyme activities were expressed in nmol/min.mg cytosolic protein.
Placental antioxidant capacity / oxidative stress
Antioxidant capacity of the cytosolic fractions was determined using the "Ferric Reducing 
Ability of Plasma" (FRAP) assay, essentially described by Benzie et al. (17) and adapted for 
tissue cytosol by Zusterzeel et al. (12). Antioxidant capacity was expressed in nmol ferrous 
ion equivalent per mg cytosolic protein.
To determine the amount oxidative protein damage, as marker for oxidative stress, we 
analysed the amount of protein carbonyls using an Enzyme Linked Immunosorbent Assay 
(ELISA) as described by Zusterzeel et al. (12). Carbonyl levels were expressed in nmol/mg 
cytosolic protein.
Statistical analysis
Since almost all parameters examined showed a large intra-individual variation, we tested if 
the between-placenta was larger than the within-placenta variation using the Wilcoxon 
matched-pairs signed rank test. Median between-placenta variation (51%) was larger than the 
within-placenta variation (33%), p=0.003. To correct for this intra-individual variation we 
transformed our data to relative values by calculating the mean of all twelve sites sampled per 
placenta. Individual sites were expressed as a percentage towards this mean. Hereafter, 
relative values of the 6  placentas were grouped per localization. To test for differences 
between "maternal"- and "foetal"-side biopsies the Wilcoxon matched-pairs signed rank test 
was performed, whereas in order to test the homogeneity of each parameter across the 
placenta a Friedman two-way ANOVA was performed to test for differences between the 12
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sites of sampling. A Bonferroni correction was used to correct for multiple testing and 
significance was reached when p< 0 .0 1 .
When appropriate, differences between individual locations were analysed using the 
Wilcoxon matched-pairs signed rank test with Bonferroni correction for multiple testing. 
When p<0.001 differences were considered significant.
Correlations between different parameters were calculated using the Spearman-Rank 
Correlation-Coefficient test. Significance was reached when p<0.05.
Results
Table 4.5 presents the median (range) levels per placenta as measured for glutathione, 
cysteine, glutathione S-transferase isoenzymes, glutathione S-transferase activity, glutathione 
peroxidase activity, antioxidant capacity and protein carbonyls. In Table 4.6 the median 
(range) of the relative values of the above mentioned parameters grouped per sample position 
are given.
No significant difference in any of the parameters investigated were found between 
"maternal"- and "foetal"-side biopsies or any of the sites sampled, except for GSTA1+A2, 
which showed a heterogeneous expression between the 12 sampled sites (P<0.001). However, 
when sample positions were mutually tested to further specify where the difference was 
located, no statistical difference could be found. This indicates that all parameters, except 
GSTA1+A2, were homogeneously distributed along the cotelydons.
Non-protein bound glutathione and cysteine
Median values of glutathione and cysteine between the six placentas varied from 7.8-15.1 and 
0.06-1.48 nmol/mg protein, respectively. A significant correlation was found between the 
amounts of glutathione and cysteine (rs=0.74, p<0.0001).
Glutathione S-transferase isoenzymes
All biopsies contained variable amounts of the four classes of the GST family, except for 
GSTM1 of which no expression was found in placenta B. The median values in the six 
placentas of GSTA1+A2, GSTP1, GSTM1 and GSTT1 varied from 107-276, 354-7113, 0­
131 and 407-1288 ng/mg protein, respectively. GSTP1 was the predominantly expressed
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isoenzyme, followed by GSTT1. Overall, the total GST isoenzyme pool was composed of 
approximately 6 8 % GSTP1, 25% GSTT1, 5% GSTA1+A2 and 2% GSTM1.
Glutathione S-transferase enzyme activity
Median GST enzyme activities in the six placentas varied between 102-289 nmol/min.mg 
protein. GST enzyme activity significantly correlated with the expression of GSTA1+A2 
(rs=0.69, p<0.0001), GSTP1 (rs=0.85, p<0.0001), GSTT1 levels (rs=0.44, p=0.0001) and the 
total sum of the GST isoenzymes (rs=0.72, p<0.0001), whereas, no significant correlation 
between expression levels of GSTM1 and the GST enzyme activity could be found (rs=0.01, 
p=0.90).
Glutathione peroxidase enzyme activity
Median values of the SeGPX enzyme activity of the six placentas varied from 286-409 
nmol/min.mg protein, whereas those of the TGPX enzyme activity ranged from 164-302 
nmol/min.mg protein. A significant correlation was found between SeGPX enzyme activity 
and GSTA1+A2 (rs=0.34, p=0.003), GSTP1 (rs=0.40, p=0.0006), all GST (rs=0.40, p=0.0006) 
isoenzyme levels or GST enzyme activity (rs=0.34, p=0.003). However, neither correlations 
between TGPX enzyme activity and GST isoenzymes nor GST enzyme activity could be 
found.
Placental antioxidant capacity / oxidative stress 
Median levels of the antioxidant capacity were between 
those of the protein carbonyls varied from 2.0-65.5 
correlation could be demonstrated between placental 
carbonyl levels.
Discussion
Non-protein bound glutathione and cysteine 
Our results indicate that the metabolic requirement for these thiols is the same in different 
placental cotyledons. Median (range) glutathione levels in our study were lower as compared 
to the study by Knapen et al. (9); 12.4 (3.3-38.6) versus 25.6 (12.9-49.7) nmol/mg protein,
8.3-20.2 nmol/mg protein, whereas 
nmol/mg protein. No significant 
antioxidant capacity and protein
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respectively, which might be due to the small number of placentas analysed or the fact that 
only placentas after caesarean were used (9).
Malloy et al. (18) assessed total (protein bound as well as free) cysteine levels, but did not 
relate them to the protein content of the tissue and reported higher levels than those in our 
study (190 versus ±50 ¡^mol/L). Since approximately 60 percent of total cysteine is protein 
bound (19,20) these higher levels can thus be explained.
The correlation between levels of cysteine and glutathione may indicate the importance of 
cysteine in glutathione synthesis and of glutathione in the storage of cysteine.
Glutathione S-transferase isoenzymes
Since the expression of GSTP1, GSTT1 and GSTM1 was homogeneous, no special 
requirement for one of these isoenzymes at specific sites in the placenta seems to be needed. 
The predominant expression of GSTP1 (approximately 65% of the total GST content) is 
similar to that in embryonic and early foetal tissue (14) and most other adult tissues, except 
for liver in which GSTAlpha is mainly expressed (7). It was proposed that class Pi 
isoenzymes act in vivo to detoxify a,ß-unsaturated aldehydes and organic peroxides, which 
levels increase during oxidative stress (4,21). It is not known whether these compounds 
represent a major group of substrates for the GSTs in placenta. However, assuming that a 
certain extent of GST isoenzyme expression may result from adaptation to toxic compounds, 
the high GSTP1 levels might indicate presence of oxidative compounds even during 
uncomplicated pregnancies (22,23).
The high median (range) levels of GSTT1, 902 (242 -  2033 ng/mg protein) are in contrast 
with those found by Zusterzeel et al. (10), 183 (0 -  363 ng/mg protein). This discrepancy 
could be due to differences in storage of placental tissue. GSTT1 is a relatively unstable 
enzyme (7) in contrast to the other GSTs quantified here, which showed to be stable up to at 
least two years storage at -20°C (24). In our study placental tissue was stored for two months 
at -80°C, whereas in the study of Zusterzeel et al. it was stored up to three years at -30°C, 
which may have resulted in some breakdown of GSTT1. Little is known about the precise role 
of GSTT1 in foetal and maternal detoxification, however, the high levels of GSTT1 
(approximately 25% of total GSTs) suggest that GSTT1 is important in placental 
detoxification.
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Table 4.5. Glutathione, cysteine, glutathione S-transferase isoenzymes, glutathione S-transferase enzyme activity, glutathione peroxidase enzyme
activity, antioxidant capacity and protein carbonyl levels in the six different placentas (A-F).
A B C D E F
Glutathione 13.2 15.1 14.7 8.1 8.8 7.8
(nmol/mg protein) (3.5-25.8) (3.66-24.7) (8.06-24.0) (3.3-31.4) (3.6-24.9) (4.1-38.6)
Cysteine 0.78 1.48 1.01 0.16 0.29 0.06
(nmol/mg protein) (0.02-2.32) (0-14.4) (0.08-9.28) (0.01-9.52) (0.06-0.97) (0.01-1.43)
GSTA1/GSTA2 120 129 117 107 276 236
(ng/mg protein) (97-219) (53-255) (41 -233) (25-122) (197-366) (163-351)
GSTP1 1151 1839 813 354 7113 3084
(ng/mg protein) (646-1867) (895-4565) (456-2100) (194-1109) (3611 -12486) (1842-5276)
GSTM1 79 131 22 97 12
(ng/mg protein) (50-143) ND (90-196) (8-67) (72-122) (7-38)
GSTT1 407 425 1049 991 973 1288
(ng/mg protein) (275-506) (242-543) (667-1339) (711-1391) (640-1637) (861-2033)
GST activity 160 226 143 102 289 197
(nmol/min.mg protein) (136-193) (161-304) (107-189) (80-123) (214-334) (130-434)
SeGPX activity 286 319 354 356 383 409
(nmol/min.mg protein) (228-341) (289-390) (205-428) (277-518) (333-471) (333-522)
TGPX activity 164 210 282 251 233 302
(nmol/min.mg protein) (140-193) (179-275) (235-325) (208-366) (217-296) (225-405)
Antioxidant capacity 
(nmol/mg protein) 14.2(12.1-20.2)
15.5
(11.6-17.6)
14.2
(8.3-15.0)
12.8
(11.1-14.2)
12.2
(10.8-13.8)
14.4
(12.9-18.2)
Carbonyls 14.0 17.0 20.0 2.0 15.0 65.5
(nmol/mg protein) (8.0-30.0) 6.0-26.0) (1.0-67.0) (0-21.0) (5.0-160) (19.0-382)
Data are presented as median (range) of the 12 biopsies per placenta. ND = not detectable
Table 4.6. Relative contributions per placental biopsy site for glutathione, cysteine, glutathione S-transferase isoenzymes, glutathione S-
transferase activity, glutathione peroxidase activity, and antioxidant capacity and protein carbonyls.
Position 1 2 3 4 5 6 7 8 9 10 11 12
Glutathione
Cysteine
75
(26-144)
8
.... (0-87).....
58
(34-186)
20
(2-271)
95
(44-210)
31
....(9-327)....
75
(30-115)
32
....(5-156)....
74
(34-201)
93
(3-431)
53
(27-120)
19
.....(1-35).....
112
(35-285)
97
(4-764)
134
(49-832)
45
(0-280)
95
(0-143)
60
(0-386)
127
(42-1276)
31
(3-177)
78
(38-262)
155
(8-330)
104
(0-234)
138
(25-348)
GSTA1/GSTA2a 101
(39-135)
81
(71-114)
73
(60-83)
63
(29-103)
73
(42-87)
89
(44-141)
148
(104-170)
130
(80-188)
120
(106-151)
105
(93-139)
96
(87-133)
110
(71-146)
GSTP1 64
(52-138)
80
(65-97)
78
(47-149)
77
(45-129)
89
(42-106)
118
(67-156)
100
(81-159)
93
(76-148)
107
(65-194)
67
(42-158)
91
(62-122)
158
(67-260)
GSTM1 83
(68-159)
85
(62-101)
147
(73-169)
72
(28-246)
66
(45-85)
104
(54-138)
113
(77-220)
94
(78-115)
144
(116-182)
88
(50-149)
101
(81-125)
83
(60-104)
GSTT1 73
(60-129)
90
(77-93)
87
(69-101)
87
(64-107)
90
(62-100)
104
(65-130)
97
(85-125)
100
(72-124)
113 
(98-133)
116
(80-132)
113
(58-158)
118
(113-142)
GST activity 
SeGPX activity
88
(75-117)
106
(89-123)
90
(79-130)
92
(76-117)
94
(75-116)
91
(88-119)
84
(69-100)
98
(88-115)
96
(76-112)
106
(93-142)
112
(84-119)
110
(89-121)
98
(86-113)
103
(79-116)
97
(89-128)
96
(86-107)
111
(101-131)
97
(90-123)
95
(77-124)
87
(59-111)
96
(60-111)
101
(80-109)
111
(102-199)
104
(92-124)
TGPX activity 97
(79-120)
90
(84-105)
97
.. (82-117)..
89
(84-114)
102
(92-142)
110
(98-138)
93
...(77-110)...
92
(81-116)
105
(92-116)
96
(84-105)
101
(86-113)
110 
(102-130)
Antioxidant
capacity
97
(88-116)
101
(87-115)
102
(84-110)
105
(87-116)
110
(93-139)
98
(74-103)
97
(88-113)
100
(92-108)
95
(77-109)
102
(91-112)
102
(69-113)
101
(64-126)
Carbonyls 108
(19-209)
56
(19-119)
35
(15-112)
39
(0-56)
67
(44-115)
119
(4-208)
89
(18-141)
60
(40-174)
98
(23-248)
80
(39-226)
98
(40-163)
254
(52-491)
Data are presented as percentages in medians (range) for the relative contribution of each biopsy site.
Statistics: a P<0.001 (Friedman two-way ANOVA)
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Expression of GSTM1 is low or even absent, therefore, no major contribution to 
detoxification in placental tissue is expected. In addition, lack of GSTM1 expression in 
placenta B, probably due to a GSTM1 null genotype (25), appeared to be consistent with an 
uncomplicated pregnancy.
In contrast with the other GST isoenzymes, expression of GSTA1+A2 was not homogeneous 
throughout the placenta, however, to which extent could not be demonstrated. Presence of 
either foetal or maternal blood in the biopsies could have only slightly influenced these levels, 
since blood hardly contains any GSTAlpha (26,27). Blood could have been removed by 
washing, but this might also influence cytosolic levels of GSTs. Additionally, the amount of 
GSTA1+A2 is relatively low as compared with those of GSTP1 and GSTT1, which may 
diminish the clinical relevance of this finding.
Glutathione S-transferase and glutathione peroxidase enzyme activities 
Our findings confirm the results by McRobie et al. (28) on placental distribution of GST 
enzyme activity at four different locations. GST enzyme activity was comparable to results of 
Polidoro et al. (29) and those reported earlier by our group (9,10). However, Poranen et al. 
(30) reported a much higher GST enzyme activity (12.6 ± 5.1 ¡^mol/min.mg protein) as 
compared to our study and those mentioned above, however, an explanation for this 
discrepancy cannot be given.
The correlation found between GST isoenzyme expression and enzyme activity indicates that 
higher expression of GSTs isoenzymes results in higher enzyme activity. However, the 
correlation between GST enzyme activity towards CDNB and GSTT1 levels was unexpected, 
since CDNB is no substrate for GSTT1 (7). Probably, levels of GSTT1 might be coupled to 
that of other GSTs. Although, GSTM1 has the highest specific activity with respect to CDNB 
(Hayes and Pulford, 1995; Satoh et al., 1995) no correlation between GSTM1 levels and GST 
enzyme activity was found. High levels of GSTP1 and GSTA1+A2, being responsible for the 
majority of the GST enzyme activity, might explain this because low GSTM1 levels 
(approximately 2% of total GSTs) may only slightly contribute.
In line with the other parameters of the GSH related detoxification system both SeGPX and 
TGPX enzyme activities were uniformly distributed throughout the placentas. The TGPX 
enzyme activity was in agreement with that found previously (30), however, both enzyme 
activities of SeGPX and TGPX were higher than found earlier by us (9). The low number of
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placentas investigated or storage conditions, as described above for GSTT1, might be reasons 
for this discrepancy. Unfortunately, no data on the stability of GPX during storage is 
available. Furthermore, in the study by Knapen et al. (9) placentas were obtained after 
caesarean section, whereas here only placentas after vaginal delivery were used. Different 
circumstances, including repeated contractions during an extended period at vaginal birth or 
anaesthesia during caesarean section, might have variable effects on placental oxidative or 
chemical stress. It is likely that during periods of contraction maternal blood flow is 
discontinuous resulting in variable oxygen tension, which may generate placental oxidative 
stress (11). Since GPX provides first line defence against ROS (4), the induction of GPX 
enzymes are an adaptive mechanism to prevent oxidative damage, which was also described 
in placentas from women with preeclampsia (9).
The absence of a correlation between TGPX enzyme activity and GST isoenzyme expression 
is in agreement with the suggestion of Hayes and McLellan (4) that the contribution of 
selenium independent GPX to TGPX enzyme activity is low. In this respect, correlations 
between SeGPX enzyme activity and GSTA1+A2, GSTP1 and total GST isoenzyme levels 
are remarkable. However, since GSTs are able to scavenge ROS and free radicals, GPX 
enzyme activity could be induced in parallel with GST expression.
Placental antioxidant capacity /  oxidative stress
Protein modifications, either caused by direct oxidative attack or by lipid peroxidation 
products, can lead to the formation of protein carbonyls ( 1 2 ), which can be counteracted by 
antioxidants. Therefore, higher protein carbonyl levels or lower antioxidant capacity may 
serve as markers of oxidative stress. Our results indicate that oxidative damage and 
antioxidant capacity are equally distributed throughout the placenta. Protein carbonyl levels 
were higher and antioxidant capacities were lower than those found by Zusterzeel et al. (12) 
in placentas obtained after caesarean section. These data may provide additional evidence for 
the hypothesis that a vaginal delivery results in more placental oxidative stress.
In line with the finding of Zusterzeel et al (12) we could not demonstrate a correlation 
between protein carbonyl levels and antioxidant capacity. This can partially be explained by 
the fact that the FRAP assay does not measure SH-containing antioxidants such as GSH (17), 
which greatly contribute to the antioxidant capacity in placental tissue (9).
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Conclusion
In placentas from uncomplicated pregnancies after vaginal delivery, components of the 
glutathione related detoxification system as well as oxidative stress markers were 
homogeneously distributed at the twelve positions investigated, whereas only GSTA1+A2 
levels seemed to vary. Assuming that in complications of pregnancy only placental function is 
reduced and the physiological structure remains intact, our results implicate that the location 
of sampling placental tissue is not important as long as biopsies are taken from a 
physiological normal cotelydon without infarctions. However, since differences were found in 
placentas obtained after vaginal deliveries and those after caesarean section of previous 
studies for most of the parameters mentioned above, this might indicate higher placental 
oxidative stress during vaginal delivery, therefore, it is important to match for type of 
delivery.
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Abstract
Objective: Data on foetal concentrations of the important thiols cysteine, homocysteine, and 
cysteinylglycine are scarce. We determined reference levels in arterial and venous umbilical 
cord plasma and investigated maternal-foetal interactions of these thiols.
Methodology: Reference levels of cysteine, homocysteine, and cysteinylglycine were 
determined by high performance liquid chromatography in 195 arterial and venous umbilical 
cord plasma samples as well as in 35 corresponding maternal plasma samples.
Results: Median reference levels in ^mol/L (central 0.95 interval) in venous and arterial 
umbilical cord plasma for cysteine, homocysteine and cysteinylglycine are 207 (146 - 299) 
and 203 (134 - 303), 9.6 (4.8 - 17.4) and 8.8 (4.9 - 20.4), and 33 (20 - 50) and 35 (20 - 51), 
respectively. Cysteine and homocysteine levels are significantly lower in arterial versus 
venous samples (p=0.0002 and p=0.009, respectively), whereas levels of cysteinylglycine 
(p=0.005) are higher in arterial umbilical cord. Arterial umbilical cord levels of homocysteine 
(p<0.0001) are lower, whereas venous umbilical cord levels of cysteine (p=0.04) were higher 
and levels of homocysteine (p<0.0001) were lower as compared to maternal concentrations. 
Conclusion: Lower homocysteine and cysteine concentrations in arterial umbilical cord as 
compared to venous levels could implicate that these thiols are used in foetal metabolism. 
Cysteine may be actively transported from maternal to foetal circulation indicating that 
cysteine is an essential amino acid for the foetus.
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Introduction
Aminothiols such as cysteine and homocysteine have important functions in the human body, 
where the presence of the reactive sulfhydryl (-SH) group dictates its chemistry (1). Several 
studies suggested that thiol metabolism is altered during pregnancy. In normal pregnant 
women plasma levels of cysteine and homocysteine are lowered, whereas elevated 
homocysteine and cysteine levels are seen in pathologic conditions such as preeclampsia, in 
which oxidative stress (disturbance of the redox-balance) seems to play an important role 
(2-4).
Thiols may have important physiological functions in foetal metabolism as well. Although 
protein and amino acid turnover in the human placenta have been studied extensively (5-7), 
currently only few data concerning foetal levels of thiols and placental maternal-foetal thiol 
interactions are available (8 ). During normal pregnancy foetal growth depends on a steady 
state supply of nutrients from the mother through the placenta and a clear correlation between 
maternal and foetal amino acid and homocysteine levels was shown (6 -8 ). Decreased levels of 
amino acids in the umbilical artery as compared to umbilical vein have been interpreted as 
uptake of amino acids into foetal tissues where they may be used in protein biosynthesis or as 
source of energy (5).
We studied foetal and maternal thiol plasma concentrations in normal pregnancies in order to 
achieve two aims: i.) to determine reference levels of cysteine, homocysteine, and 
cysteinylglycine in arterial and venous umbilical cord plasma, and ii.) to get more insight into 
maternal-foetal thiol interactions by correlating umbilical cord thiol levels with those of the 
mother.
Materials and Methods
Arterial and venous umbilical cord plasma samples from 320 consecutive neonates were 
drawn immediately after birth in preheparinised 2 mL tubes (no 260545, Kemper Medical 
BV, Uden, The Netherlands) from March 1997 to January 1998 at the Department of 
Obstetrics and Gynecology of the ‘Nij Smellinghe’ Hospital, Drachten, The Netherlands, of
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which the Institutional Review Board approved the study protocol. A small volume was used 
for the assessment of blood gas values on an ABL-330 analyzer (Radiometer Nederland BV, 
Zoetermeer, The Netherlands). Samples with a difference between arterial and venous pH 
smaller than 0.02 pH units or neonates born from women with a diastolic blood pressure 
during gestation above 90 mmHg, an umbilical artery pH below 7.20, a birth weight below 
the 10th percentile according to Kloosterman (9), or a gestational age of less than 37 weeks 
were excluded from the study. In parallel with the umbilical cord samples antecubital 
maternal venous blood samples were collected after informed consent was given. Samples 
were taken in sitting position after 5 min of rest in 5 mL heparinised tubes (no 367684, 
Becton and Dickinson, Leiden, The Netherlands), either less than 4 hours before elective 
caesarean delivery or less than 15 minutes after vaginal birth. Umbilical cord and maternal 
blood was centrifuged within 10 min at 1,200xg for 10 min at room temperature. Both 
umbilical and maternal plasma samples were stored at -30°C until analysis. Plasma levels of 
cysteine, homocysteine, and cysteinylglycine in 195 umbilical cord (102 males / 92 females; 
no gender was recorded from 1 neonate) and 35 maternal samples were determined by high 
performance liquid chromatography as described previously (2 ).
After log transformation to approach normalization, data were analysed by the paired t-test in 
order to assess statistical differences between maternal, venous and arterial umbilical cord 
values. The Spearman rank coefficient of correlation was calculated when appropriate using 
Astute for Microsoft Excel 5.0. A p-value less than 0.05 was considered significant.
Results
Both maternal characteristics studied (age, gestational age, blood pressure, birth weight, and 
placental weight) and blood gas values (pO2, pHCO3-, pH, base deficit, and pCO2) are 
representative of the population as admitted for term deliveries in the ‘Nij Smellinghe’ 
Hospital. The characteristics of the subgroup (n=35) were not statistically different from the 
total study group.
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Levels of cysteine and homocysteine are significantly lower in arterial as compared to venous 
umbilical cord plasma (p=0.0002 and p=0.009, respectively), whereas levels of 
cysteinylglycine are significantly higher (p=0.005), Table 5.1.
Table 5.1. Thiol levels in umbilical cord plasma (n=195).
Venous Arterial P-level
Cysteine 207 (146 - 299) 203 (134 - 303) 0.0002
Homocysteine 9.6 (4.8 - 17.4) 8.8 (4.9 - 20.4) 0.009
Cysteinylglycine 33 (20 - 50) 35 (20 - 51) 0.005
Notes: Data are presented as medians (central 0.95 interval) in |jmol/L.
In the sub-population of 35 cases, venous maternal cysteine levels are lower than those in 
venous umbilical cord (p=0.04), whereas there was a tendency for higher cysteine levels in 
venous umbilical cord compared with arterial levels (p=0.06), Figure 5.1. Also arterial 
umbilical cord cysteine tended to be higher than maternal concentrations, however, no 
significant difference was found (p=0.1). A positive correlation was found between levels of 
cysteine in maternal and venous umbilical cord plasma (r=0.84, p<0.0001), venous and 
arterial umbilical cord (r=0.82, p<0 .0 0 0 1 ), and arterial umbilical cord and maternal plasma 
(r=0.81, p<0 .0 0 0 1 ).
Homocysteine showed a decreasing concentration gradient from maternal to venous and 
arterial umbilical cord plasma (p=0.001 and p=0.04, respectively). This gradient resulted in a 
significant lowered level of homocysteine in arterial umbilical cord plasma as compared with 
maternal plasma (p<0.0001). Levels of homocysteine were positively correlated between 
maternal and venous umbilical cord, venous and arterial umbilical cord, and arterial umbilical 
cord and maternal plasma (r=0.83, p<0.0001; r=0.82; p<0.0001; r=0.79, p<0.0001; 
respectively). No correlations were found between maternal, arterial and venous umbilical 
cord homocysteine levels and neonatal weight (r=0.07, p=0.9; r=0.12, p=0.1; and r=0.0076, 
p=0.9; respectively).
No significant differences were found for cysteinylglycine levels between maternal and 
umbilical venous or arterial samples. However, a positive correlation was found between 
levels of cysteinylglycine in the umbilical artery and the umbilical vein (r=0.59, p<0.001).
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P-values:
CYS : 0.1 
HCY : 0.001 
C G S: NS
Maternal:
CYS : 176 (105 -292) 
HCY: 9.8 (5.1 -  34) 
CGS : 32 (19 -  51)
Arterial:
CYS : 181 (101 -  263)
HCY: 7.8 (3.6 -  23.8)
CGS : 33 (9 -49)
P-values:
CYS : 0.06 
HCY : 0.04 
CGS : NS
P-values:
CYS : 0.001 
HCY : 0.001 
C G S: NS
Venous:
CYS : 191 (97 -  266) 
HCY: 8.4 (3.2 -  23.5) 
CGS : 32 (98 -  47)
Figure 5.1. Maternal and corresponding venous and arterial umbilical cord plasma thiol levels 
(n=35). Data are presented as median (central 0.95 interval) in |jmol/L. Abbreviations: CYS = cysteine, 
HCY = homocysteine, CGS = cysteinylglycine, and NS = non-significant.
Discussion
Plasma samples analysed here are from pregnancies with uncomplicated outcome and 
consequently the values for cysteine, homocysteine, and cysteinylglycine in neonates can be 
used as reference levels.
Levels of cysteine and homocysteine are lower in arterial umbilical cord plasma as compared 
to venous levels, indicating the uptake of both thiols into foetal circulation, where they may 
be used in the biosynthesis of glutathione and protein. Homocysteine passes the maternal- 
foetal barrier through a decreasing concentration gradient. In contrast, cysteine is transported 
from maternal to foetal side against a concentration gradient, probably by an active transport
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mechanism. Cysteine needs to be taken up in this way by the foetus, because homocysteine 
cannot be converted to cysteine in the foetus due to the absence of cystathionine-ß-synthase, 
the enzyme that converts homocysteine to cysteine in adults ( 1 0 ).
Homocysteine values are higher as compared with those in Northern American population 
(8,11), which might be explained by a higher intake of folate and B vitamins in the American 
populations as discussed earlier by den Heyer et al. (12). However, maternal levels in this 
study were comparable (p=0.45) to those previously reported in another study group (2), 
where we also presented that non-pregnant values of plasma thiols were higher as compared 
to corresponding values in normal pregnancy, most probably due to an increased plasma 
volume in pregnancy (2 ).
In summary; cysteine, which is an essential amino acid in the human foetus may be actively 
transported in the placenta from the maternal to the foetal circulation, where it is used in 
biosynthesis processes. Similarly, the foetus may extract homocysteine from the maternal 
circulation.
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Umbilical glutathione levels are higher after vaginal birth than after 
cesarean section.
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Abstract
Objective(s): The primary goals of our study were to establish reference levels for glutathione 
in arterial and venous umbilical plasma and to investigate possible differences between 
vaginal delivery and delivery by cesarean section.
Study design: Glutathione levels were assessed in both arterial and venous umbilical plasma 
samples of neonates after vaginal delivery (n=140) or after delivery by cesarean section 
(n=38). From a subset of women who delivered vaginally, also maternal plasma glutathione 
levels (n=14) were measured.
Results: Both median (5th-95th percentile) glutathione levels in venous as well as arterial 
umbilical samples were higher after vaginal delivery compared with cesarean section, 2.7 
(0.9-7.3) versus 2.0 (0.6-11.5) ^mol/L (P<0.03) and 3.5 (0.6-22.7) versus 2.3 (0.7-24.3) 
^mol/L (P<0.02), respectively. Maternal glutathione levels were higher, 7.8 (4.3-10.6) 
^mol/L, as compared to both venous (P<0.001) and arterial (P<0.02) umbilical levels of their 
offspring.
Conclusion: Since during oxidative stress high amounts of oxidised glutathione may be 
excreted from the erythrocyte, the higher umbilical glutathione levels after vaginal delivery 
suggests that vaginal delivery is associated with higher oxidative stress than delivery by 
cesarean section.
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Introduction
The presence of the reactive sulfhydryl (-SH) group dictates the chemistry of aminothiols 
such as cysteine, homocysteine and glutathione (1). In humans, glutathione has several 
important functions. Besides storage and transport of amino acids, glutathione plays an 
important role in detoxification of toxic compounds by action of glutathione S-transferases 
and in scavenging of free radicals and reactive oxygen species by action of glutathione 
peroxidases. By the latter process glutathione is important in the maintenance of the cellular 
redox balance (1,2). Several studies suggested that glutathione metabolism is altered during 
pregnancy. In normal pregnancy plasma levels of glutathione are lower as compared to those 
in the non-pregnant state, whereas even lower levels are seen in gestational complications 
including preeclampsia, in which oxidative stress (disturbance of the redox-balance) seems to 
play an important role (3-6).
Foetal growth depends on a continuous supply of nutrients from the mother through the 
placenta and a clear correlation between levels of maternal and foetal amino acids was 
demonstrated (7-9). Lower levels of amino acids in the umbilical artery as compared to the 
umbilical vein have been interpreted as uptake of amino acids into foetal tissues, where they 
may be used in protein biosynthesis or as source of energy (10). Drugs and other toxic 
compounds are able to pass the placental barrier. Therefore, besides the storage and transport 
of amino acids, glutathione may have important physiological functions in foetal 
detoxification (11). Although protein- and amino acid turnover in the human placenta has 
been studied extensively (7-10), no data on glutathione concentrations and placental-maternal 
glutathione interactions are available yet. In a previous study we hypothesised that repeated 
contractions for a prolonged period may lead to more placental oxidative stress during vaginal 
delivery as compared with delivery by cesarean section (12). Therefore, we studied foetal and 
maternal glutathione plasma concentrations in normal pregnancies after vaginal and cesarean 
deliveries in order to a) define reference levels of glutathione in arterial and venous umbilical 
cord plasma, b) to investigate possible differences between vaginal and cesarean deliveries, 
and c) to study maternal-foetal thiol interactions by correlating umbilical cord glutathione 
levels with those of the mother.
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Materials and Methods
Arterial and venous umbilical cord plasma samples from 320 consecutive neonates were 
drawn immediately after birth in preheparinised 2 mL tubes (Kemper Medical BV, Uden, The 
Netherlands) from March 1997 to January 1998 at the Department of Obstetrics and 
Gynecology of the ‘Nij Smellinghe’ Hospital, Drachten, The Netherlands (13). The 
Institutional Review Board approved the study protocol. Samples of neonates born from 
women with gestational diabetes or other complications of pregnancy, a diastolic blood 
pressure during gestation above 90 mmHg, a gestational age less than 37 or more than 42 
weeks, an umbilical artery pH below 7.20, or a birth weight below the 10th or above the 90th 
percentile according to Kloosterman (14), were excluded from the study. A small volume was 
used for the assessment of blood gas values on an ABL-330 analyzer (Radiometer Nederland 
BV, Zoetermeer, The Netherlands). When the difference between arterial and venous pH was 
smaller than 0.02 pH units, samples were excluded from further analysis. In parallel with the 
umbilical cord samples, antecubital maternal venous blood samples of 14 women, who 
delivered vaginally, were collected after informed consent was given (15). Maternal samples 
were taken in sitting position after 5 min of rest in 5 mL heparinised tubes (Becton and 
Dickinson, Leiden, The Netherlands) less than 15 minutes after vaginal birth. Umbilical and 
maternal blood was centrifuged within 10 min at 1,200xg for 10 min. Plasma was stored at - 
30°C until analysis.
Table 5.2. Population characteristics.
Cesarean Section 
(n=38)
Vaginal delivery 
(n=140)
Maternal age (years) 29 (20 -  40) 29 (21 -  37)
Gestational age (weeks+days) 40+2 (38+3 -  42+0) 40+1 (37+5 -  41+6)
Parity 1 (0 -  2) 1 (0 -  3)
Diastolic blood pressure (mmHg) 80 (60 -  90) 78 (67 -  85)
Male offspring (number) 25 (63%) 76 (54%)
Birth weight (gram) 3490 (3094 -  3950) 3244 (2850 -  4055)
Placental weight (gram) 665 (525 -  810) 673 (500 -  875)
Data are presented as medians (5th -  95th percentiles)
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Umbilical and maternal total glutathione levels in plasma (i.e. protein bound, reduced and 
oxidised non-protein bound glutathione) of 180 and 14 subjects respectively were determined 
by high performance liquid chromatography as described previously (3). Umbilical cord 
samples were divided into two groups, samples obtained after cesarean section (n=38) and 
samples collected after vaginal delivery (n=140) of which the characteristics are depicted in 
Table 5.2 and Table 5.3.
Table 5.3. Blood gas parameters in umbilical cord after cesarean section and vaginal delivery.
Cesarean Section 
(n=38)
Vaginal delivery 
(n=140)
Venous:
pO2 (kPa) 28 (16-40) 27 (16 -  39)
pCO 2  (kPa) 43 (35 -  58) 39 (32 -  50)
HCO3- (mmol/L) 20 (16 -  23) 20 (16 -  23)
pH 7.33 (7.23 -  7.38) 7.34 (7.22 -  7.42)
BD -4.0 (-8.1 -  -0.9) -4.4 (-9.0 -  -1.1)
Arterial:
pO 2  (kPa) 15 (9 -  31)1 18 (10 -  32) 1
pCO 2  (kPa) 53 (41 -  64) 1 53 (38 -  68) 1
HCO3- (mmol/L) 20 (15 -  23) 2 19 (15 -  23) 1
pH 7.27 (7.15 -  7.33) 1 7.26 (7.11 -  7.36) 1
BD -4.4 (-11.8 -  -0.5) -4.9 (-12.0 -  -1.6) 1
Data are presented as medians (5th -  95th percentiles). Abbreviations used: BD, base deficit
Statistics:
1 P<0.0001 and 2 P<0.001 venous versus arterial umbilical cord
To assess differences between vaginal birth versus cesarean section, different type of vaginal 
delivery, elective cesarean section versus cesarean section during labor, or anesthetics used 
during cesarean section the Wilcoxon-Mann-Whitney test was performed. Statistical 
differences in glutathione levels and blood gas parameters between arterial and venous 
umbilical samples as well as differences in maternal, venous and arterial umbilical cord 
values of glutathione in the subgroup with vaginal deliveries were assessed with the Wilcoxon 
matched-pairs signed-ranks test. The Spearman rank coefficient of correlation was calculated 
when appropriate. All statistical tests were performed with Astute for Microsoft Excel 5.0. A 
P-value less than 0.05 was considered statistically significant.
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Results
The characteristics of the population studied are representative for the population as admitted 
for term deliveries after uncomplicated pregnancies at the ‘Nij Smellinghe’ Hospital (Table
5.2). In the group with vaginal deliveries 42 neonates were born either by forceps (n=26) or 
vacuum extraction (n=16). The type of extraction did not significantly influence the results. 
Cesarean sections (n=38) were performed electively (n=15), without prior contractions, for 
breech presentation (n=1), cephalo-pelvic disproportion (n=8 ), repeat cesarean section (n=5) 
and neonatal auto-immune trombocytopenia (n=1), and during labor (n=23) for foetal distress 
(n=4), breech presentation (n=2), failure to progress during the first (n=9) or second stage 
(n=8 ). No differences in umbilical glutathione concentrations or blood gas values were found 
between elective cesarean sections compared with those during labor. Type of anesthesia 
(spinal (n=23), epidural (n=1) or general anesthesia (n=15)) during cesarean section did not 
influence glutathione levels. No statistical differences in population characteristics were 
found between women who delivered either vaginally or by cesarean section (Table 5.2). The 
characteristics of the subset of women who delivered vaginally, of whom also maternal 
plasma was analysed, were not statistically different from the total group of women with 
vaginal deliveries.
In neonates born after cesarean section, the following umbilical blood gas values (see Table
5.3) were significantly higher in venous as compared to arterial samples: pO2  (P<0.0001), 
HCO3- (P<0.001) and pH (P<0.0001), whereas pCO2  was lower (P<0.0001). After vaginal 
delivery the following parameters were significantly higher in venous than in arterial 
umbilical samples: pO2  (P<0.0001), HCO3- (P<0.0001), base deficit (P<0.0001), and pH 
(P<0.0001), whereas pCO2  (P<0.0001) was lower.
Levels of glutathione in both venous and arterial umbilical plasma (Table 5.4) were higher 
after vaginal compared with cesarean delivery, 2.7 (0.9 -  7.3) versus 2.0 (0.6 -  11.5) ^mol/L 
(P<0.03) and 3.5 (0.8 -  18.7) versus 2.3 (0.7 -  24.3) ^mol/L (P<0.02), respectively. After 
vaginal delivery median arterial umbilical concentrations of glutathione were higher as 
compared with those in venous umbilical cord (P<0.0001), whereas no statistical differences 
between arterial and venous umbilical samples were found after cesarean delivery. Maternal 
levels of glutathione, 7.8 (0.6 -  22.7) ^mol/L, were higher as compared to both venous, 2.6
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(0.9 -  7.3) ¡jmol/L (P<0.001), and arterial, 3.6 (0.6 -  22.7) ^mol/L (P<0.02), umbilical 
samples.
Table 5.4. Glutathione concentrations in umbilical and maternal plasma.
n Venous Arterial Maternal
Cesarean Delivery 39 2.0 (0.6 - 11.5) 2.3 (0.7 -  24.3)
Vaginal Delivery 140 2.7 (0.9 -  7.3)1 3.5 (0.8 -  18.7)2,3
Vaginal Subgroup 14 2.6 (0.9 - 7.3)4 3.6 (0.6 - 22.7)5 7.8 (4.3 - 10.6)
Values are given as |jmol/L; median (5th -  95th percentile)
1 P < 0.03 and 2 P < 0.02 cesarean versus vaginal delivery
3
P < 0.0001 venous umbilical versus arterial umbilical plasma.
4 P < 0.001 venous umbilical versus maternal plasma 
P < 0.02 arterial umbilical versus maternal plasma
Levels in venous and arterial umbilical cord plasma showed a positive correlation after both 
vaginal and cesarean deliveries (rs=0.71, P<0.0001 and rs=0.59, P<0.0001, respectively). 
However, in the smaller subgroup of vaginal deliveries no significant associations were found 
between maternal plasma levels and those in both arterial and venous umbilical cord (rs=0.45, 
P=0.1 and rs=0.32, P=0.3, respectively). Gestational age or blood gas parameters did not 
correlate with glutathione levels in umbilical samples of both cesarean and vaginal deliveries. 
Furthermore, neither significant associations between the duration of the first stage nor 
second stage of labor and the levels of glutathione could be found in both arterial (rs=0.06, 
P=0.5 and rs=-0.09, P=0.3, respectively) and venous umbilical samples (rs=0.15, P=0.1 and 
rs=-0.04, P=0.7, respectively) in the group of women with vaginal delivery.
Comment
Foetal glutathione concentrations were studied only in pregnancies with uncomplicated 
outcome, therefore the values presented here can be used as reference levels in neonates after 
vaginal or cesarean deliveries.
To our knowledge this is the first study that describes differences in arterial as well as venous 
umbilical glutathione concentrations between vaginal and cesarean deliveries. Both arterial
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and venous levels of glutathione were found to be higher in umbilical samples taken from 
neonates after vaginal delivery compared with those after cesarean delivery. Furthermore, 
after vaginal delivery, but not cesarean section, arterial umbilical glutathione concentrations 
were higher than those in venous umbilical samples. These results might indicate that vaginal 
delivery is characterised by a higher level of oxidative stress as compared with cesarean 
delivery. In vaginal deliveries, the repeated contractions or the expulsion period may lead to 
differences in the oxygen tension of the foetal-placental unit, which probably causes local 
oxidative stress.
In periods of oxidative stress, characterised by the presence of high levels of reactive oxygen 
species (ROS), glutathione may by oxidised to glutathione disulfide by glutathione peroxidase 
in order to scavenge ROS (1,2). Subsequently, oxidised glutathione may be converted into 
reduced glutathione again by glutathione reductase, thereby consuming NADPH. Both 
enzymes were shown to be present during foetal development (16-18). However, when high 
amounts of oxidised glutathione are produced during extended periods of oxidative stress the 
erythrocyte may excrete oxidised glutathione in order to maintain intracellular redox-balance, 
which may result in higher glutathione levels in plasma (19). In this way the higher level in 
umbilical arterial plasma may be explained.
We could not demonstrate significant differences between umbilical glutathione levels in 
normally delivered neonates and that of neonates delivered by forceps or vacuum extraction. 
However, the similar glutathione levels in elective cesarean section and those found in 
cesarean section during labor, suggest that oxidative stress assumable arises during the second 
stage of vaginal delivery. Furthermore, absence of a correlation between venous and arterial 
umbilical glutathione levels with duration of first and second stage of labor may suggest that 
the physiological process of vaginal birth is associated with (local) oxidative stress and not 
the duration of delivery.
We previously showed that in placental tissue obtained after vaginal delivery the expression 
levels and enzyme activity of glutathione S-transferases and glutathione peroxidase were 
higher compared to those after cesarean section ( 1 2 ), which is in accordance with the above 
presented findings.
In the transport of amino acids across the placental basal and microvillous membranes, 
several distinctive transport systems have been characterised leading to a number of different 
metabolic pathways in which amino acids are utilised in the placenta (7). However, a 
placental transport system for glutathione has not yet been described. Venous umbilical levels
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are lower than those in arterial umbilical plasma, whereas maternal concentrations are higher 
than those in both arterial and venous umbilical cord. Additionally, no association was found 
between maternal and umbilical glutathione concentrations. Therefore, maternal glutathione 
probably is not able to pass the placental barrier into the foetal circulation. Besides direct 
transport of amino acids, protein breakdown and direct synthesis of amino acids play an 
important role in placental transport processes. Breakdown of glutathione to its amino acids 
might be important since glutamate is an essential fuel for the placenta (7). On the membranes 
of most endothelial cells, including the microvillous membrane of throphoblast cells, y- 
glutamyl transpeptidase is present ( 1 ,2 0 ), which initiates the breakdown of glutathione to 
glutamate and cysteinylglycine, which is further metabolised by the enzymes of the y- 
glutamyl cycle (1,21). Cysteine and glycine might be released into the foetal circulation by 
placental transport and this may result in foetal synthesis of glutathione. Thus, the foetus may 
be able to synthesize glutathione instead of taking it up from the maternal circulation.
In summary, we presented reference values for glutathione in arterial and venous umbilical 
cord plasma after vaginal as well as cesarean deliveries. In addition, vaginal delivery may be 
associated with higher levels of oxidative stress during the second stage of labor as compared 
with delivery by cesarean section. Furthermore, our data suggest that maternal glutathione is 
not transported into the foetal circulation, but the foetus itself may be capable to synthesize 
glutathione.
References
(1) Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related 
disease. Nutr Rev 1996;54:1-30.
(2) Knapen MFCM, Zusterzeel PLM, Peters WHM, Steegers EAP. Glutathione and glutathione- 
related enzymes in reproduction. A review. Eur J Obstet Gynecol Reprod Biol 1999;82:171- 
184.
(3) Raijmakers MTM, Zusterzeel PLM, Steegers EAP, Hectors MPC, Demacker PNM, Peters 
WHM. Plasma thiol status in preeclampsia. Obstet Gynecol 2000;95:180-184.
(4) Knapen MFCM, Mulder TPJ, Van Rooij IALM, Peters WHM, Steegers EAP. Low whole 
blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, 
elevated liver enzymes, low platelets syndrome. Obstet Gyn 1998;92:1012-1015.
105
Chapter 5, Paragraph 5.2
(5) Kharb S. Low whole blood glutathione levels in pregnancies complicated by preeclampsia and 
diabetes. Clin Chim Acta 2000;294:179-183.
(6) Davidge ST. Oxidative stress and altered endothelial cell function in preeclampsia. Semin 
Reprod Endocrinol 1998;16:65-73.
(7) Battaglia FC, Regnault TRH. Placental transport and metabolism of amino acids. Placenta 
2001;22:145-161.
(8) Ronzoni S, Marconi AM, Cetin I, Paolini CL, Teng C, Pardi G, Battaglia FC. Umbilical amino 
acid uptake at increasing maternal amino acid concentrations: effect of a maternal amino acid 
infusate. Am J Obstet Gynecol 1999;181:477-483.
(9) Malinow MR, Rajkovic A, Duell PB, Hess DL, Upson BM. The relationship between maternal 
and neonatal umbilical cord plasma homocyst(e)ine suggests a potential role for maternal 
homocyst(e)ine in fetal metabolism. Am J Obstet Gynecol 1998;178:228-233.
(10) Chien PF, Smith K, Watt PW, Scrimgeour CM, Taylor DJ, Rennie MJ. Protein turnover in the 
human fetus studied at term using stable isotope tracer amino acids. Am J Physiol 
1993;265:E31-E35.
(11) Raijmakers MTM, Steegers EAP, Peters WHM. Glutathione S-transferases and thiol levels in 
embryonic and early fetal tissues. Hum Repr 2001;16:2445-2451.
(12) Raijmakers MTM, Bruggeman SWM, Steegers EAP, Peters WHM. Distribution of 
components of the glutathione detoxification system across the human placenta after 
uncomplicated vaginal deliveries. Placenta 2002; in press
(13) Raijmakers MTM, Roes EM, Steegers EAP, Van der Wildt B, Peters WHM. Umbilical cord 
and maternal plasma thiol concentrations in normal pregnancy. Clin Chem 2001;47:749-751 .
(14) Kloosterman GJ. On intrauterine growth. The significance of prenatal care. Int J Gynaecol 
Obstet 1970;8:175-177.
(15) Knapen MFCM, van der Wildt B, Sijtsma EG, Peters WHM, Roelofs HMJ, Steegers EAP. 
Glutathione S-transferase Alpha 1-1 and aminotransferases in umbilical cord blood. Early 
Hum Dev 1999;54:129-135.
(16) Qanungo S, Sen A, Mukherjea M. Antioxidant status and lipid peroxidation in human feto­
placental unit. Clin Chim Acta 1999;285:1-12.
(17) Buonocore G, Berni S, Gioia D, Bracci D. Characteristics and functional properties of red 
cells during the first days of life. Biol Neonate 1991;60:137-143.
(18) Arikan S, Konukoglu D, Arikan C, Akcay T, Davas I. Lipid peroxidation and antioxidant 
status in maternal and cord blood. Gynecol Obstet Invest 2001;51:145-149.
(19) Uhlig S, Wendel A. The physiological consequences of glutathione variations. Life Science 
1992;51:1083-1094.
106
Foetal oxidative stress during delivery.
(20) Iioka H, Moriyama I, Kyuma, Akasaki M, Katoh Y, Itoh K, Saitoh M, Hino K, Okamura Y, 
Itani Y. Human placental glutathione transport mechanism. Nippon Sanka Fujinka Gakkai 
Zasshi 1987;39:725-730
(21) Meister A. Glutathione metabolism and its selective modification. J Biol Chem 
1988;263:17205-17208.
107
Part III
Thiol status in hypertensive disorders
of pregnancy
Chapter 6
Plasma thiol status in preeclampsia.
Maarten T.M. Raijmakers, Petra L.M. Zusterzeel, Eric A.P. Steegers, 
Magda P.C. Hectors, Pierre N.M. Demacker, and Wilbert H.M. Peters.
Obstetrics & Gynecology 2000; 95:180-184.
Chapter 6
Abstract
Objective: To measure plasma thiol levels in control women, uncomplicated pregnant women 
and women with preeclampsia, in order to define their role in the glutathione homeostasis and 
in the pathophysiology of preeclampsia.
Methods: Total plasma cysteine, y-glutamylcysteine, homocysteine, cysteinylglycine, and 
glutathione levels were measured in ten non-pregnant women, ten women during 
normotensive pregnancy, and twenty women during preeclampsia at the time of delivery. 
Results: Median total plasma levels of all thiols in the normotensive pregnant women were 
significantly lower than in non-pregnant women. Median total plasma cysteine and 
homocysteine levels in the women with preeclampsia were significantly higher compared to 
those in pregnant controls (254 versus 190 ^mol/L, P<0.001; and 13.3 versus 8.4 ^mol/L, 
P<0.02, respectively), whereas glutathione levels were significantly lower in women with 
preeclampsia as compared to those in pregnant controls (5.1 versus 6.3 ^mol/L, P<0.05). 
Conclusion: In women with preeclampsia homocysteine and cysteine levels, which are 
lowered in normotensive pregnancy, are comparable to levels in non-pregnant women, 
whereas glutathione levels are lower. These results suggest that in women with preeclampsia 
glutathione utilization is higher or its synthesis is disturbed. Therefore, glutathione may play a 
role in the pathophysiology of preeclampsia.
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Introduction
Preeclampsia is a multisystem disorder that affects about 3% of the primigravida mostly after 
20 weeks of gestation. It is classically defined by hypertension and proteinuria (1) In severe 
cases preeclampsia might be complicated by the hemolysis, elevated liver enzymes, and low 
platelets (HELLP) syndrome (2). Both diseases of pregnancy are associated with an increased 
maternal and perinatal morbidity (3). Although the etiology of preeclampsia and the HELLP 
syndrome is unknown, data point to a dysfunction of the endothelial layer lining the blood 
vessel wall, which is probably caused by the release of a factor from placental origin (4-6). In 
this respect plasma homocysteine levels may be relevant, because increased concentrations 
are associated with vascular diseases (7-9). In support of this, elevated homocysteine levels 
were found in women with preeclampsia ( 1 0 ;1 1 ).
Amino acid-
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Figure 6.1. Schematic overview of the glutathione metabolism. Glutathione is synthesised in two 
consecutive steps catalysed by Y-glutamylcysteine synthethase and glutathione synthethase. In 
breakdown of glutathione Y-glutamyltranspeptidase cleaves the Y-bond resulting in glutatmate and 
cysteinylglycine.
Homocysteine is situated at a critical regulatory branchpoint in sulfur metabolism. It can be 
remethylated to methionine, an important amino acid in protein synthesis, or it can be 
converted to cysteine in the transsulfuration pathway (7;9;12). Cysteine is the only free thiol 
containing amino acid in proteins. The metabolism of this amino acid is complex and is still
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incompletely understood (7). It’s degradation proceeds by several pathways leading to 
formation of taurine or inorganic sulfate (13). In addition, cysteine is needed for glutathione 
synthesis and provides its thiol residue (7). As shown in Figure 6.1, synthesis of glutathione 
takes place in two steps. At first, y-glutamylcysteine synthetase couples glutamate to cysteine 
forming y-glutamylcysteine. The availability of cysteine is regulatory in this step. Glutathione 
is than directly synthesised by coupling y-glutamylcysteine to glycine catalysed by 
glutathione synthetase (7;14).
In the human body glutathione has diverse important functions such as storage and transport 
of cysteine, maintaining the reduced state of proteins and thiols, and protecting cells from 
toxic compounds; such as reactive oxygen species, drugs, or heavy metal ions (7;14;15). Two 
different types of detoxification enzymes need glutathione as a substrate. Glutathione 
peroxidases catalyze the reaction of glutathione with (oxygen) free radicals, whereby 
glutathione is oxidised. Subsequently, the inactive oxidised form of glutathione can be 
reduced again by glutathione reductase. Glutathione S-transferases catalyze the conjugation 
between glutathione and toxic compounds. This glutathione conjugate is then excreted and 
additional glutathione has to be synthesised.
Earlier we found that whole blood levels of glutathione were lowered in women with 
preeclampsia (16). We now investigated total (the additional sum of reduced, oxidised and 
protein-bound) plasma thiol levels in healthy non-pregnant women, women with 
uncomplicated pregnancies and women with preeclampsia, some of whom developed the 
HELLP-syndrome as well, in order to better understand the reasons of these lower glutathione 
levels.
Materials and Methods
DL-homocysteine, DL-cysteine, cysteinylglycine, y-glutamylcysteine, and glutathione 
(reduced form) were obtained from SIGMA Chemical (St. Louis, USA). Tris (2- 
carboxyethyl)-phosphine hydrochloride was obtained from Pierce (Rockford, USA). 7- 
Fluorobenzofurazane-4-sulfonic acid and K2 B4 07 '4H20 were obtained from Fluka Chemie AG 
(Buchs, Switzerland). All other chemicals were analytical grade and were obtained from 
Merck (Darmstadt, Germany).
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Table 6.1. Characteristics of Women Studied.
Non Pregnant 
Controls 
(n=10)
Pregnant Controls 
(n=10)
Preeclampsia
(n=20)
Age (years) 25 (23 -34) 33 (25-42) 28 (19-33)
Gestational age (weeks+days) ---
T
83 -
T
9(2
T
4 3 32+2(26+3-37+s)
Diastolic BP (mm Hg; Korotkoff IV) --- 75 (70-90) 115(100-120)
Aspartate aminotransferase (IU/L) --- --- 94(12-155)
Alanine aminotransferase (IU/L) --- --- 82(5-160)
Lactic dehydrogenase (IU/L) --- --- 598(236-1607)
Protein/creatinine ratio (g/10mmol) --- --- 5.45 (1.12-21.54)
Data are given as median (range)
Abbreviations: n = number of subjects; --- = Data not available; BP = blood pressure.
The experimental protocol was approved by the Medical Ethical Review Committee of the 
University Hospital Nijmegen. Preeclampsia was defined as pregnancy induced hypertension 
(diastolic blood pressure above 90 mm Hg on two or more consecutive occasions, each more 
than 4 hours apart) and proteinuria (protein/creatinine ratio above 0.30 g/10 mmol). The 
HELLP syndrome was defined as a lactic dehydrogenase level above 600 IU/L, both aspartate 
aminotransferase and alanine aminotransferase above 70 IU/L, and thrombocyte count under 
100 x109/L. After informed consent was given blood samples were collected of ten non­
pregnant healthy women, ten normotensive pregnant and twenty preeclamptic women, of 
whom ten developed the HELLP syndrome as well. All pregnant women were nulliparous. 
Patients and controls were randomly selected in the period from July 1995 to May 1998. All 
women were Caucasians and were matched for age and gestational age on a one-to-one base 
for non-pregnant versus normotensive pregnant women, and a one-to-two base for 
normotensive pregnancy versus preeclampsia. Characteristics of subjects studied are 
described in Table 6.1. Women with diabetes mellitus or essential hypertension were 
excluded. Seven preeclamptic and all normotensive pregnant women also contributed to 
studies published previously (16;17).
Directly after admission to the hospital whole blood was collected into sterile vacutainers 
containing ethylenediaminetetra-acetic acid (EDTA) (Sherwood Medical, Ballymore, 
Northern Ireland). Whole blood was centrifuged at 1,500xg for 10 min in a Heraeus Christ 
centrifuge within one hour after blood collection and plasma was stored in small aliquots at - 
30 °C until analysis.
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Plasma was analysed for total cysteine, y-glutamylcysteine, homocysteine, cysteinylglycine, 
and glutathione concentrations (the sum of reduced, oxidised and protein-bound). Sample 
analysis was performed by high performance liquid chromatography with fluorescent 
detection using an autosampler (Model Marathon, Spark Holland), solvent delivery system 
(High Precision Pump model 480, Gynkotek), and fluorescent detector (Intelligent 
Spectrofluorometric Detector model 821-FP, Jasco), operating at an excitation wavelength of 
385 nm and an emission wavelength of 515 nm (Separations, H.I. Ambacht, the Netherlands). 
The column (Inertsil ODS-2, 100 x 3 mm, 5 ^m particle size) and the guard column (R2, 10 x 
2 mm) were from Chrompack (Middelburg, The Netherlands). Data obtained were analysed 
with the GynkoSoft chromatography data-system, Gynkotek (München, Germany).
The analysis of thiols is essentially as described by Fortin et al. (9) with some modifications. 
Shortly: after thawing on ice, 100 plasma was reduced by adding 10 tris (2- 
carboxyethyl)-phosphine hydrochloride (10 % in 0.9 % sodium chloride / 4.0 mM EDTA) for 
30 min. Proteins were precipitated with 100 ^L perchloric acid (0.6 M) / EDTA (1 mM) 
during 5 min followed by centrifugation for 5 min at 10,000xg in an Eppendorf centrifuge. 
Subsequently the supernatant (100 ^L) was incubated with 20 ^L sodium hydroxide (1.55 M), 
200 ¡^L borate buffer (125 mM and 4 mM EDTA, pH 9.5) and 20 ^L 7-fluorobenzofurazane-
4-sulfonic acid (5 mg/mL borate buffer) at 60°C for 1 hour. Of the derivatised sample 20 ^L 
was injected and thiols were eluted with an isocratic eluent (2.0 % methanol in 0.1 M acetic 
acid pH 5.0) at flow rates of 350 ^L/min for 5 min. and 600 ^L/min for another 5 min. 
Concentrations of thiols were determined using calibration curves containing mixtures of all 
thiols.
Calibration curves for each thiol (100 - 400 ^mol/L cysteine, 10 - 40 ^mol/L homocysteine 
and y-glutamylcysteine, and 5 - 20 ^mol/L glutathione) were prepared by diluting stock 
solutions with 0.9 % sodium chloride / 4 mM EDTA. Stock solutions containing 20 mM of 
cysteine, y-glutamylcysteine, homocysteine, cysteinylglycine, or glutathione were prepared in 
0.9 % sodium chloride / 4 mM EDTA and stored in small aliquots at -30 °C. In an aqueous 
matrix calibration curves were linear, correlation coefficients exceeded 0.999 for all analytes 
in the ranges studied (data not shown). Pastore et al. (18) noticed no substantial matrix effects 
performing linearity studies on diluted plasma samples.
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Sample size of 10 patients was determined based on the homocysteine data reported by 
Rajkovic et al. (10) assuming a  = 0.05 and ß = 0.95. The Mann-Whitney U test with 
Bonferroni correction for multiple comparison was used to assess statistical significance of 
differences in thiols between groups. Differences were considered significant if P<0.05. 
Correlation between cysteine and homocysteine concentrations was determined with 
Spearman rank correlation test. Correlation was considered significant if P<0.05.
Results
Cysteine, y-glutamylcysteine, homocysteine, cysteinylglycine, and glutathione eluted in this 
order with retention times of 3.0, 3.8, 4.3, 5.1, and 6.2 min, respectively. Mean recoveries for 
cysteine, y-glutamylcysteine, homocysteine, cysteinylglycine, and glutathione were 99, 101, 
102, 101, and 98 %, respectively. In plasma samples all thiols except y-glutamylcysteine were 
detectable. Within-run coefficients of variation in plasma were 2.2 % for cysteine, 1.3 % for 
homocysteine, 3.9 % for cysteinylglycine and 5.9 % for glutathione. Day-to-day coefficients 
of variation were 1.0 % for cysteine, 7.0 % for homocysteine, 1.0 % for cysteinylglycine and
5.0 % for glutathione.
Table 6.2. Plasma Thiol Concentrations in Preeclamptics and Controls.
Thiol
Non Pregnant Controls 
(%)
Pregnant Controls 
(%)
Preeclampsia
(%)
Cysteine 253 (205- 270) 190 (138 - 232) a 254 (222 - 533) c
(100%) (75 %) (100 %)
y-Glutamylcysteine nd nd nd
Homocysteine 13.7 (9.2 - 17.3) 8.4(7.0 - 15.6) a 13.3 (7.5 - 26.4) d
(100%) (61 %) (97 %)
Cysteinylglycine 28.5 (21.6 - 34.1) 22.0 (17.7 - 29.8) b 21.8 (6.0 - 38.6)
(100%) (77 %) (76 %)
Glutathione 11.6 (8.6 - 15.5) 6.3 (4.3 - 9.5) a 5.1 (1.5 -.10.7) e
(100%) (54 %) (44 %)
Data are given as median (range) and expressed as |jmol/L
nd = not detectable; % = Percentage as compared to non-pregnant controls.
Statistics: a: p<0.001, b: p<0.03 (Non-pregnant versus pregnant controls)
c: p<0.001, d: p<0.02, e: p<0.05 (Preeclampsia versus pregnant controls)
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Median levels of cysteine, homocysteine, cysteinylglycine and glutathione in healthy non­
pregnant women were 253, 13.7, 28.5, and 11.6 ^mol/L, respectively (Table 6.2). Levels of 
cysteine, homocysteine, cysteinylglycine and glutathione were significantly lower in women 
with normotensive pregnancy as compared to healthy non-pregnant women.
No significant differences were found between preeclamptics with or without the HELLP- 
syndrome. In preeclamptic women median cysteine and homocysteine levels were 
significantly higher as compared to levels in normotensive pregnant, whereas glutathione 
concentrations were significantly lower (Table 6.2). Individual data for glutathione levels are 
shown in Figure 6.2. No significant differences in cysteinylglycine levels were found.
A significant correlation between plasma cysteine and homocysteine levels for all subjects 
was found (r=0.74, P<0.001).
Discussion
Thiol levels found in healthy non-pregnant women are consistent with those reported by 
Pastore et al. (18) and Mansoor et al. (19). However, homocysteine levels were slightly higher 
than reported by Mansoor et al., but are within the normal range and are comparable to 
normal levels for the Dutch population (20).
Cysteine, homocysteine, cysteinylglycine, and glutathione levels were significantly lower 
during normotensive pregnancy as compared to healthy non-pregnant women (75, 61, 77 and 
54% of control values, respectively). Changed steroid levels during pregnancy as reported by 
Kim et al. (21) may contribute to this effect. However, in an overall analysis of 31 studies 
revealed an increase in plasma volume of approximately 40% during pregnancy (22). It is 
likely that this also contributes to the decrease of plasma thiol levels in pregnant women. This 
effect of hemodilution was also shown for homocysteine by Anderson et al. (23). Glutathione 
levels, however, were even lower than can be explained by hemodilution only. This might 
point to a higher utilization or lower synthesis of glutathione during pregnancy.
We found higher plasma homocysteine levels in preeclampsia compared to normal pregnancy, 
which is in agreement with the findings of Rajkovic et al. (10). However, the homocysteine 
concentrations found in our study were higher than those of Rajkovic et al. (13.3 versus 8.7 
¡^mol/L). The subjects in our study were not uniformly fasting and it is known that this can 
affect homocysteine levels (24;25), although this effect seems to be minimal. Probably more
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important is that different populations were studied, since it is known that homocysteine 
levels in the Northern American population are lower as compared to the Dutch population, 
due to a higher dietary intake of folate and vitamin supplements in the United States (26).
Figure 6.2. Individual glutathione concentrations in plasma of non-pregnant (NP), normotensive 
pregnant (P), and preeclamptic (PE) women.
Homocysteine is linked to cysteine by the enzyme cystathione-ß-synthase, which converts 
homocysteine to serine and cystathione, which is further metabolised to cysteine (9;12). 
Rajkovic et al. (10) suggested that a deficiency of cystathione-ß-synthase may be responsible 
for the increased homocysteine levels. However, this would result in normal or even lower 
cysteine levels in normotensive pregnancies, which is not in line with the observed correlation 
between cysteine and homocysteine. This suggests that a disturbance in the remethylation of 
homocysteine to methionine has to be considered. Low vitamin B12 or folate levels, both 
essential for this remethylation, might be contributing factors to the elevated homocysteine 
levels in preeclampsia. However, Rajkovic et al. (10) found no significant differences in both 
vitamin B12 and folate levels in women with normotensive pregnancy and preeclampsia.
The levels of homocysteine and cysteine in preeclampsia, which are higher than in 
normotensive pregnant women, are comparable to the levels in healthy non-pregnant women. 
These elevated levels during preeclampsia can possibly be explained by the 
pathophysiological reduction of plasma volume during preeclampsia, which may be as much 
as 40% in severe cases (5;22). In this line of thinking, higher levels of cysteinylglycine and 
glutathione were expected than those we actually found in women with preeclampsia. In 
preeclampsia, plasma glutathione concentrations were even lower than in normotensive
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pregnancies. These results are in agreement with our previous findings that whole blood 
glutathione levels are lower in preeclampsia as compared to normotensive pregnancy (16). 
Glutathione is essential in the defense against oxidative stress and is important in a wide 
variety of detoxification reactions in humans (14;27). Therefore, oxidative stress in pregnancy 
and preeclampsia in particular might cause a higher consumption of glutathione, resulting in 
low glutathione levels. Another possibility is that the synthesis of glutathione is disturbed in 
women developing preeclampsia. As a result the amount of glutathione may not be sufficient 
to fully protect against oxidative stress or toxic factors.
Elevated homocysteine levels may contribute to damage of the vascular endothelium in 
women with preeclampsia. The question arises whether the slightly elevated homocysteine 
levels found here, which are comparable to levels in healthy non-pregnant women, may 
damage the vascular endothelium of preeclamptic women. Vascular endothelium of women 
with preeclampsia might, however, be more sensitive towards injury. Therefore the moderate 
elevation in homocysteine levels during preeclampsia may lead to endothelial damage with 
subsequent activation of several factors such as adhesion molecules or von Willebrand’s 
factor, as shown by several studies (4;5). Damage of the endothelium is more likely caused by 
an increased oxidative stress due to pregnancy or by the release of a toxic factor from 
placental origin both resulting in the low glutathione levels observed.
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Abstract
Objective: Analyses of oxidised and free thiols in whole blood of normotensive pregnant and 
preeclamptic women, with or without HELLP syndrome, in order to evaluate the role of 
oxidative stress, which may play an important role in the pathogenesis of preeclampsia. 
Methods: We measured whole blood oxidised and free levels of cysteine, homocysteine, 
cysteinylglycine, and glutathione by high performance liquid chromatography in women with 
normotensive pregnancies (n=50), preeclampsia (n=29), and preeclampsia complicated by the 
hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome (n=16).
Results: In preeclampsia both oxidised and free levels (median (range) in ¡^mol/L) of cysteine 
and homocysteine were higher than in normotensive pregnancy (45 (27 -  81) vs. 29 (9 -  91), 
P<0.001 and 98 (57 -  193) vs. 69 (33 -  215), P<0.001; 0.8 (0.2 -  4.4) vs. 0.4 (0.01 -  1.6), 
P<0.001 and 2.1 (0.7 -  9.4) vs. 1.2 (0.2 -  21.2), P=0.01; respectively). The ratios of free to 
oxidised cysteine, homocysteine and cysteinylglycine were lower in preeclampsia compared 
with normotensive pregnancy (2.2 (1.3 -  3.0) vs. 2.4 (1.7 -  4.3), P<0.001; 2.3 (0.5 -  5.4) vs.
2.9 (1.1 -  24), P<0.001; 4.1 (2.3 -  11.6) vs. 5.4 (2.6 -  24.3). P=0.02 respectively), indicating 
a shift in favour of the oxidised form of these thiols. In HELLP syndrome levels of oxidised 
and free cysteine and levels of oxidised homocysteine were elevated compared with 
normotensive pregnancy (44 (33 -  63) vs. 29 (9 -  91), P<0.001 and 102 (82 -  133) vs. 69 (33 
-  215), P<0.001; 1.0 (0.3 -  2.9) vs. 0.4 (0.01 -  1.6), P<0.001; respectively). No statistical 
differences were found in oxidised glutathione levels in women with preeclampsia (22 (5 - 
49) vs. 17 (2 - 60), P=0.06, or free levels in preeclamptic women with HELLP syndrome (757 
(624 - 993) vs. 842 (539 - 1516), p=0.09) as compared with normotensive pregnant women. 
The ratios of free to oxidised cysteinylglycine and glutathione were higher in women with 
HELLP syndrome compared with preeclampsia (5.4 (3.3 -  12.7) vs. 4.1 (2.3 -  11.6), P=0.02; 
56 (28 -  124) vs. 45 (16 -  166), P=0.02; respectively).
Conclusion: The significantly lower free to oxidised ratios of cysteine, homocysteine, and 
cysteinylglycine in preeclampsia might indicate oxidative stress.
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Introduction
Preeclampsia is one of the most frequent complications of pregnancy (5-7%) leading to foetal 
growth retardation, premature delivery, and maternal and foetal morbidity and mortality (1 ). 
The haemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome may 
complicate preeclampsia in approximately 10% of the cases. Although the aetiology of these 
disorders remains obscure, rising evidence indicates that dysfunction of the vascular 
endothelium may result in increased vasoconstriction leading to maternal hypertension (2) and 
reduced uteroplacental blood flow (3). Endothelial dysfunction can be mediated by oxidative 
stress defined as disturbance of the redox-balance, caused either by an increased amounts of 
oxidants such as cytokines or free radicals, or a deficiency of antioxidants resulting in an 
overall oxidant insult (3-7). In women with preeclampsia lipid peroxidation products are 
elevated (3;5;7) and they might contribute to the aetiology of preeclampsia (8). In normal 
pregnancy lipid peroxidation has been shown to progressively increase with gestational age, 
whereas the antioxidant capacity, the vitamins A, C, E, and erythrocyte levels of thiols, 
increased in parallel (3;5;7).
Figure 7.1. Glutathione cycling in detoxification of reactive oxygen species.
Reactive oxygen species (RO), hydrogen peroxide (H2O2) and organic peroxides (ROOH) can be 
detoxificated by action of glutathione peroxidase (GPX) with reduced glutathione (GSH) as a 
substrate, yielding the oxidised form of glutathione (GSSG) and relative harmless ROH. Oxidised 
glutathione can be regenerated to GSH by glutathione reductase (GR) thereby consuming 
nicotinamide adenine dinucleotide phosphate (NADPH).
Red blood cells contain high concentrations (up to 2 mM) of reduced glutathione accounting 
for almost 98% of the total blood content (7;9). In addition to their detoxification function by 
conjugation of noxious compounds, glutathione and other thiols, maintain the redox-balance 
of cells, thereby preventing oxidative damage (7). Glutathione maintains the redox-balance by
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action of glutathione peroxidases, which couple the reduction of organic peroxides or 
(oxygen) free radicals to the oxidation of glutathione (10;11). Subsequently, a glutathione 
reductase catalysed reaction converts the inactive oxidised glutathione back into the active 
reduced form (10; Figure 7.1).
Oxidative stress in preeclampsia has already been demonstrated indirectly by high levels of 
lipid peroxidation products such as malondialdehyde (3;5;6;12;13) and low levels of 
antioxidants such as the vitamins A, C and E (2;3;5-8;13). We previously noticed lower whole 
blood (14) and plasma (15) levels of glutathione in patients with preeclampsia, whereas 
plasma concentrations of cysteine and homocysteine were increased (15). In this present study 
we report free and oxidised levels of the thiols cysteine, homocysteine, cysteinylglycine, and 
glutathione in whole blood for the direct assessment of oxidative stress in women with 
preeclampsia and preeclampsia complicated by HELLP syndrome.
Materials and Methods
The experimental protocol was approved by the Medical Ethical Review Committee of the 
University Hospital St. Radboud, Nijmegen. Preeclampsia was defined according to the 
standards of the International Society for the Study of Hypertension in Pregnancy as 
pregnancy induced hypertension (a diastolic blood pressure above 90 mm Hg on two or more 
consecutive occasions, each more than 4 hours apart) and proteinuria (protein/creatinine ratio 
above 0.3 g/10 mmol). HELLP syndrome was defined as hemolysis (lactic dehydrogenase 
above 600 IU/L), elevated liver enzymes (both aspartate aminotransferase and alanine 
aminotransferase above 70 IU/L), and low platelets (thrombocyte count under 100 x109/L). 
After written informed consent was given, blood samples of normotensive pregnant women 
(n=50), women with preeclampsia (n=29), and women with preeclampsia complicated by the 
HELLP syndrome (n=16) were collected before anti-hypertensive treatment was started. 
Patients and controls were included in the period from July 1998 to November 1999. All 
women were Caucasian and respectively 40%, 40%, and 70% of women included were 
nulliparous. Women with diabetes mellitus or essential hypertension were excluded from 
participation in the study.
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N-ethylmaleimide, 3-[N-morpholino]-propanesulfonic acid, and bathophenanthroline- 
disulfonic acid were obtained from Sigma Chemical (St. Louis, USA). All other chemicals 
were analytical grade and were obtained from Merck (Darmstadt, Germany).
Whole blood was collected into sterile vacutainers containing ethylenediaminetetra-acetic 
acid (EDTA) (Sherwood Medical, Ballymore, Northern Ireland) and handled within 1 hour 
after collection. For assay of the free thiol levels (both reduced and oxidised non-protein 
bound thiols), proteins were precipitated by adding 500 ¡^L whole blood to 500 ¡^L 12% 
perchloric acid containing 2.0 mM bathophenanthrolinedisulfonic acid. For assay of oxidised 
free thiols, another 500 ¡^L whole blood was added to 500 ¡^L 12% perchloric acid containing
2.0 mM bathophenanthrolinedisulfonic acid and 40 mM N-ethylmaleimide. After thorough 
mixing and centrifugation at 16,000xg for 20 minutes and 4 °C, supernatants were collected 
and stored at -80 °C until analysis. Samples were analysed within two weeks. Just before 
analysis of the oxidised and free thiols the excess of N-ethylmaleimide was removed by 
adding 70 ¡^L KOH (2.0 M) followed by 60 ¡^L HCl (0.01 M in 0.3 M 3-[N-morpholino]- 
propanesulfonic acid buffer) to 100 ¡^L of sample. Samples were analysed for levels of 
cysteine, homocysteine, cysteinylglycine, and glutathione by high performance liquid 
chromatography with fluorescent detection as described previously (15). Data obtained were 
analysed with the Chromeleon chromatography data-system, Gynkotek (München, Germany). 
After analysis the ratio of free over oxidised thiol were calculated for each subject.
To be able to detect a difference in whole blood glutathione concentration of 250 ^mol/L a 
sample size of at least 15 women in each group was needed, assuming a=0.05 and ß=0.95. 
Kruskal-Wallis ANOVA and, when appropriate a Mann-Whitney U-tests were performed to 
assess statistical significance in thiols between groups; P < 0.05 was considered significant.
Results
In Table 7.1 the characteristics of the women studied are summarised. The control women did 
not differ from the patients in the preeclamptic nor the HELLP group regarding age, 
gestational age, and hemoglobin and hematocrit levels.
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Table 7.1. Characteristics of the Women Studied.
Controls
(n=50)
Preeclampsia
(n=29)
Preeclampsia + 
HELLP 
(n=16)
Age (years) 33 (22 -  44) 31 (23 - 38) 30 (24 - 35)
Gestational Age (weeks+days) 32+0 (28+0 - 38 +2) 32+3 (2 2 + 3  - 37+2) 29+1 (24+4 - 40+4)
Diastolic BP (mmHg; Korotkoff V) 70 (55 -  90) 110 (95 - 135) f 105 (90 - 120) *
Hemoglobin (mmol/L) 7.3 (6.1 - 8.3) 7.6 (6 . 6  - 9.1) 7.5 (6.5 - 8.2)
Hematocrit (L/L) 0.35 (0.30 - 0.40) 0.36 (0.30 - 0.93) 0.35 (0.31 - 0.37)
Protein / Creatinine ratio (g/10 --- 1.7 (0.3 - 21.1) 6 . 6  (0.3 - 33.8)
mmol)
Uric acid (mmol/L) --- 0.43 (0.18 - 0.58) 0.44 (0.32 - 0.69)
Lactic Dehydrogenase (IU/L) --- 434 (182 - 1250) 1305 (706 - 4380) *
Aspartate Aminotransferase (IU/L) --- 32 (14 - 312) 222 (100 - 1690) *
Alanine Aminotransferase (IU/L) --- 21 (9 - 276) 179 (40 - 1760) *
Thrombocytes (x109/L) --- 200 (62 - 391) 55 (28 - 110) *
Data are given as median (range)
Abbreviations: --- = data not available, n = number of subjects, BP = blood pressure
Statistics:
*: P<0.001 controls versus preeclampsia + HELLP
f : P<0.001 controls versus preeclampsia
*: P<0.001 preeclampsia versus preeclampsia + HELLP
Median values of whole blood free levels of cysteine, homocysteine, cysteinylglycine and 
glutathione are shown in Table 7.2. Levels of cysteine and homocysteine were significantly 
higher in the preeclamptic group, whereas cysteine alone was significantly higher in the 
HELLP group both compared with corresponding values in controls. No significant 
differences were found for cysteinylglycine and glutathione between controls and either 
preeclampsia with or without HELLP syndrome.
Oxidised levels of cysteine and homocysteine in both groups of complicated pregnancies were 
significantly higher compared with those in controls. No significant differences were found 
for oxidised cysteinylglycine and glutathione levels in preeclamptic women with or without 
HELLP syndrome compared with control women, however in women with preeclampsia 
glutathione levels nearly reached significance (P=0.06).
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Table 7.2. Free, Oxidised, and Ratios of Free to Oxidised Thiols in Pregnancy
Normtensive (n=50) Preeclampsia (n=29) Preeclampsia + HELLP (n=16)
Free Oxidised Ratio Free Oxidised Ratio Free Oxidised Ratio
Cysteine 69
(33 - 215)
29 
(9 - 91)
2.4 
(1.7 - 4.3)
98* 
(57- 193)
45* 
(27 - 81)
2.2* 
(1.3 - 3.0)
102* 
(82 - 133)
44*
(33 - 63)
2.3 
(2.0 - 3.7)
Homocysteine 1.2 
(0.2 - 21.2)
0.4 
(0.01- 1.6)
2.9 
(1.1 - 24)
2.1* 
(0.7 - 9.4)
0.8* 
(0.2 -4.4)
2.3* 
(0.5 - 5.4)
1.5 
(0.6 - 3.9)
1.0* 
(0.3 - 2.9)
2.6 
(1.0 -7.1)
Cysteinylglycine 9.0 
(5.3 - 18.1)
1.6 
(0.3 - 3.3)
5.4 
(2.6 - 24.3)
8.9 
(0.7 - 13.0)
1.8 
(0.3 - 3.2)
4.1** 
(2.3 - 11.6)
8.3 
(2.5 - 12.0)
1.9 
(0.2 - 3.2)
5.4f 
(3.3 - 12.7)
Glutathione 842 
(539 - 1516)
17 
(2 - 60)
50 
(19 - 496)
827 
(565 - 1303)
22 
(5 - 49)
45 
(16 - 166)
757 
(624 - 993)
14
(7 - 34)
56f 
(28 - 124)
Data are given as median (range) and are expressed as |jmol/L.
Ratio = ratio of free to oxidised thiol level.
Statistics:
*: P<0.001 and **: P=0.02 normotensive versus complicated pregnancy 
f : P=0.02 preeclampsia versus preeclampsia + HELLP
Chapter 7
As reported by Ueland et al. (16) and Droge (17) the ratio of free to oxidised thiol is a 
measure for the balance between oxidants and antioxidants. Changes of this ratio can 
therefore be used as a measure of oxidative stress. These ratios were calculated for each thiol 
in every subject. Median ratios of free to oxidised cysteine, homocysteine, cysteinylglycine 
and glutathione are summarised in Table 7.2. In the preeclamptic group these ratios were 
significantly lower for cysteine, homocysteine, and cysteinylglycine compared with the 
corresponding values in the control group, whereas no significant difference was found for 
glutathione. No significant differences in free to oxidised ratios were found between HELLP 
patients and controls. Free to oxidised ratios of cysteinylglycine and glutathione were 
significantly higher in the HELLP group as compared to the preeclamptic group.
Discussion
Values for free glutathione and cysteine in whole blood are well documented and data in 
normotensive pregnancies as measured in this study are comparable with those of non­
pregnant controls reported elsewhere (9;18;19). However, no whole blood reference values 
are known for free and oxidised cysteinylglycine and homocysteine levels.
We earlier reported that whole blood glutathione/hemoglobin ratios in women with 
preeclampsia or HELLP syndrome were lower compared with those in normotensive 
pregnancy, whereas whole blood glutathione levels tended to be lower but reaching only 
borderline significance (P=0.05) (14). In this more extensive study we found that free whole 
blood glutathione levels tended to be lower in the HELLP group, whereas values were not 
different in women with preeclampsia compared with normotensive pregnant controls. These 
data appear to contrast with our previous findings. Two reasons for this discrepancy may be 
valid. At first; in the former report other patient and control populations and smaller groups 
were studied. The size of the study groups may particularly be important because the whole 
blood values for glutathione, as reported in literature, vary between 500 and 1500 ^mol/L 
(9;14;18;19). In our study the values in controls showed a similar range (539 -1516 ^mol/L). 
At second; another assay method was used; earlier we used monobromobimane as a 
fluorescent probe for quantification of glutathione (14), whereas in the present study 
glutathione and other thiols were estimated simultaneously by using 7-fluorobenzofurazane-4-
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sulfonic acid (15). The method using 7-fluorobenzofurazane-4-sulfonic acid is more specific 
due to absence of breakdown products of monobromobimane and lesser background peaks. In 
addition the run-time is considerably shortened.
In preeclampsia both free and oxidised levels of cysteine and homocysteine are higher 
compared to normotensive pregnancy. The ratios of free to oxidised thiol are significantly 
lower for cysteine, cysteinylglycine, and homocysteine. This points to a shift in redox-balance 
towards more oxidised levels of cysteine, cysteinylglycine, and homocysteine in women with 
preeclampsia. As reviewed by Davidge (4) and Walsh (3) preeclampsia can be characterised 
by an imbalance between oxidants and antioxidants. However, in these former studies 
oxidative stress was only indirectly demonstrated by assessment of lipid peroxidation 
products or antioxidant levels (3;4), whereas we now report the direct measurement oxidative 
stress. It is relevant therefore that Chappell et al. (20) recently showed that oxidative stress 
could partly be overcome by supplementation with vitamins C and E early in pregnancy, 
which resulted in lower incidence of preeclampsia in women at high risk for preeclampsia.
Thiols are an important component of the total redox-buff er system (21). Reduced 
glutathione, particularly, is a well-recognised endogenous scavenger of free radicals and 
peroxides, maintaining the redox-potential and being highly protective against oxidative stress 
(10;18;22). In deactivating free radicals and reactive oxygen species the reduced form of 
glutathione and other thiols is oxidised, thereby changing the ratio of free over oxidised thiol. 
We anticipated therefore that this ratio for glutathione would be lower in women with 
preeclampsia, which we did not find. An explanation could be that the oxidised form of 
glutathione is rapidly reduced by glutathione reductase, thereby consuming nicotinamide 
adenine dinucleotide phosphate (10) (Figure 7.1), whereas such an efficient reducing system 
is not present for the other thiols. In addition, when increasing amounts of glutathione are 
oxidised, some of the oxidised glutathione will undergo renal degradation by y-glutamyl 
transpeptidase resulting in an irreversible loss of glutathione (21). As a result of either or both 
of these mechanisms the free to oxidised ratio might remain unchanged.
Lowered free to oxidised ratios for cysteine, homocysteine, and cysteinylglycine were also 
expected in preeclamptic women with HELLP syndrome. Although oxidised levels of 
cysteine and homocysteine were significantly higher, significantly lowered ratios were not 
found in these women, indicating that the reduced levels of these thiols were elevated in
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parallel with the oxidised levels and oxidative stress is probably absent. Hemolysis and 
especially impairment of liver function might influence whole blood levels of the thiols, since 
the liver plays an important role in thiol metabolism.
Reduced thiols, specifically cysteine and homocysteine, may combine with the common 
active nitric oxide radical (NO') yielding S-nitrosothiol intermediates, which may be more 
functional in vasodilatation than NO' itself (10). Although free levels of cysteine and 
homocysteine are high in women with preeclampsia, levels of the reduced form of both thiols 
are low, because free to oxidised ratios are elevated in this group. These lower levels of 
reduced thiols may possibly lead to a lower nitric oxide mediated vasodilatation resulting in 
elevation of the blood pressure as seen in these women. In addition, lower levels of reduced 
cysteine and homocysteine in combination with increased biosynthesis of NO' (23) might 
result in elevation of oxidative species through reaction of NO' with superoxide, leading to the 
formation of peroxynitrite. Peroxynitrite is a strong oxidant able to initiate lipid peroxidation
(3) which has been reported to be elevated in placentas from women with preeclampsia 
compared with those from normotensive pregnant women (4).
In this study whole blood thiol levels in normotensive pregnancies and those complicated by 
preeclampsia with or without HELLP syndrome were investigated for a better understanding 
of the pathophysiology of both diseases. Some reports suggest that preeclampsia and HELLP 
syndrome are different clinical syndromes with the same underlying pathology. Our results 
confirm this view, because both complications of pregnancy exert pressure on the thiol 
detoxification system. Oxidised levels of cysteine and homocysteine were significantly higher 
in women with HELLP syndrome. Free to oxidised ratios of cysteine, homocysteine, and 
cysteinylglycine were significantly lower in preeclampsia compared with normotensive 
pregnancy, however this was not found in preeclamptic women with HELLP syndrome. The 
free to oxidised ratios for cysteinylglycine and glutathione were significantly lower in women 
with preeclampsia than in preeclamptic women with HELLP syndrome. These results suggest 
that elevated oxidative stress and/or disturbance in detoxification processes may play a role in 
the etiology or maintenance of preeclampsia or HELLP syndrome.
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Pregnancy is characterised by oxidative stress, which is more 
pronounced in preeclampsia.
Maarten T.M. Raijmakers, Eva Maria Roes, Eric A.P. Steegers, and 
Wilbert H.M. Peters.
Chapter 8
Abstract
Background: Oxidative stress plays an important role in the pathophysiology of 
preeclampsia. In defence against reactive oxygen species glutathione and other thiols can be 
oxidised, thereby maintaining the intracellular redox status. Therefore, the free-to-oxidised 
ratio of these thiols can be seen as a measure of oxidative stress.
Aim: To compare the free and oxidised levels as well as the free-to-oxidised ratios of cysteine 
(Cys) homocysteine (Hcy), cysteinylglycine (CysGly), and glutathione (GSH) in whole blood 
of women with severe preeclampsia with those in normotensive pregnant women during 
pregnancy and 6-8 weeks post partum.
Subjects and Methods: At onset of disease and at 6-8 weeks post partum, whole blood of 41 
women with severe preeclampsia and of 31 women with normotensive pregnancies was 
analysed for the free and oxidised levels of thiols by high performance liquid 
chromatography. The free-to-oxidised ratio for each thiol was calculated. Differences between 
pregnancy and post-partum values were analysed with the paired t-test, whereas differences 
between preeclamptic and control pregnancies were analysed using the t-test.
Results: Both in women with severe preeclampsia and control subjects free levels of GSH 
were lower during pregnancy compared with those post partum (P<0.0001 and P<0.0001, 
respectively). Free-to-oxidised ratios of Hcy are lower in preeclampsia (P<0.01) as well as 
normotensive pregnancy (P<0.01) compared with those after pregnancy. These ratios were 
significantly lower in preeclamptic women compared with normotensive controls during as 
well as after pregnancy (P<0.01 and P<0.01, respectively).
Conclusion: During normotensive pregnancy more oxidative stress is present as compared 
with the non-pregnant state, whereas in women with severe preeclampsia oxidative stress is 
higher during the disease as well as in the non-pregnant state afterwards as compared to 
corresponding values in normotensive pregnant women.
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Introduction
Preeclampsia is a severe complication of pregnancy with a prevalence of 5-7% and high 
maternal as well as foetal mortality and morbidity. It is classically defined by pregnancy 
induced hypertension and concurrent proteinuria (1). Preeclampsia may be complicated by the 
haemolysis elevated liver enzymes and low platelets (HELLP) syndrome. The pathogenesis of 
both these disorders is not yet elucidated, however, it is thought that they have a placental 
origin (2), since removal of the placenta resolves the clinical symptoms of preeclampsia. Poor 
trophoblast invasion in early pregnancy may result in a reduced placental perfusion (3). At a 
certain level the oxidant challenge may exceed the amount of antioxidants, which may trigger 
placental and maternal oxidative stress.
During uncomplicated pregnancies levels of lipid peroxidation products increase with 
gestational age, which are counteracted by a parallel increase of antioxidant capacity (4-8). 
Unless properly controlled, these lipid peroxidation products may result in oxidative damage 
of cellular membranes, mitochondrial as well as nuclear DNA, and loss of protein function 
and synthesis (9). This may cause the general dysfunction of vascular endothelium as seen in 
preeclampsia (1 ;10;11). For scavenging free radicals and reactive oxygen species (ROS) 
several enzymatic and non-enzymatic antioxidant defence mechanisms are present. They all 
react with reactive oxygen species (ROS) or reduce the levels of free transition metals, which 
are capable to initiate the chain reaction of lipid peroxidation (11). The glutathione / 
glutathione dependent enzyme system is an important first line defence against oxidative 
damage (12;13). Glutathione is a non-specific free radical scavenger, which is able to donate 
its proton to unpaired electrons, thereby "quencing" the free radical. However, it also serves 
as co-factor in the reaction with glutathione S-transferases and glutathione peroxidases, which 
scavenge ROS upon oxidation of glutathione (12). To maintain the cellular redox-balance, the 
oxidised form of glutathione is quickly reduced by glutathione reductase, or it is excreted 
when excessive amounts are formed (12; 14) .
Besides its antioxidant capacity glutathione is important in storage and transport of cysteine. 
In the two-step synthesis of glutathione a very stable y-bond instead of a normal peptide bond 
is formed between cysteine and glutamate. This reaction is immediately followed by the 
addition of glycine (15;16). Cysteine serves as -S H  donor thereby providing the reactive 
centre of glutathione. The chemistry of cysteine is complex, but it plays an important role in 
protein synthesis. Cysteine is often seen as an intermediate of homocysteine breakdown, since
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homocysteine is irreversible converted into cysteine in the transsulphuration pathway. Further 
breakdown of cysteine leads to the formation of taurine or inorganic sulphate (15;16).
In a previous study we showed that during preeclampsia higher oxidative stress is present and 
that free and oxidised levels of cysteine and homocysteine were higher as compared to those 
in normotensive control pregnancies (17). However, possible due to large individual variation 
no significant differences were found for glutathione. In this study we investigated the levels 
of free and oxidised cysteine, homocysteine, cysteinylglycine and glutathione, and the free-to- 
oxidised ratio of these thiols in women with preeclampsia as well as normotensive pregnant 
women during and after pregnancy.
Materials and Methods
The Institutional Medical Ethical Review Committee approved the study protocol. 
Preeclampsia was defined according to the standard of the International Society for the Study 
of Hypertension in Pregnancy as pregnancy induced hypertension (diastolic blood pressure > 
90 mmHg on two or more occasions each more than 4 hours apart) with proteinuria 
(protein/creatinine ratio >0.30 g/10 mmol). The HELLP syndrome was defined by hemolysis 
(lactic dehydrogenase enzyme activity >600 IU/L), elevated liver enzymes (both aspartate and 
alanine aminotransferase enzyme activity >70 IU/L) and low platelets (trombocyte count 
<100x109/L). Participants were recruited between 1999 and 2001. Five of the preeclamptic 
subjects have participated in another study (18), whereas four of those also contributed to the 
previous study (17). All women gave their informed consent to participate.
At onset of disease we recruited forty-one women with hypertensive disorders of pregnancy; 
severe preeclampsia (n=21), preeclampsia with HELLP syndrome (n=18), or HELLP 
syndrome with pregnancy induced hypertension (n=2); and thirty-one women with 
uncomplicated pregnancy outcome. Characteristics of the study populations are described in 
Table 8.1.
Whole blood, anti-coagulated with EDTA, was collected by venapuncture immediately after 
admittance to the University Medical Centre Nijmegen and 6-8 weeks after pregnancy. After 
venapuncture whole blood was handled within one hour for assessment of free (the sum of
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reduced and oxidised non-protein bound) and oxidised levels of cysteine (fCys and oCys), 
homocysteine (fHcy and oHcy), cysteinylglycine (fCys-Gly and oCys-Gly) and glutathione 
(GSH and GSSG) as described before by our group (17).
Table 8.1. Pregnancy characteristics of women with severe preeclampsia and normotensive 
pregnant controls at time of study.
Normotensive controls 
(n=31)
Severe preeclamspia 
(n=41)
Maternal age (years) 33 (27 -  41) 29 (21 -  38)*
Nulliparous 11 (35) 32 (78)*
Birht weigth (gram) 3305 (2335 -  4675) 943 (370 -  3045)f
Gestational age (weeks+days) 39+1 (37+6 -  42+1) 28+3 (22+4 -  37+5)f
Hb (mmol/L) 7.3 (6.3 -  8.5) 7.7 (5.0 -  9.0)
Ht 0.34 (0.28 -  0.48) 0.36 (0.28 -  0.45)
Diastolic BP (mmHg; Korotkoff V) 68 (55 -  80) 110 (80 -  135)f
Protein/Creatinine ratio (g/10 mmol) 4.2 (0.1 -  27.4)
LDH (IU/L) 586 (92 -  3870)
ALAT (IU/L) 34 (8 -  936)
ASAT (IU/L) 63 (12 -  1291)
Platelet count (x109/L) 121 (20 -  378)
Uric Acid 0.4 (0.2 -  34.0)
Creatinine (|jmol/L) 71 (49 -  146)
Data are presented as median (range), except for nulliparous, which is expressed as number 
(percentage).
Abbreviations: Hb -  haemoglobin, Ht -  haematocrit, BP -  blood pressure, LDH -  lactate 
dehydrogenase enzyme activity, ALAT -  alanine aminotransferase enzyme activity, ASAT -  aspartate 
aminotransferase.
Statistics:
*: P<0.001 and t  P<0.0001 normotensive controls versus severe preeclampsia
In short, for assay of free thiol levels, 500^L whole blood was added to 500^L ice-cold 12% 
perchloric acid (PCA) containing 2.0mM bathophenanthrolinedisulfonic acid (BPDS; Sigma 
Chemicals). For assay of oxidised thiols, another 500 ^L whole blood was added to 500 ^L 
12% PCA containing 2.0 mM BPDS and 40 mM N-ethylmaleimide (NEM). After thorough
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mixing and centrifugation at 16,000xg for 20 minutes and 4 °C, supernatants were collected 
and stored at -80 °C. Samples were analysed within two weeks. The excess of NEM was 
removed by adding 70^L KOH (2.0M) followed by 60^L HCl (0.01M in 0.3M 3-(N- 
morpholino)-propanesulfonic acid buffer) to 100 ^L of sample. In the assay 100^L sample or 
standard was reduced by adding 10^L tris(2-carboxyethyl)phospine (Fluka, Bornem, The 
Netherlands;10% (w/v) in 0.9% sodiumchloride / 4.0 mM EDTA) and incubation at room 
temperature for 30 min. After reduction, 100^L PCA (0.6M with 1.0mM EDTA) was added 
and subsequently samples were mixed and centrifuged for 5 min at 10,000xg. Clear 
supernatant (100^L) was incubated for 1 hour and 60°C with 240^L reaction-mix containing 
20^L NaOH (1.55M), 200^L boratebuffer (125mM K2B4O74H2O and 4.0 mM EDTA, pH 
9.0), and 20^L 7-fluorobenzofurazane-4-sulfonic acid (5mg/mL in borate buffer). Of the 
derivatised sample 20^L was injected into the high performance liquid chromatography 
system (16). Data obtained were analysed with the Chromeleon chromatography data-system 
(Gynkotek, München, Germany). The free-to-oxidised ratio for each thiol (rCys, rHcy, rCys- 
Gly and rGSH) was calculated from the free and oxidised thiol data.
Characteristics of pregnancy between patients and controls were compared with the 
Wilcoxon-Mann-Whitney test. Differences in pregnancy as well as post-partum levels 
between patients and controls were calculated with the Student' s t-test, whereas differences 
between pregnancy and post-partum levels in the patient and control group were calculated 
with the paired-Student' s t-test. In view of the multiple testing a significant difference was 
reached if the P-value < 0.01. All statistical tests were performed using the Astute Statistical 
Add-In for Microsoft Excel 5 version 1.50.
Results
Women with severe preeclampsia were significantly younger, were more often nulliparous 
and had offspring with a lower birth weight as compared with control women (Table 8.1). 
Gestational age at time of study of preeclamptic women was lower compared with that of 
control women. Table 8.2 shows the results of the free and oxidised concentrations as well as 
the free-to-oxidised ratios of cysteine (fCys, oCys and rCys, respectively), homocysteine
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(fHcy, oHcy and rHcy), cysteinylglycine (fCys-Gly, oCys-Gly, rCys-Gly) and glutathione 
(GSH, GSSG and rGSH).
Table 8.2. Whole blood free and oxidised levels, and free-to-oxidised ratios of cysteine, 
homocysteine, cysteinylglycine and glutathione in women with severe preeclampsia and 
normotensive pregnant controls during pregnancy and in their post-partum period.
Severe preeclampsia 
Pregnancy Post-partum
Controls 
Pregnancy Post-partum
Cysteine
Free (|jmol/L) 
Oxidised (|jmol/L) 
Ratio
106.3 ± 29.8 
47.7 ± 13.6 
2.3 ± 0.4
88.6 ± 19.7*
38.6 ± 10.0* 
2.3 ± 0.3
68.8 ± 10.3# 
31.2 ± 6.1** 
2.2 ± 0.3
76.0 ± 8.7*:tt 
35.7 ± 4.6* 
2.1 ± 0.2*
Homocysteine
Free (|jmol/L) 
Oxidised (|jmol/L) 
Ratio
2.7 ± 1.6 
1.4 ± 0.6 
2.1 ± 0.9
3.0 ± 2.1 
1.2 ± 0.7 
2.6 ± 0.9f
2.7 ± 1.2 
1.1 ± 0.5
2.7 ± 0.9tt
3.4 ± 1.4* 
1.2 ± 0.7
3.1 ± 0.8t,tt
Cysteinylglycine
Free (|jmol/L) 
Oxidised (|jmol/L) 
Ratio
7.8 ± 2.7 
1.6 ± 0.6 
5.4 ± 2.4
10.1 ± 2.4* 
2.2 ± 0.9* 
5.7 ± 3.8
8.5 ± 1.5 
1.9 ± 0.6 
4.7 ± 0.9
11.2 ± 7.9 
2.4 ± 0.7* 
5.0 ± 3.7
Glutathione
Free (|jmol/L) 
Oxidised (|jmol/L) 
Ratio
830 ± 179 
18.3 ± 9.2 
54.8 ± 24.2
966 ± 176** 
19.0 ± 8.2 
60.8 ± 33.2
788 ± 124
17.5 ± 5.5
48.6 ± 14.0
949 ± 161** 
24.2 ± 9.4*:tt 
46.2 ± 21.3
Data are given in mean ± range.
Statistics:
f : P<0.01, *: P<0.001, **: P<0.0001 pregnancy versus post-partum.
: P<0.01, *: P<0.001, # : P<0.0001 severe preeclampsia versus normotensive controls.
In women with severe preeclampsia fCys as well as oCys levels are higher during pregnancy 
as compared to the levels after pregnancy, in contrast with controls, who showed lower fCys 
and oCys levels during pregnancy. This resulted in an unchanged rCys in both groups. During 
pregnancy women with severe preeclampsia had higher level of fCys and oCys, of which the
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fCys level remained higher after pregnancy as compared with corresponding values in control 
women. After pregnancy also rCys was higher in women with severe preeclampsia than in 
controls.
During pregnancy fHcy was lower in control women, whereas rHcy was lower in both 
patients and controls as compared with corresponding values after pregnancy. In women with 
severe preeclampsia rHcy was lower compared with that of controls. This higher oxidative 
status of homocysteine remained higher after pregnancy since women with severe 
preeclampsia had also lower post partum rHcy as compared with control women.
In women with severe preeclampsia both fCysGly and oCysGly were lower, whereas in 
control subjects only oCysGly was lower during pregnancy as compared with corresponding 
post partum levels. No differences were found between patient and control subjects during 
pregnancy or in the post partum period.
During pregnancy free levels of GSH were lower as compared with post partum values in 
both women with severe preeclampsia and control subjects. Furthermore GSSG levels were 
elevated in control women after pregnancy and were also higher compared with post partum 
values of women with severe preeclampsia. No differences between pregnancy and post­
partum values were found for rGSH in both groups.
Discussion
Until now only few studies have described the increase of oxidative stress with gestational 
age in normotensive pregnancies as well as pregnancies complicated with preeclampsia. 
However, these studies only indirectly showed oxidative stress by measuring products of 
oxidative damage or antioxidant capacities (19), or performed no measurements in the non­
pregnant state (7;8;20) . In contrast, we directly measured oxidative stress by quantification of 
the free-to-oxidised ratios of cysteine, homocysteine, cysteinyglycine and glutathione. We 
now demonstrate a transient increase of oxidative stress in normotensive pregnancy, which 
was even higher in women with preeclampsia as measured by the lower rHcy. Furthermore, in 
normotensive women as well as women with preeclampsia the levels of glutathione were
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transiently decreased during pregnancy, which may point to a higher utilisation of glutathione 
as also described in women with pregnancy-induced hypertension or mild preeclampsia (19).
In non-pregnant women only reference values for free levels of both cysteine and glutathione 
in whole blood (21) or only for free levels of glutathione (22;23) are documented. Values as 
described in these studies are similar to the data in the post partum period reported here. 
However, no data on whole blood levels of free as well as oxidised homocysteine and 
cysteinylglycine have been described so far. During uncomplicated pregnancies total plasma 
volume expands, whereas in preeclampsia a reduction of plasma volume is reported, which 
might be up to 40% lower in severe cases (24;25). This could explain the transient lower thiol 
levels during normotensive pregnancy and higher fCys and oCys levels during preeclampsia.
The free and oxidised levels as well as the free-to-oxidised ratios for the thiols during 
pregnancy in the present study are in line with those described in a previous study of our 
group (17). Except for the fHcy and oHCy levels in control subjects, which seem to be higher 
as compared with those in the previous study (2.7±1.2 versus 1.2 (0.2-21.1) ^mol/L and
1.1 ±0.5 versus 0.4 (0.01-1.6) ¡^mol/L, respectively), however, the rHcy was similar. It is 
known that amounts of lipid peroxides increase with gestational age (5;7), which also results 
in parallel oxidation of homocysteine. In addition, high levels of free homocysteine are easily 
(auto)oxidised to homocystine or mixed disulphides, which may induce oxidative stress 
(26;27). The difference in gestational age between the former (17) and the present study (39+1 
(37+6-42+1) versus 32+0 (28+0-38+2) weeks) may explain the higher levels of oxidised 
homocysteine in the control group here presented. Therefore, the trend towards a higher oHcy 
level in women with preeclampsia (P=0.05) suggests that in women with severe preeclampsia 
a more pronounced oxidative stress is present as compared to that in normotensive pregnant 
controls. Furthermore, it is interesting, that despite the rather large difference in gestational 
age between both control groups, we did not find any difference in whole blood values of the 
other thiols (17). This might indicate that in the third trimester the concentrations of cysteine, 
cysteinylglycine and glutathione are relatively stable.
In discrepancy with the results of an earlier study (19), we could not confirm the significant 
higher rGSH 6 weeks post partum in both the patient and control groups. However, in the 
previous study a different patient population was studied (mild hypertensive diseases versus 
severe preeclampsia in this study) and only a small number of subjects was investigated.
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However, the significant lower ratio for GSH during pregnancy in the previous study 
emphasises the presence of a transient elevation of oxidative stress in pregnancy. Other 
studies have only assessed the presence of oxidative stress indirectly by measurement of 
antioxidant capacity or products of oxidative damage. Davidge et al. (20) reported a higher 
ratio of malondialdehyde level over antioxidant capacity in women with preeclampsia 
compared with control subjects, which points to more oxidative stress in preeclampsia. This 
ratio decreased within 24 hours after delivery in both groups. Furthermore, Little et al.(20) 
described increasing levels of lipid peroxides with gestational age and a drop of these levels 
after birth. For vitamin E a longitudinal increase with gestational age was shown by Cikot et 
al (6), which normalised to preconceptional values within 6 weeks after pregnancy. Our 
results are in line with those of the above-mentioned studies, which all indicate that during 
pregnancy oxidative stress increases that normalises after birth.
Barden et al. (28) reported that most biochemical and haematological parameters normalised 
within 6 weeks after pregnancy. The results of the free-to-oxidised ratios of homocysteine, 
cysteinylglycine and glutathione in women with preeclampsia and normotensive controls after 
pregnancy were similar to those in a study of women with severe preeclampsia or 
normotensive pregnancy who were analysed at least 6 months after their last pregnancy (this 
thesis, chapter 9). The significant difference for rCys as described here was not present 
anymore 6 months post partum, which might point to a pregnancy-induced effect. The 
significant difference for rHcy remained present even after subsequent successful pregnancies 
and an extended post partum period (pregnancy (this thesis, chapter 9). This might indicate 
that in women who develop preeclampsia an underlying disturbance in homocysteine redox 
status is present, which might also predispose to vascular related diseases in later life (9).
In summary, we conclude that during pregnancy more oxidative stress exists as compared 
with non-pregnant women, whereas in preeclampsia even more oxidative stress is present. 
This higher level of oxidative stress in women with preeclampsia may be caused by a disorder 
in homocysteine metabolism, which may also predispose them to vascular related diseases in 
later life.
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Abstract
Recent studies suggest that women with a history of preeclampsia are at higher risk to 
develop cardiovascular diseases (CVD), since the aetiology of both diseases have common 
characteristics including oxidative stress and activation of vascular endothelium. Therefore, 
we investigated total plasma levels of cysteine (tCys), homocysteine (tHcy), cysteinylglycine 
(tCysGly) and glutathione (tGSH), the free-to-oxidised ratio in whole blood of these thiols, 
the glucose 6-phosphate dehydrogenase enzyme activity and antioxidant capacity in non­
pregnant women with a history of severe preeclampsia (n=131) and control women with an 
uncomplicated obstetrical history (n=94) more than 6 months after their last pregnancy. 
Former patients showed a higher level (mean ± SD) of tHcy (13.1 ± 5.0 versus 11.5 ± 4.8 
¡jmol/L; P<0.03) and tCysGly (37.5 ± 5.6 versus 34.0 ± 5.8 ^mol/L; P<0.0001) compared to 
controls, whereas tCys was lower (232 ± 31 versus 242 ± 39; P<0.002). The lower free-to- 
oxidised ratio of homocysteine (2.3 ± 0.82 versus 2.9 ± 1.0, P<0.001) among women with a 
history of severe preeclampsia as compared to control subjects might indicate a higher 
oxidant status for homocysteine. Former patients had also a higher antioxidant capacity as 
compared to controls (0.79 ± 0.14 versus 0.74 ± 0.11 mmol Fe2+/L, P=0.002). Since women 
with a history of severe preeclampsia showed elevated total homocysteine levels, which is an 
independent risk factor for CVD by (auto)oxidation of homocysteine, these women may have 
an enhanced risk for the subsequent development of cardiovascular-related problems in later 
life.
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Introduction
Preeclampsia is classically defined as pregnancy induced hypertension with proteinuria (1). 
This severe complication of pregnancy has a prevalence of 5-7% and is accompanied by 
substantial perinatal as well as maternal morbidity and mortality (2). In the last decade, more 
and more evidence is found for the role of oxidative stress and endothelial damage in the 
development of this disease (3-5). Oxidative stress may be counteracted by enzymatic as well 
as non-enzymatic antioxidants. First line defence against oxidative damage by free radicals, 
superoxide, lipid peroxides, hydrogen peroxides and other reactive oxygen species (ROS) is 
provided by the glutathione / glutathione dependent enzyme systems (6;7). Glutathione itself 
can serve as an antioxidant, in addition to its role as co-factor in the reactions of glutathione
S-transferases and glutathione peroxidases, the latter scavenging ROS upon oxidation of 
glutathione (6;8). To maintain the cellular redox-balance, the oxidised form of glutathione is 
either quickly reduced by glutathione reductase, or it is excreted when excessive amounts are 
formed (8).
Women with a history of severe preeclampsia are thought to be at higher risk to develop 
cardiovascular diseases (CVD) in later life (9;10). It has been proposed that similar 
pathophysiological pathways lead to the development of both preeclampsia and CVD. 
Underlying disorders including trombophilia, chronic hypertension and pre-existing 
endothelial dysfunction, all increase the risk for the development of preeclampsia and are also 
associated with an increased risk for CVD (11-15). Another common feature in both diseases 
is the presence of lipid peroxidation (3;16). Hyperhomocysteinemia, which is an independent 
risk factor for CVD (17;18), may initiate the process of lipid peroxidation by autooxidation of 
homocysteine, whereby ROS are formed (16).
The goal of our study was to investigate whether risk factors for the development of CVD 
such as increased levels of homocysteine or oxidative stress are present in non-pregnant 
women with a history of severe preeclampsia.
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Materials and Methods
Patient and Control Subjects
The Institutional Medical Ethical Review Committee approved the study protocol. 
Preeclampsia was defined according to the standard of the International Society for the Study 
of Hypertension in Pregnancy as pregnancy induced hypertension (diastolic blood pressure 
(BP) > 90 mmHg on two or more occasions each more than 4 hours apart) with proteinuria 
(urinary protein/creatinine ratio >0.30 g/10 mmol). Severe preeclampsia was defined as 
preeclampsia with a diastolic BP over 110mmHg or the presence of the HELLP syndrome. 
The HELLP syndrome was defined by hemolysis (lactic dehydrogenase (LDH) enzyme 
activity >600 IU/L), elevated liver enzymes (both aspartate aminotransferase (ASAT) and 
alanine aminotransferase (ALAT) enzyme activity >70 IU/L) and low platelets (platelet count 
<100x109/L). We recruited 131 women (19), who had experienced severe preeclampsia with 
or without HELLP syndrome, or HELLP syndrome with or without gestational hypertension 
(for characteristics see Table 9.1) and 94 women with uncomplicated pregnancies only, at 
least 6 months after their last pregnancy. All women gave their informed consent. After their 
index pregnancy 78 (60%) of the former-preeclampsia patients became pregnant again once 
(n=60; 77%) or more than once (n=18; 23%). Some of these women developed recurrent 
preeclampsia with or without the HELLP syndrome (27%) or pregnancy induced 
hypertension (30%), whereas the others remained normotensive (40%) or had a miscarriage 
(3%). Median (interquartile range) of the time period between blood sampling and last 
pregnancy did not differ between former-preeclampsia patients and controls (28 (14-54) 
versus 28 (9-72) months).
Blood Sampling
Whole blood was obtained by venapuncture in sterile vacutainer tubes anti-coagulated with 
EDTA. Blood was transported without delay to the laboratory at room temperature, where it 
was handled for analyses of free and oxidised thiols and where the immediate analysis of 
glucose-6-phoshate dehydrogenase (G6PDH) enzyme activity was performed. The remainder 
was centrifuged at 1,500xg for 10 min and room temperature. Clear plasma was stored in 
aliquots at -30°C  until analysis.
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Table 9.1. Characteristics of women with a history of severe preeclampsia during pregnancy.
Gestational age at delivery (weeks+days) 
Systolic BP (mmHg; Korotkoff V) 
Diastolic BP (mmHg; Korotkoff V) 
Protein/Creatinine ratio (g /10 mmol) 
LDH (IU/L)
ASAT (IU/L)
ALAT (IU/L)
Platelet count (*109 / L)
Hb (g/dL)
Ht
Serum creatinine (|jmol/L)
Serum uric acid (|jmol/L)
31+3 (28+e _ 35+3)
165 (150 -  180) 
110 (100 -  115) 
2.9 (0.4 -  6.5) 
631 (377 -  1148) 
84 (28 -  230)
75 (21 -  230) 
94 (56 -  165) 
7.3 (6.8 -  8.0)
0.35 (0.31 -  0.38)
76 (69 -  83) 
0.40 (0.34 -  0.46)
Note: Values are presented as median (interquartile range).
Abbreviations: Hb -  haemoglobin, Ht -  haematocrit, BP -  blood pressure, LDH -  lactate 
dehydrogenase enzyme activity, ALAT -  alanine aminotransferase enzyme activity, ASAT -  aspartate 
aminotransferase.
Biochemical Analyses
For the measurement of the G6PDH enzyme activity the method as described by Fairbanks et 
al. was used (20). In short; hemolysates were prepared by adding 900¡^L hemolysis buffer 
(5% (v/v) Triton-X 100, EDTA pH 7.0 (2.7 mM), and dithiotreitol (4 mM) in milliQ) to 
100¡^L whole blood followed by thoroughly mixing. 20-^L sample or blank (hemolysis buffer 
without Triton-X 100) was added to a reaction tube containing 880^l reaction mix (100 ^L 
Tris (1 M) / EDTA-pH 8.0 (5 mM), 100^L MgCl2 (100 mM), and 100^L NADP (2.0 mM) in 
milliQ) and incubated for 10 min at 37°C. Hereafter, samples were mixed with 100^L 
glucose-6-phosphate (0.6 mM) in Tris/EDTA buffer) and transferred to a disposable cuvet. 
The increase of absorbance at 340nm was measured during 10 min at 37°C. Slopes were used 
to calculate the G6PDH enzyme activity and expressed as U/L.
For the measurement of free and oxidised thiols whole blood was handled within one hour as 
described earlier by our group (8). In short, for assay of the free thiol levels (both reduced and 
oxidised non-protein bound thiols), 500^L whole blood was added to 500^L ice-cold 12% 
perchloric acid (PCA) containing 2.0 mM bathophenanthrolinedisulfonic acid (BPDS). For
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assay of oxidised free thiols, another 500 whole blood was added to 500 12% PCA 
containing 2.0 mM BPDS and 40 mM N-ethylmaleimide (NEM). After thorough mixing and 
centrifugation at 16,000xg for 20 min and 4 °C, supernatants were collected and stored at -80 
°C until analysis. Before analysis the excess of NEM was removed by adding 70^L KOH (2.0 
M) followed by 60^L HCl (10 mM in 300 mM 3-[N-morpholino]-propanesulfonic acid 
buffer) to 100 ^L of sample.
Whole blood as well as plasma samples were analysed for levels of cysteine (Cys), 
homocysteine (Hcy), cysteinylglycine (CysGly), and glutathione (GSH) by high performance 
liquid chromatography with fluorescent detection as described previously (8;21). In short, 
100^L sample or standard was reduced by adding 10^L tris(2-carboxyethyl)phospine (10% 
(w/v) in NaCl (0.9%)/ EDTA (4.0 mM)) and followed by incubation at room temperature for 
30 min. After reduction, 100^L PCA (0.6 M with 1.0 mM EDTA) was added and 
subsequently samples were mixed and centrifuged for 5 min at 10,000xg. Clear supernatant 
(100^L) was incubated with 240^L reaction-mix containing 20^L NaOH (1.55 M), 200^L 
boratebuffer (K2B4O7'4H2O (125 mM) and EDTA (4.0 mM); pH 9.0), and 20^L 7- 
fluorobenzofurazane-4-sulfonic acid (5mg/mL in borate buffer) for 1 hour and 60°C. Of the 
derivatised sample 20^L was injected into the high performance liquid chromatography 
system. Data obtained were analysed with the Chromeleon chromatography data-system, 
Gynkotek (München, Germany). Thiol levels were calculated using four-point calibration 
curves for each thiol and were expressed in ^mol/L. As a measure of the oxidant status we 
calculated the free-to-oxidised ratio, which has no dimension.
The antioxidant capacity of each subject was measured using the Ferric Reducing Ability of 
Plasma (FRAP) assay as described by Benzie and Strain (22). Briefly; 33^L sample, blank 
(H20) or Fe2+-standard was added to 1.0mL FRAP solution (25mL sodiumacetaat-pH 3.6 (300 
mM), 2.5mL 2,4,6-tripyridyl-s-triazine (40mM), and 2.5mL FeCl3'6H20 (20 mM)) and 
incubated for 3 min at 37°C. Absorbance against the blank was read at 593nm. The 
antioxidant capacity was calculated using a seven-point calibration curve of known amounts 
of Fe2+ and expressed as mmol Fe2+/L.
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Statistical Analysis
Differences in biochemical parameters between the patient and control population were 
calculated with the Student' s t-test using the Astute Statistical Add-In for Microsoft Excel 5 
version 1.50. A difference was considered significant when P<0.05.
Table 9.2. Whole blood glucose 6-phosphate dehydrogenase enzyme activity, plasma 
antioxidant capacity, total plasma concentrations and free-to-oxidised ratios in whole blood of 
thiols in women with uncomplicated pregnancy or with a history of severe preeclampsia.
History of uncomplicated 
pregnancy
History of severe 
preeclampsia
G6PDH enzyme activity (U/L) 3.5 ± 0.6 3.4 ± 0.6
FRAP (mmol Fe2+/L) 0.74 ± 0.11 0.79 ± 0.14*
Cysteine:
Plasma (|jmol/L) 242 ± 39 2 3 2 ± 31*
Ratio free-to-oxidised 2.3 ± 0.3 2.4 ± 0.5
Homocysteine:
Plasma (|jmol/L) 11.5 ± 4.8 13.1 ± 5.0 *
Ratio free-to-oxidised 2.9 ± 1.0 2.3 ± 0.8*
Cysteinylglycine:
Plasma (|jmol/L) 34.0 ± 5.8 37.5 ± 5.6*
Ratio free-to-oxidised 4.7 ± 2.3 5.0 ± 3.7
Glutathione:
Plasma (|jmol/L) 8.3 ± 1.9 8.3 ± 1.7
Ratio free-to-oxidised 51.1 ± 20.1 56.4 ± 22.3
Data are given as mean ± SD, Number of subjects (normotensive -  preeclampsia) investigated are 
G6PDH enzyme activity (84 -  125), FRAP (86 -  124) and thiol measurements (94 -  131).
Abbreviations: G6PDH -  glucose 6-phosphate dehydrogenase enzyme activity; FRAP -  ferric 
reducing ability of plasma.
Statistics: *: P<0.0001, *:P< 0.002, *: P<0.03 normotensive versus preeclamptic pregnancy.
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Results
Table 9.2 shows the results of the whole blood G6PDH enzyme activity, plasma antioxidant 
capacity, total concentrations of cysteine (tCys), homocysteine (tHcy), cysteinylglycine 
(tCysGly) and glutathione (tGSH) in plasma, and free-to-oxidised ratios of these thiols in 
whole blood in both study groups.
The enzyme activity of G6PDH was similar in both groups. Plasma levels of tCys were 
significantly lower in women with a history of severe preeclampsia as compared with those in 
control women, whereas tHcy and tCysGly levels were higher. No significant differences 
were found for tGSH levels between former severe preeclampsia patients and control women. 
We did not find any differences between patient and control subjects for the free-to-oxidised 
ratio of Cys, CysGly and GSH. Only the free-to-oxidised ratio of Hcy was significantly lower 
in women with a history of severe preeclampsia as compared with that of control women, 
which indicates the presence of a higher oxidative Hcy status in former severe preeclampsia- 
patients. Former severe preeclampsia-patients showed a significant higher antioxidant 
capacity, as measured by the FRAP assay, in comparison to control women.
Discussion
Preeclampsia and cardiovascular diseases (CVD) have common characteristics including 
genetic thrombophilia, endothelial dysfunction and oxidative stress (3;4;12;23;24). 
Furthermore, in follow-up studies a clear association between preeclampsia and the 
subsequent development of CVD was found (9;10). Previous studies have looked at these 
common characteristics in former patients with preeclampsia respectively 10 weeks (25), 3 
months (26), or 5 months (11) after the index pregnancy. In our study we investigated the 
thiol status and antioxidant capacity in former severe preeclampsia-patients at least 6 months 
after their last pregnancy. Our main finding was that both plasma tHcy concentrations and the 
homocysteine oxidant status in whole blood were higher in former severe preeclampsia- 
patients as compared with control subjects, whereas also antioxidant capacity was higher in 
women with a history of severe preeclampsia.
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Hyperhomocysteinemia is an independent risk factor for the development of CVD, including 
those of coronary, cerebral as well as peripheral arteries (16;27), which affects females more 
than males (18). The pathways how Hcy may lead to endothelial dysfunction and CVD are 
still unclear, however, it has been hypothesised that oxidative stress might play a role, since 
(auto)oxidation of Hcy, indicated by a decrease of tCys levels (28) as noticed in our study, 
results in the formation of several types of reactive oxygen species (ROS) (17). Furthermore, 
the induction of endothelial dysfunction by oral methionine loading (27;28), which results in 
temporal elevated homocysteine levels, could be prevented by pre-treatment with vitamin C
(29). In the defence against oxidative damage by ROS glutathione plays an important role. In 
scavenging ROS, glutathione is oxidised (GSSG) either by autooxidation or in a reaction 
catalysed by glutathione peroxidases (8). Since increasing amounts of intracellular GSSG may 
cause metabolic perturbations, including demolished protein synthesis (30), two different 
ways to preserve intracellular redox state exist. GSSG can quickly be reduced by glutathione 
reductase in a NADPH dependent reaction (8;31), or GSSG can be excreted from the 
erythrocyte to plasma for which a Mg-ATP dependent transporter is described (30;32;33). 
However, the efflux of intracellular glutathione is the initial step of glutathione breakdown by 
y-glutamyltranspeptidase, which might cleave the y-glutamyl bond of glutathione resulting in 
glutamate and cysteinylglycine (33). Therefore, in the prevention of intracellular oxidative 
stress the plasma levels of cysteinylglycine might increase. Indeed in our study former severe 
preeclampsia patients showed lower plasma cysteine and higher cysteinylglycine levels as 
compared with control subjects.
Surprisingly, the antioxidant capacity, as measured by the FRAP assay, was higher in former 
severe preeclampsia patients as compared with those in control subject. Since glutathione is a 
very potent antioxidant, we also expected a higher plasma glutathione concentration in 
women who had severe preeclampsia. However, this was not found which could be explained 
by the fact that during homeostasis glutathione disulfide is quickly reduced by glutathione 
reductase (8;31) instead of secreted from the cell. Since the FRAP assay does not measure -  
SH containing antioxidants (22), this indicates that other non thiol-related antioxidants are 
probably elevated. The higher antioxidant capacity may be an adaptive mechanism to prevent 
oxidative damage in these women during their non-pregnant state, however due to continuous 
generation of ROS oxidative damage may slowly accumulate, which could result in problems 
during later life. The antioxidant capacity might not be sufficient during pregnancy, because
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the level of oxidative stress progressively increases during gestation (34) and is even more 
elevated in preeclampsia (3).
After their index pregnancy 60% of the former severe preeclampsia patients had one or more 
subsequent pregnancies. Of those pregnancies 40% remained normotensive, whereas in 57% a 
recurrence of hypertensive complications being either pregnancy induced hypertension or 
preeclampsia / HELLP was reported. Women with recurrent preeclampsia may represent a 
different subset of women with a history of severe preeclampsia with regard to underlying 
pathophysiological mechanism. We could not demonstrate any significant differences, 
however, for all the parameters investigated between former patients without or with recurrent 
preeclampsia after the index-pregnancy (Table 9.3).
Table 9.3. Whole blood glucose 6-phosphate dehydrogenase enzyme activity, plasma 
antioxidant capacity, total plasma concentrations and free-to-oxidised ratios in whole blood of 
thiols in preeclamptic women with recurrent hypertensive disorders of pregnancy after the 
index-pregnancy and those without further complications.
No complications after index- 
pregnancy 
(n=31)
Recurrent hypertensive 
disorders of pregnancy 
(n=45)
G6PDH enzyme activity (U/L) 3.4 ± 0.6 3.3 ± 0.5
FRAP (mmol Fe2+/L) 0.79 ± 0.15 0.80 ± 0.14
Cysteine:
Plasma (|jmol/L) 227 ± 30 235 ± 32
Ratio free-to-oxidised 2.3 ± 0.5 2.4 ± 0.3
Homocysteine:
Plasma (|jmol/L) 13.4 ± 6.0 12.9 ± 4.1
Ratio free-to-oxidised 2.2 ± 0.8 2.3 ± 0.7
Cysteinylglycine:
Plasma (|jmol/L) 37.8 ± 5.4 37.3 ± 5.9
Ratio free-to-oxidised 5.0 ± 3.0 5.1 ± 4.1
Glutathione:
Plasma (|jmol/L) 8.1 ± 1.5 8.4 ± 1.9
Ratio free-to-oxidised 56.8 ± 24.6 56.5 ± 19.3
Data are given as mean ± SD
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Furthermore, in most former patients blood was collected in the period after pregnancies, 
which were not complicated by severe preeclampsia. This may indicate that the differences 
found in former patients compared to controls may represent underlying factors instead of 
being initiated or influenced by pregnancy. Therefore, we postulate that the higher redox- 
status of homocysteine in women with a history of severe preeclampsia as compared to 
uncomplicated pregnancy outcome may be a pre-existing factor, which predisposes these 
women to develop preeclampsia and eventually CVD in later life. Consequently our results 
indicate that homocysteine-lowering therapy, in addition to antioxidant supplementation that 
showed to decrease the risk of preeclampsia in a high-risk population (35), might be 
beneficial in prevention of preeclampsia.
In conclusion, the higher oxidative homocysteine status in whole blood, the higher tHcy and 
tCysGly and lower tCys levels in plasma of non-pregnant women with a history of severe 
preeclampsia compared to corresponding values in women after uncomplicated pregnancies, 
may be involved in the pathophysiological mechanisms contributing to the increased risk for 
the subsequent development of CVD. The higher antioxidant capacity might be an adaptive 
mechanism to prevent general oxidative stress in these women.
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Abstract
Background: Preeclampsia is a pregnancy related multisystem disorder characterised by 
elevation of blood pressure and proteinuria, in which oxidative stress may play an important 
role. Blood pressure is partly controlled by O2 production by NADPH/NADH oxidase and 
recently it was shown that a C242T substitution in the p22phox gene was associated with 
coronary artery disease, in which elevated blood pressure and oxidative stress are also 
important pathophysiologic features.
Aim: To study the prevalence of the C242T polymorphism in the NADPH/NADH oxidase 
gene in women with preeclampsia and / or hemolysis, elevated liver enzymes and low 
platelets (HELLP) syndrome as compared to women with a normotensive pregnancy.
Methods and Results: DNA from control women (n=78), women with preeclampsia (n=40), 
HELLP syndrome (n=9) or women with HELLP complicated by pregnancy induced 
hypertension or preeclampsia (n=46) was tested for the presence of the C242T polymorphism 
by polymerase chain reaction followed by restriction fragment length polymorphism. The 
prevalence of the homozygous CC-genotype was similar in the patient groups compared with 
controls. The allele frequency of the T-allele was 31% in both control and patient groups. 
Conclusions: The C242T polymorphism in the p22phox subunit of the NADPH/NADH 
oxidase gene is not associated with preeclampsia. Therefore, oxidative stress generated by 
NADPH/NADH oxidase probably does not play a role in the development of preeclampsia.
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Introduction
Preeclampsia is a pregnancy related multi-system disorder with considerable maternal and 
foetal mortality and morbidity (1). It is clinically characterised by an elevated blood pressure 
and proteinuria. Although the pathogenesis of the disorder is not yet elucidated, it is thought 
that oxidative stress and damage of the endothelium lining the blood vessel wall are important 
contributing factors (2). Regulation of blood pressure is partly controlled by NADPH/NADH 
oxidase, which releases the superoxide anion O2- upon angiotensin II activation, resulting in 
vasoconstriction and elevation of blood pressure (3). The localisation of NADPH/NADH 
oxidase, mainly on the cell membrane of neutrophils and endothelial cells, suggests that this 
enzyme may play an role in the pathophysiology of disorders in which oxidative stress is 
involved. Recently it was shown that a C242T substitution in the gene of the p22phox subunit 
of NADPH/NADH oxidase, changing histidine-72 to tyrosine in the heme-binding site, which 
reduces the superoxide production (4), might reduce the susceptibility to coronary artery 
disease (CAD) in Japanese populations (5-6). Although a controversy exists between the 
reports in Caucasian populations (7-8), the C242T polymorphism was associated with 
progression of CAD (9). Since the aetiology of CAD seems to be comparable to that of 
preeclampsia and the higher risk of preeclamptic women to develop vascular related diseases 
in later life (10-11), we studied the prevalence of the CC-genotype, which is associated with 
highest superoxide production, in women with preeclampsia and/or hemolysis, elevated liver 
enzymes, low platelets (HELLP) syndrome and compared it with controls.
Materials and Methods
The Institutional Medical Ethical Review Committee approved the study protocol. After 
informed consent was obtained, whole blood from women hospitalised for preeclampsia 
(n=40), women with the HELLP syndrome only (n=9) or both HELLP syndrome and 
preeclampsia or pregnancy induced hypertension (n=46) was collected. Preeclampsia was 
defined according to the ISSHP criteria, being a pregnancy induced hypertension (diastolic 
blood pressure >90 mmHg on two or more occasions, each more than 4 hours apart) with 
proteinuria (protein/creatinine ratio >0.30 g/10 mmol). The HELLP syndrome was 
biochemically characterised by the simultaneous occurrence of hemolysis (lactic
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dehydrogenase level >600 IU/L), elevated liver enzymes (both aspartate and alanine 
aminotransferase activity >70 IU/L) and low platelets (thrombocyte count under 100x109/L). 
Women with at least one completed normotensive pregnancy served as control subjects 
(n=78). The characteristics of the women studied are depicted in Table 10.1.
DNA was isolated using the Puregene genomic DNA isolation kit (Gentra Systems, 
Minneapolis, USA), according the instructions of the manufacturer. DNA was analysed for 
the C242T polymorphism in the p22phox subunit of the NADPH/NADH oxidase gene using 
PCR/RFLP as described previously (5). In short, a 348 bp DNA fragment containing the 
polymorph C242T site was amplified from genomic DNA using sterile H2O as a negative 
control. The PCR product was digested with RsaI. When an allele bears a T instead of a C at 
position 242 this results in a RsaI digestion site yielding two fragments of 160 bp and 188 bp. 
Otherwise, when a C is present, the 348 bp PCR product is not digested. The presence of both 
heterozygous or homozygous polymorph subjects indicates that the digestion in the RFLP 
analysis was successful. Genotypes at position 242 were assigned as follows: CC, 
homozygous wildtype; CT: heterozygous; TT: homozygous polymorph.
Differences between patient characteristics were analysed with the non-parametric Wilcoxon- 
Mann-Whitney test and significance was reached at P<0.05. Prevalence of the different 
genotypes was calculating using Chi-square test. Both statistical tests were performed using 
the Astute Statistical Add-In for Microsoft Excel 5 version 1.50.
Results
A similar distribution of the three possible C242T polymorph genotypes in the p22phox gene 
of NADPH/NADH oxidase was found in the different patient and control groups (Table 10.2). 
This resulted in non-significant odds ratios (95% CI) of 0.95 (0.44-2.04), 0.87 (0.42-1.81) and
1.9 (0.44-8.14) for the women with preeclampsia, HELLP with preeclampsia or pregnancy 
induced hypertension and HELLP solely, respectively. Also the prevalence of the 242 C- or 
T-genotypes for the total patient population were found to be similar when compared to the 
control group. The odds ratio (95% CI) of the total patient population compared with controls 
was 0.97 (0.53-1.77).
The T-allele frequency was 0.31 for both the control and the total patient population.
166
Table 10.1. Characteristics of the women studied.
Controls
(n=78)
Preeclampsia
(n=40)
PE/PIH + HELLP 
(n=46)
HELLP
(n=9)
All patients 
(n=95)
Age (y) 32 [22 -  42] 31 [20 -  37] 30 [19 -  41] 30 [25 -  34] 30 [19 -  41]
Gestational age (wk+days) 33+4 [24+4 -  38+0] 30+6 [26+3 -  39+5] 4]
+
04-6
+
7[20
+
03 31 +3 [24+4 -  40+4]
Diastolic BP (mmHg; Korotkoff V) 115 [95 -  140] 115 [90 -  140] 80 [80 -  95]** 115 [80 -  140]
Protein/creatinine ratio (g/10mmol) 3.3 [0.1 -33.8] 6.9 [0.01 -  47.0] 0.1 [0.03 -  0.23]** 5.2 [0.01 -  47.0]
Alanine aminotransferase (IU/L) 18 [6 -  596] 206 [40 -  1760]* 455 [220 -  727]** 137 [6 -  1760]
Aspartate aminotransferase (IU/L) 27 [12 -  593] 238 [73 -  1780]* 518 [338 -  768]** 152 [12 -  1780]
Lactic dehydrogenase (IU/L) 464 [292 -  1974] 1179 [319 -  5980]* 1349 [715 -  1927] t 780 [292 -  5980]
Thrombocyte count (x109) 185 [101 -  573] 52 [15 -  98]* 58 [39 -  98]* 72 [15 -  573]
Abbreviations: BP -  blood pressure; PE -  preeclampsia; PIH -  pregnancy-induced hypertension; HELLP -  hemolysis, elevated liver enzymes and 
low platelets syndrome
Statistics:
*: P<0.0001 Preeclampsia versus PE/PIH + HELLP and Preeclampsia versus HELLP
f : P<0.001 Preeclampsia versus HELLP
*: P<0.03 PE/PIH + HELLP versus HELLP
T able 10.2. Distribution of C242T polym orhism  in th e  p 22p h ox  su b u n it o f th e  NADPH/NADH-oxidase g en e .
Controls
(n=78)
Preeclampsia
(n=40)
PE/PIH + HELLP 
(n=46)
HELLP
(n=9)
All patients 
(n=95)
CC 40 (51.3) 20 (50.0) 22 (47.8) 6 (67.7) 48 (50.5)
TC + TT 38 (48.7) 20 (50.0) 24 (52.2.) 3 (33.3) 47 (49.5)
Odds Ratio (95% CI) 0.95 (0.44 -  2.04) 0.87 (0.42 -  1.81) 1.9 (0.44 -  8.14) 0.97 (0.53 -  1.77)
T allele frequency 0.31 0.30 0.35 0.17 0.31
Abbreviations: PE -  preeclampsia; PIH -  pregnancy-induced hypertension; CI -  confidence interval; 
HELLP -  hemolysis, elevated liver enzymes and low platelets syndrome
Percentages of the prevalence of the different genotypes are given in parenthesis.
Polymorpic genotypes at position 242 were assigned as follows:
CC: homozygous wildtype; both alleles bearing cytosine
CT: heterozygous; bearing cytosine at one allele and thymidine at the other
TT: homozygous mutant; both alleles bearing thymidine
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Discussion
Previously it was shown by Inoue et al. (5) that the C242T polymorphism in the p22phox 
subunit of NADPH/NADH oxidase gene decreased the susceptibility to coronary artery 
diseases (CAD) in a Japanese population. They postulated that this polymorphism in the 
heme-binding site might have an effect on activity and regulation of NADPH/NADH oxidase. 
Individuals with the CT or TT genotypes might have lower oxidative stress as result of lower 
O2- production as compared to individuals bearing the CC genotype (4). Since mechanisms 
contributing to CAD may also be important in the aetiology of preeclampsia (2) we 
hypothesised that women who develop preeclampsia may have a higher prevalence of the CC 
genotype. Although our subgroups are small and as a consequence the power to detect 
differences is relatively low, the similar distribution of the CC-genotype in the patient and 
control populations provide evidence that the CC genotype was not associated with 
preeclampsia in a Dutch study population. Our findings in a Caucasian population are in line 
with the findings of Guzik et al. (4), Gardemann et al. (7) Li et al. (8), and Cahilly (9), who 
found similar prevalences of the CC-genotype (45.4%, 44.3%, 45.6%, and 43.5%, 
respectively) and T-allele frequency (33%, 32%, 34%, and 34%, respectively) in large 
Caucasian populations. However, in Japanese control subjects the prevalence of the CC 
genotype was 73.6% (5) or 86.7% (6) compared with 51.3% in our Caucasian population. 
Racial differences between the two study populations could explain these different findings 
for the prevalence of the C242T-polymporhic variants in controls.
In conclusion, since preeclampsia is a multi-factorial condition (1), in which oxidative stress 
seems to plays a central role, the finding of a similar distribution of the C242T polymorph 
variants between patients and controls suggests that superoxide radical production by 
NADPH/NADH oxidase does not play a role in development of preeclampsia (2).
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Abstract
Background: Haptoglobin (Hp) is a glycoprotein that consists of three phenotypes, Hp1-1, 
Hp1-2 and Hp2-2, which are encoded by different alleles. Hp is protective against oxidative 
damage by its capacity to bind free haemoglobin for which Hp2-2 has the lowest affinity. In 
the pathogenesis of preeclampsia and the haemolysis, elevated liver enzymes, low platelets 
(HELLP) syndrome, oxidative stress may play an important role, which might be exaggerated 
by elevated levels of free haemoglobin generated by haemolysis.
Aim: To investigate the prevalence of the Hp2-2 genotype in women with a history of severe 
preeclampsia with or without HELLP syndrome as compared to women with uncomplicated 
pregnancies only.
Materials & Methods: Haptoglobin genotypes were assessed in genomic DNA samples of 
women with severe preeclampsia with or without HELLP syndrome (n=131) and control 
women (n=166) using polymerase chain reaction. A subset of patients with HELLP syndrome 
(n=90) was analysed separately. Data were analysed using the Chi-square test.
Results: Women with severe preeclampsia tended to have a lower prevalence of Hp2-2 
genotype as compared with that of control women (27% versus 35%; %2=1.9 and P=0.2), 
however the difference was significant in the subset of women with HELLP syndrome (20% 
versus 35%; %2=6.2 and P=0.01).
The Hp2 allele frequency in women with preeclampsia was similar to that of control women 
(0.52 and 0.57, respectively), whereas that of women with HELLP syndrome was lower (0.44; 
X2=6.3 and P=0.01).
Conclusion: Women with the Hp2-2 genotype have a lower risk to develop HELLP 
syndrome.
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Introduction
Haptoglobin (Hp) is an acute-phase a 2-sialoglycoprotein, which is characterised by molecular 
heterogeneity (1). Due to a genetic polymorphism different Hp phenotypes exist of which 
Hp1-1, Hp1-2 and Hp2-2 are the three major isoforms in humans. Hp consists of two different 
polypeptide chains, the heavy ß-chain, which is identical in all haptoglobins, whereas 
modifications in the light a-chain lead to the different Hp phenotypes. The a 1-chain can be 
divided in a slow (a 1S) and fast ( a 1F) migrating chain. These two chains differ in one amino 
acid; at position 54 the lysine of the a 1F-chain is substituted for a glutamic acid in the a 1S-
2 1S 1Fchain. The a  -chain is the result of a fusion of the a  - and the a  -allele (2).
The most important function of Hp is capturing haemoglobin, thereby preventing iron loss 
and subsequent oxidative damage generated by free iron in the vascular system of the kidneys. 
Binding of haemoglobin to Hp is beneficial for the human body in several other ways. Hp is 
protective against cell damage by scavenging free radicals, such as the hydroxyl radical, of 
which the formation is promoted by the presence of free haemoglobin. Furthermore, the Hp- 
haemoglobin complex inhibits the vasodilatory effect of nitric oxide and provides a non­
specific defence against bacterial invasion, since free haeme iron is necessary for bacterial 
growth. Furthermore, Hp itself was identified as a serum angiogenic factor and plays a role in 
proliferation and differentiation of vascular endothelium. Hp2-2 has stronger angiogenic 
functionality than Hp1-1, whereas Hp1-1 has the highest affinity for haemoglobin and is 
therefore associated with antioxidant capacity and other functional properties of Hp (1).
Preeclampsia, which is characterised by pregnancy-induced hypertension and concurrent 
proteinuria, can be complicated by the haemolysis, elevated liver enzymes and low platelets 
(HELLP) syndrome, which may also occur solely (3). The pathogenesis of preeclampsia and 
HELLP is largely unknown, although, it is postulated that maladaptation of throphoblast 
invasion may results in poor placental perfusion and local oxidative stress (4), which could 
subsequently affect maternal circulation. Systemic maternal oxidative stress may result in the 
clinical manifestations as seen in women with preeclampsia including dysfunction of the 
vascular endothelium (5).
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A previous study associated a higher incidence of the Hp2-2 phenotype with the occurrence of 
pregnancy induced hypertension (6). Since Hp2-2 has the lowest antioxidant capacity by poor 
affinity for haemoglobin and therefore may be less capable to prevent oxidative damage 
induced by free haemoglobin present after haemolysis, we hypothesised that occurrence of the 
Hp2-2 genotype was associated with the HELLP syndrome. Therefore, we investigated the 
prevalence of the Hp2-2 genotype in patients with a history of severe preeclampsia with or 
without HELLP syndrome as compared to women with uncomplicated pregnancies only.
Materials and Methods
The Institutional Review Board approved the study protocol. After informed consent was 
obtained whole blood was collected from 131 women, who had experienced severe 
preeclampsia with or without HELLP syndrome, or HELLP syndrome solely (7). Since 
haptoglobin is associated with the binding of free haemoglobin we separately analysed a 
subset of 90 women with HELLP syndrome with or withoud gestational hypertension. 
Characteristics of the total patient group and the subgroup of women with HELLP syndrome 
are depicted in Table 11.1. Preeclampsia was defined as a diastolic blood pressure >90 mmHg 
on two or more occasions each more than 4 hours apart, with proteinuria (protein/creatinine 
ratio >0.30 g/10 mmol) according to the standard of the International Society for the Study of 
Hypertension in Pregnancy. HELLP was defined as haemolysis (lactic dehydrogenase level 
>600 IU/L), elevated liver enzymes (both aspartate and alanine aminotransferase activity >70 
IU/L) and low platelets (platelet count <100x109/L). As a control group 166 women, who 
experienced uncomplicated pregnancies only, were recruited.
DNA was isolated using the Puregene genomic DNA isolation kit (Gentra Systems, 
Minneapolis, USA), according to the instructions of the manufacturer. Genomic DNA was 
analysed for the presence of the three different main genotypes encoding for haptoglobin 
using polymerase chain reactions with primer sets and conditions exactly as described before 
by Yano et al. (2).
The differences between the two study groups were calculated with the Chi-square test using 
Astute Statistical Add-In for Microsoft Excel 5 version 1.50. Odds ratios (OR) with 95%
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confidence interval (95% CI) were calculated for the Hp2-2 genotype versus the other 
genotypes.
Table 11.1. Characteristics of women with severe preeclampsia and the subset of women with 
HELLP syndrome.
Severe Preeclampsia 
(n=131)
HELLP Syndrome 
(n=90)
GA at delivery (weeks+days) 31+3 (29+3 -  35+3) 31+1 (29+0 -  33+4)
Systolic BP (mmHg; Korotkoff V) 160 (150 -  175) 160 (150 -  180)
Diastolic BP (mmHg; Korotkoff V) 110 (100 -  115) 110 (100 -  115)
Protein/Creatinine ratio (g /10 mmol) 3.5 (0.4 -  6.0) 1.4 (0.3 -  4.6)
LDH (IU/L) 735 (506 -  1295) 845 (614 -  1732)
ASAT (IU/L) 143 (55 -  320) 202 (94 -  397)
ALAT (IU/L) 140 (51 -  270) 202 (85 -  362)
Platelet count (*109 / L) 78 (52 -  142) 65 (50 -  95)
Haemoglobin (g/dL) 7.6 (6.8 -  8.0) 7.4 (6.7 -  7.9)
Haematocrit 0.35 (0.32 -  0.48) 0.35 (0.31 -  0.37)
Serum creatinine (|jmol/L) 75 (68 -  83) 74 (68 -  83)
Serum uric acid (|jmol/L) 0.40 (0.34 -  0.46) 0.41 (0.34 -  0.46)
Data are given as medians (25th -  75th percentiles)
Abbreviations: GA -  gestational age; BP -  blood pressure; LDH -  lactic dehydrogenase; ASAT -  
aspartate aminotransferase enzyme activity; ALAT -  alanine aminotransferase enzyme activity
Results
The distribution of the different Hp genotypes is summarised in Table 11.2. In one woman 
from the HELLP group none of the specific Hp alleles could be amplified and this patient 
therefore most probably bears the rare Hp null-genotype (Hp0-0) (1). The prevalence of the 
Hp2-2 genotype in women with a history of severe preeclampsia was not different as 
compared with that of control women (27% versus 35%, respectively; %2 = 1.9 and P = 0.2), 
which resulted in an odds ratio (OR) (95% CI) of 1.0 (0.6 -  1.6). In the subset of women with 
HELLP syndrome, however, a lower prevalence of the Hp2-2 genotype (20%) was noticed as 
compared to controls (%2 = 6.2 and P = 0.01) resulting in an OR (95% CI) of 2.1 (1.2 -  3.9).
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Table 11.2. Distribution of haptoglobin genotypes.
Genotype Severe Preeclampsia 
(n=131)
HELLP syndrome 
(n=90)
Controls
(n=166)
Hp2-2 36 (27%) 18 (20%)a 58 (35%)
Hp2-1 65 (50%) 43 (48%) 73 (44%)
Hp1-1 29 (23%) 28 (31%) 35 (21%)
Hp0-0 1 (0.8%) 1 (1%)
Frequency of Hp2-allele 0.52 0.44 a 0.57
Percentages are given between parenthesis.
Statistics:
a: P=0.01 complicated pregnancy versus control women.
1S 1 f
Genotypes: Hp1-1: Both alleles encoding for a  or a
Hp1-2: One allele encoding for a 1S or a1F and the other for a2
Hp2-2: Both alleles encoding for a
Hp0-0: No amplification of one of the alleles
The Hp2-allele frequency was 0.57 in the control women. Women with a history of severe 
preeclampsia had a similar allele frequency (0.52; OR (95% CI) of 1.1 (0.8 -  1.6)), whereas in 
women with HELLP syndrome the Hp2 allele was less frequently present (0.44; % = 6.3, P = 
0.01). This resulted in an OR (95% CI) of 1.6 (1.1 -  2.3).
Discussion
The pathogenesis of preeclampsia and cardiovascular related diseases, e.g. essential 
hypertension and coronary artery diseases, share common characteristics including 
thrombophilia, endothelial damage and oxidative stress (5,8-11). Furthermore, follow-up 
studies show that women who had preeclampsia during their pregnancy are at higher risk to 
develop vascular related diseases (12,13). Higher incidence of the Hp 2-2 phenotype was 
associated with an increased risk for pregnancy induced hypertension (6), severity of 
cardiovascular diseases like established essential hypertension (14) or coronary artery disease
(15). Therefore, we hypothesised that a higher incidence of the Hp 2-2 genotype could be 
present in women with severe preeclampsia as compared to control women. In contrast,
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however, we found a tendency to a lower incidence of the Hp 2-2 genotype in women with 
severe preeclampsia, whereas in a subset of women with the HELLP syndrome, a significant 
lower incidence of the Hp2-2 genotype was present as compared to control women. Also the 
Hp2-allele frequency was lower in women with HELLP syndrome than in control women. 
However, control women showed a similar Hp2-allele frequency as reported in other control 
populations by other investigators (1,14). Therefore, our results indicate that women with the 
Hp2-2 genotype have a lower risk to develop the HELLP syndrome.
This unexpected finding of the lower prevalence of the Hp2-2 genotype in women with 
HELLP syndrome as compared with that in control women may be explained by a 
combination of factors. Firstly, preeclampsia and HELLP syndrome are multifactorial 
diseases in which placental development and maternal defence against oxidative stress among 
many other factors may play an important role (3,9,16). Secondly, Hp1-1 and Hp2-2 
phenotypes have different efficiency for the various functional properties of Hp (1), therefore 
each phenotype may be protective at another stage of the disease. Hp has angiogenetic 
properties with Hp2-2 being the most potent polymorph variant, consequently Hp2-2 may be 
beneficial for placental development. However, during the clinical stage of preeclampsia the 
antioxidant properties of Hp, i.e. binding of free haemoglobin and direct scavenging of free 
radicals, may be more important. Since Hp1-1 has the highest affinity to bind haemoglobin, it 
may provide the best protection against oxidative stress (1). Our results might suggest that Hp 
is important as one of the factors regulating placental development during early pregnancy, 
where absence of Hp2-2 could lead to a disturbed placental development. This could explain 
the lower incidence of the Hp2-2 genotype in women with the HELLP syndrome. Thus, the 
angiogenetic role of Hp2-2 during early pregnancy might be more important than the 
antioxidant capacity of binding free haemoglobin during a later stage of gestation of Hp1-1.
In conclusion, the Hp2-2 genotype is associated with a lower risk for the development of the 
HELLP syndrome.
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Abstract
Background: A genetic predisposition is known to be involved in the development of 
preeclampsia. In previous studies maternal protein levels as well as genotype of 
biotransformation enzymes, such as glutathione S-transferase P1-1 and epoxide hydrolase 
(EPHX), were associated with the development of preeclampsia. In addition, for the 
polymorphism in glutathione S-transferase P1-1 also a paternal and foetal contribution to the 
risk for preeclampsia could be demonstrated.
Objective: To investigate the association of the Tyr113His polymorphism in EPHX in 
families (mother, father and offspring) with a history of preeclampsia as compared to control 
families who experienced uncomplicated pregnancies only
Study-design: Genomic DNA of families who experienced preeclampsia (n=134) and control 
families with a normotensive obstetrical history (n=126) was analysed for the presence of the 
Tyr113His polymorphism in EPHX by polymerase chain reaction / restriction fragment length 
polymorphism.
Results: In former preeclamptic women the incidence of the His1 1 3 /His1 1 3  genotype was 
higher as compared with that of controls (23% versus 11%; % =4.4 and P<0.05), whereas a 
similar distribution was found for paternal as well as foetal genotype between cases and
113controls. The transmission disequilibrium test showed that the Tyr allele was more often 
transmitted to offspring born after preeclampsia than could be expected by chance (%2 =4.7 
and P<0.05).
Conclusion: The His1 1 3 /His1 1 3  genotype of EPHX in mothers was associated with a higher 
susceptibility to develop preeclampsia, but not in fathers and offspring.
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Introduction
Preeclampsia is characterised by pregnancy-induced hypertension and concurrent proteinuria
(1). Despite extensive research the pathogenesis of preeclampsia and HELLP is still largely 
unknown. Although, it is postulated that insufficient throphoblast invasion may result in poor 
placental perfusion and local oxidative stress (2 ), which could subsequently affect maternal 
circulation resulting in dysfunction of the vascular endothelium (3). A genetic susceptibility 
for preeclampsia has been proposed years ago (4) and a wide variety of involved genes have 
been previously reviewed by Broughton-Pipkin (5).
Biotransformation enzymes, such as glutathione S-transferase P1-1 (GSTP1-1) and 
microsomal epoxide hydrolase (EPHX), are important in scavenging free radicals and 
detoxification of xenobiotics (6,7). EPHX mainly metabolises reactive epoxide intermediates 
to more water-soluble transdihydrodiol derivatives. However, under certain circumstances, 
the chemical products resulting from cytochrome P450 and microsomal EPHX interactive 
metabolism include highly reactive electrophiles (7). Polymorphisms of genes encoding for 
these enzymes have been associated with an increased susceptibility for preeclampsia (8,9). 
Homozygosity for Tyr113His polymorphism in exon three of the EPHX gene has been 
associated with low enzyme activity (7), therefore prolonged exposure to reactive 
intermediates due to malfunctioning of the EPHX enzyme might contribute to maternal 
endothelial damage. Also a local effect on placental development and growth of reactive 
intermediates or other toxic compounds can be assumed ( 1 0 ).
Both GSTP1-1 and EPHX have been found in placental tissue (11,12). Since placenta is of 
foetal origin and therefore is characterised by both a maternal and paternal contribution, the 
risk for preeclampsia might by modified by maternal as well as paternal genetic variations in 
detoxification activities. Recently, we demonstrated a paternal as well as foetal contribution 
of the polymorphism in GSTP1-1 to the susceptibility to develop preeclampsia (13). The 
present study was performed to investigate the role of the Tyr113His polymorphism in EPHX 
in families (mother, father and offspring) with a history of preeclampsia as compared to 
control families with uncomplicated obstetrical history.
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Materials and Methods
Patient and Control Subjects
The Institutional Medical Ethical Review Committee approved the study protocol. 
Preeclampsia was defined according to the standard of the International Society for the Study 
of Hypertension in Pregnancy as pregnancy induced hypertension (diastolic blood pressure > 
90 mmHg on two or more occasions each more than 4 hours apart) with proteinuria (urinary 
protein/creatinine ratio >0.30 g/10 mmol). The HELLP syndrome was defined by haemolysis 
(lactic dehydrogenase level >600 IU/L), elevated liver enzymes (both aspartate and alanine 
aminotransferase activity >70 IU/L) and low platelets (trombocyte count <100x109 /L).
We recruited 134 women, who had experienced severe preeclampsia (diastolic blood pressure 
> 110 mmHg or the presence of the HELLP syndrome) during singleton pregnancy, or 
HELLP syndrome with or without gestational hypertension, their male partners and offspring 
of preeclamptic pregnancies concerned. One-hundred-and-twentysix women who had 
experienced uncomplicated pregnancies only, their male partners and offspring of their last 
singleton pregnancy were recruited as control families. All investigated subjects gave written 
informed consent. One-hundred-and-thirteen families with severe preeclampsia have 
contributed in another study (13).
DNA analysis
Whole blood from women and their partners was obtained by venapuncture in sterile 
vacutainer tubes anti-coagulated with ethylenediaminetetra-acetic acid (EDTA) and DNA was 
isolated using the Puregene genomic DNA isolation kit (Gentra Systems, Minneapolis, USA) 
according to the instructions of the manufacturer. DNA from offspring was collected from 
buccal cell samples collected on sterile swaps as described by Richards et al. (14).
Genomic DNA was analysed for the presence of the Tyr113His polymorphism in exon 3 of 
EPHX, according to the polymerase chain reaction / restriction fragment length polymorphism 
(PCR/RFLP) method as described by Harrison et al. (15). In short, during PCR amplification 
a digestion site for EcoRV is created in the wild-type allele. After restriction with this 
enzyme, fragments were separated on 3% agarose resulting in fragments of 140 en 25bp for a 
wild-type allele and an undigested fragment of 165bp for the polymorph allele.
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Statistics
The distribution of the different genotypes of the EPHX polymorphism between the two study 
groups was calculated with the Chi-square test.
Association analysis was performed using the transmission disequilibrium test (TDT), which 
evaluates the observed number of parent-offspring transmission of alleles, compared with the 
number of transmissions expected by chance, as described by Spielman et al (16).
All analyses were performed with the Statistical Package for Social Sciences (SPSS Inc, 
Chicago, USA). A p-value below 0.05 was considered significant.
Table 12.1. Characteristics of women with severe preeclampsia.
GA at delivery (weeks+days) 31 +3 (26+0 -  40+6)
Systolic BP (mmHg; Korotkoff V) 165 (110 -  220)
Diastolic BP (mmHg; Korotkoff V) 110 (75 -  140)
Protein/Creatinin ratio (g /10 mmol) 2.9 (0 -  27.4)
LDH (IU/L) 631 (65 -  7670)
ASAT (IU/L) 84 (5 -  2640)
ALAT (IU/L) 75 (4 -  1920)
Platelet count (*109 / L) 94 (10 -  483)
Haemoglobin (g/dL) 7.3 (3.7 -  9.4)
Haematocrit 0.35 (0.18 -  0.45)
Serum creatinine (|jmol/L) 76 (49 -  215)
Serum uric acid (|jmol/L) 0.40 (0.22 -  0.80)
Data are given as median and ranges.
Abbreviations: GA -  gestational age; BP -  blood pressure; LDH -  lactic dehydrogenase enzyme 
activity; ASAT -  aspartate aminotransferase enzyme activity; ALAT -  alanine aminotransferase 
enzyme activity
Results
The data for analysis included 127 women, 122 partners, and 110 children of the preeclampsia 
families and 80 women, 104 partners, and 8 6  children of the control families. Other DNA 
samples could not successfully be evaluated. In Table 12.1 clinical data of the former 
preeclamptic patients are depicted during their disease, whereas Table 12.2 shows the 
distribution of the three genotypes.
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The His1 1 3 /His1 1 3  genotype was more often found in women with a history of preeclampsia as 
compared to that of control women (23% versus 11%; %2 = 4.4 and P<0.05), however, we 
could not find a different distribution of this genotype between partners and offspring from 
the former preeclamptic and those of control women.
113TDT analysis revealed that the wildtype Tyr allele was significantly more often transmitted 
to offspring than the rare His1 1 3  allele (%2 =4.7; P<0.05).
Table 12.2. Distribution of polymorph genotypes of EPHX.
Genotype
Preeclampsia Control
Mother
(n=127)
Father
(n=122)
Offspring 
(n=110)
Mother
(n=80)
Father
(n=104)
Offspring
(n=86)
Tyr11o/T yr11o 50 (39%) 65 (54%) 61 (56%) 47 (59%) 51 (49%) 43 (50%)
o
1
is/Hio/
>
48 (38%) 36 (30%) 39 (36%) 24 (30%) 31 (30%) 32 (37%)
His11o/His11o 29 (23%)* 21 (18%) 10 (9%) 9 (11%) 22 (21%) 11 (13%)
OR (95% CI) 2.3 (1.0-5.2) 0.9 (0.5-1.7) 0.7 (0.3-1.7) 1 1 1
Note: The number of DNA samples that successfully could be evaluated are given in parenthesis.
‘ Statistics: x 2 = 4.4, P<0.05
Discussion
We have demonstrated an association between the Tyr113His polymorphism in EPHX and
113 113susceptibility to develop preeclampsia, since the prevalence of His1 1 3 /His1 1 3  genotype is 
significantly higher in women with a history of preeclampsia as compared to controls. The 
rare His1 1 3 /His1 1 3  genotype is known to be associated with a lower enzyme activity of epoxide 
hydrolase as compared with the wildtype genotype (7). Therefore, former patients may have a 
lower enzyme activity, which might result in an accumulation of highly reactive intermediates
(17). In addition, the imbalance between oxidants and antioxidants plays a prominent role in 
the pathophysiology of preeclampsia (18) and it is proposed that lipid peroxidation might 
contribute to lipid epoxide formation (19). Thus lower EPHX activity might also result in an 
accumulation of lipid epoxide and peroxides, which in turn may lead to oxidative stress.
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Contradictory, in an earlier study from our group we found an association between the 
Tyr1 1 3 /Tyr1 1 3  genotype of EPHX with the development of preeclampsia (9), however, 
population-based control values of that study were comparable to those found for other 
Chinese control populations (20,21) whereas present control values, which were selected for 
uncomplicated pregnancy outcome, are comparable to those found for Caucasians (15, 22­
25). In addition, different PCR/RFLP methods were used, in the previous study the rare 
polymorph allele was digested versus the wild-type allele in the present study, and both 
studies consisted of different and relatively small study populations. This could have resulted 
in the difference found between these studies.
Heterozygous parents who had a history of preeclampsia significantly more often transmitted
113 113the Tyr than the His allele to their offspring. Hassett et al. presumed that alleles at amino
113acid 113 were not in Hardy-Weinberg equilibrium, since the His is less often found than 
expected (7). However, in contradiction, recent studies demonstrated Hardy-Weinberg 
equilibrium at this position of EPHX (22-24). Therefore, it can be presumed that the
113transmission disequilibrium for the Tyr allele, as found in this study for the families who 
experienced severe preeclampsia, might be the result of the disease. Recurrent abortion is 
associated with a higher frequency of the 113His allele among women (21). Therefore, 
pregnancies of mothers or foetuses with the homozygous rare genotype might more frequently 
end in an abortion. However, preeclampsia is a multifactorial complication and therefore 
heterozygous foetuses may be presumably protected from an early abortion by an adaptive 
mechanism, which however does not prevent them to develop preeclampsia. This could 
explain the higher incidence of the His1 1 3 /His1 1 3  genotype in former preeclampsia patients as 
found in this study. Furthermore, in this way foetuses should have received the Tyr1 1 3  allele 
from the father, which resulted in a positive TDT-test for this allele.
This could also explain the absence of an association between paternal or foetal genotype and 
preeclampsia for EPHX. Recently, we found a paternal and foetal association between 
GSTP1-1 genotype and preeclampsia (13), therefore we hypothesised to find such an 
association for EPHX as well. Another possibility is that EPHX enzyme activity is less 
important for placental detoxification than GSTP1-1 enzyme activity is (11).
In conclusion, the His1 1 3 /His1 1 3  genotype of EPHX in mothers was associated with severe 
preeclampsia, whereas no contribution of paternal or foetal genotype was found.
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Abstract
Background: Microsomal epoxide hydrolase (EPHX) as well as glutathione S-transferase P1 
(GSTP1) play an important role in the metabolism of xenobiotics. In previous studies 
polymorphisms in the genes encoding for these detoxification enzymes were associated with 
an increased risk for complications of pregnancy. Perinatal mortality is a multifactorial event, 
in which also a genetic predisposition to impaired detoxification could play a role.
Aim: To study the prevalence of the genetic polymorphism in exon 3 of the EPHX gene 
(Tyr113His) and that of the GSTP1 gene (Ile105Val) in both women and their partners who 
experienced perinatal mortality as compared with control couples with uncomplicated 
obstetrical histories.
Design: Genomic DNA of case couples (79 females and 52 males) and control couples (73 
females and 69 males) was analysed for the presence of polymorphisms in both the EPHX and 
GSTP1 gene by polymerase chain reaction / restriction fragment length polymorphism. 
Results: A similar distribution of the GSTP1 polymorphism was found in all subjects 
investigated. In women, who experienced perinatal mortality, we demonstrated a higher
113 113prevalence of the EPHX His1 1 3 /His1 1 3  genotype as compared with controls (26% versus 11%; 
X2 of 4.8 and P<0.03) with an odds ratio (95% CI) of 3.0 (1.1 -  8.2).
Conclusion: The Tyr113His-polymorphism in the microsomal epoxide hydrolase gene of the 
mother seems to be a risk factor for perinatal mortality, while there is no association with the 
paternal genotype.
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Introduction
Perinatal mortality rates include both still births and live-born infants dying within the first 
week of live (1). Although the past decades a strong decline of perinatal mortality in Western 
Europe is seen, the prevalence of perinatal mortality in the Netherlands is still approximately 
7 cases per 1,000 births (2). Perinatal mortality can be regarded as a multifactorial event, main 
causes being acute or chronic placental pathology, congenital malformations and 
complications of prematurity (3).
Many carcinogens or mutagens present in tobacco smoke or drugs contain polycyclic 
aromatic hydrocarbons (PACs) (4,5). In the human body the defence against such compounds 
is provided by the two-stage process of phase I and phase II biotransformation reactions. In 
phase I reactions PACs are metabolised by cytochrome monooxygenases to arene and alkene 
oxides, also called epoxides. Due to their electronic polarisation and ring tension, epoxide 
metabolites are highly reactive compounds, which often are mutagenic or carcinogenic and 
therefore may influence normal functioning of the cell. Epoxides can be further metabolised 
in several distinct pathways (4). One of the main enzymes involved is microsomal epoxide 
hydrolase (EPHX), which catalyses the hydrolysis of epoxides into their corresponding trans- 
dihydrodiols. Epoxides can also directly be conjugated to glutathione (GSH) either non- 
enzymatically or catalysed by one of the glutathione S-transferases (GSTs) (4), of which 
GSTP1 is predominantly expressed in placental tissue.
Several complications of pregnancy, such as preeclampsia and recurrent early pregnancy loss, 
are associated with the Tyr113His polymorphism in exon 3 of the EPHX gene (6 ) or the 
Ile105Val polymorphism in the gene for glutathione S-transferase P1 (GSTP1) (7,8). Both 
polymorphisms result in a lower enzyme activity and decreased detoxification capacity. In 
addition, also the paternal genotype of the polymorphism in GSTP1 is associated with an 
increased risk for preeclampsia (9). The aim of the present study is to investigate whether the 
genetic polymorphisms of the EPHX and GSTP1 genes in both mothers and their partners are 
risk factors for perinatal mortality.
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Materials and Methods
Subjects
Perinatal mortality was defined according to the WHO criteria for standard national perinatal 
mortality figures using a birthweight of 500 grams or more (10). Between December 1999 
and May 2000, seventy-nine women who participated in a prospective study on perinatal 
mortality, which was performed from 1983 to 1992 (3), were recruited for the present study.
Table 13.1. Pregnancy characteristics of women with perinatal mortality and causes of 
perinatal mortality.
Pregnancy characteristics:
Gestational age at delivery (weeks)
Parity 
Smoking
Causes of perinatal mortality:
Infection (transamnionic or haematogenous) 6 (8%)
Placental pathology 48 (62%)
Incompatability of blood group 1 (1 %)
Congenital disorders 19 (24%)
Complications of premature delivery 4 (5%)
All values expressed as numbers (percentage) except for gestational age and parity, 
which are expressed in medians (range),
Note: For one woman cause of perinatal mortality was reported unknown.
Pregnancy characteristics and causes of perinatal mortality of the cases are summarised in 
Table 13.1. Out of 79 male partners 52 could be included in the present study. Reasons for 
non-inclusion were divorce (n=10), recent death (n=2) or refusal to participate (n=15). 
Seventy-one control women, with no history of perinatal mortality, and 6 6  of their partners 
were recruited by public advertisement. The local medical-ethical committee of the "Reinier 
de Graaf Hospital", Delft, The Netherlands approved the study protocol and informed consent 
was obtained from all women and their partners.
35 (23-43) 
3 (2-7)
24 (30%)
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Sample collection and analysis
Whole blood was obtained by venapuncture in sterile vacutainer tubes anti-coagulated with 
EDTA. DNA was isolated from whole blood using the Puregene genomic DNA isolation kit 
(Gentra Systems, Minneapolis, USA) according to the instructions of the manufacturer. 
Genomic DNA was analysed for the presence of the Ile105Val polymorphism in the GSTP1 
gene (7) and the Tyr113His polymorphism in exon 3 of the EPHX gene (11) exactly as 
described previously.
Statistics:
Statistical evaluation of the distribution of the polymorpisms between cases and controls was 
performed with the Chi-square test. A P-value less than 0.05 was considered significant.
Results
Distribution of the polymorph variants in both GSTP1 and EPHX are shown in Table 13.2. 
Not all DNA samples available could be successfully evaluated. In exon 3 of EPHX the
113 113polymorph His /His genotype was more prevalent in female cases (26%) than in female 
controls (11%; %2= 4.8 and P<0.03). This resulted in an odds ratio (95% CI) of 2.9 (1.1 -  8.2).
Table 13.2. Distribution of polymorph variants in GSTP1 and EPHX.
Female Cases Female Controls Male Cases Male Controls
EPHX: (n=77)1 (n=56) (n=51) (n=59)
3ryrT3ryrT 27 (35%) 28 (50%) 19 (37%) 28 (47%)
Tyr113 / His113 30 (39%) 22 (39%) 21 (41%) 20 (34%)
His113 / His113 20 (26%)* 6 (11%) 11 (22%) 11(19%)
GSTP1: (n=79) (n=71) (n=52) (n=66)
Ile105 / Ile105 44 (56%) 33 (46%) 23 (44%) 32 (48%)
Ile105 / Val105 31 (39%) 29 (41%) 24 (46%) 26 (39%)
Val105 / Val105 4 (5%) 9 (13%) 5 (10%) 8 (12%)
Data are presented as number (percentage)
1Note: The number of DNA samples analysed is given in parenthesis 
Statistics: *: %2 = 4.8 with P<0.03
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A similar distribution between cases and controls of the EPHX genotypes was found in their 
partners.
No differences were found in the prevalence of the polymorph Val1 0 5 /Val1 0 5  genotype in 
GSTP1 gene between cases and controls both for females and males.
Discussion
In a previous report, the His1 1 3 /His1 1 3  genotype EPHX was associated with an increased risk 
for spontaneous abortion in a Chinese population (12). In our study we now describe for the 
first time an association between a polymorphism in the detoxification pathway and perinatal
113 113mortality. The His /His genotype of EPHX, which may result in a lower enzyme activity, 
appears to be more prevalent in women with perinatal mortality. Although, the prevalence of 
the His1 1 3 /His1 1 3  genotype in the present study (11%) was similar to those described in other 
Caucasian populations (5,11,13-16), it was much lower than that reported in Chinese controls 
(42%) (12). Furthermore, we were not able to demonstrate a paternal contribution as was 
previously found for preeclampsia (9).
113 113The exact contribution of the His /His genotype on the multifactorial biochemical 
mechanisms leading to perinatal mortality remains to be determined. Smoking during 
pregnancy, which is a risk factor for perinatal mortality ( 1 ), could be one of those 
mechanisms. In cigarette smoke several PACs are abundantly present and in metabolism of 
PACs reactive and toxic epoxide intermediates are frequently formed (5,15). However, when 
non-smoking and smoking women who experience perinatal mortality were compared a 
similar distribution of the His1 1 3 /His1 1 3  genotype in EPHX was found in both groups (22% 
and 25%, respectively). This might indicate that EPHX genotype is a risk factor independent 
from smoking habits.
The Ile105Val-polymorphism in GSTP1 has been shown to be associated with several 
complications of pregnancy including recurrent early pregnancy loss (8 ) and preeclampsia 
(7,9). However, in our study we found no association between the Val1 0 5 /Val1 0 5  genotype and 
perinatal mortality in both mothers as well as their partners. The prevalence of the polymorph 
genotype was in line with the data previously reported for controls by other investigators
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(7,9,16,17). Since GSTPI is the predominant GST isoform in placental tissue (18), we 
investigated the presence of the Val1 0 5 /Val1 0 5  genotype in a subgroup of cases with perinatal 
mortality related to placental pathology (Table 13.1). The incidence of the Val1 0 5 /Val1 0 5  
genotype was similar in cases with placental pathology and cases with other cause of perinatal 
mortality (5% and 7%, respectively). In addition, the prevalence of the Val1 0 5 /Val1 0 5  genotype 
in the subset of cases with placental pathology (5%) was not different to that of control 
women (13%; x of 2.1 and P=0.15). Since placental tissue is of foetal origin and its 
constitution is regulated by maternal as well as paternal genes, an association of paternal 
genotype with perinatal mortality could be expected, however no such association was found 
for both investigated genes with the risk for perinatal mortality.
In conclusion, we found no evidence for a contribution of the paternal genotype of the 
Ile105Val polymorphism in GSTP1 and the Tyr113His polymorphism of EPHX to the risk for 
perinatal mortality. Women homozygous for the Tyr113His polymorphism of EPHX have an 
increased risk for perinatal mortality and further studies should be performed to elucidate the 
pathophysiological mechanism involved.
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Summary and Conclusions
Introduction
Oxidative stress is a key factor in the pathogenesis of preeclampsia. Inadequate trophoblast 
invasion may result in poor placental perfusion and placental oxidative stress. In time also the 
maternal circulation will be affected, in which defence against oxidative stress is provided by 
numerous exogenous antioxidants (e.g. vitamins E and C) or endogenous enzyme systems 
(e.g. catalase and glutathione-related enzymes). When maternal antioxidant capacity is 
insufficient to deal with the increased load of oxidative compounds during pregnancy, 
preeclampsia or the hemolysis, elevated liver enzymes and low platelets syndrome may occur. 
Since 1995 numerous investigations have been performed on the topics described above in a 
collaboration between the departments of Gastroenterology and Obstetrics & Gynaecology of 
the University Medical Centre Nijmegen. In this thesis several studies on glutathione and 
glutathione-related enzymes on male fertility, embryonic, foetal and placental development 
are presented (Part II). In addition, studies on the redox-balance of glutathione and other 
thiols in preeclampsia (Part III), and genetic polymorphisms in association with oxidative 
stress in preeclampsia (Part IV) are described.
Part I
In Chapter 1 the objectives of the thesis are outlined. Objectives are 1) To investigate the 
importance of the glutathione / glutathione biotransformation system in male fertility and 
embryonic, foetal and placental development, 2) To study the role of the aminothiol redox- 
balance in women with severe preeclampsia, and 3) To investigate the association between 
polymorphisms in oxidative-stress-related-genes and the pathogenesis of severe preeclampsia.
Chapter 2 provides a schematic overview of the concept of detoxification (Paragraph 2.1) 
and oxidative stress (Paragraph 2.2), followed by the description of changes in these 
metabolic features in both physiological pregnancies and those complicated by (severe) 
preeclampsia and/or HELLP syndrome (Paragraph 2.3). Glutathione S-transferases and 
glutathione peroxidases as well as their co-factor glutathione play an important role in the 
detoxification of numerous toxic compounds including xenobiotics, carcinogens, reactive 
oxygen species (ROS), and other harmful metabolic products. Oxidative stress is defined as a
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disturbance in the balance between (pro)oxidants and antioxidants, in favour of the former. 
During normal pregnancy products of oxidative damage transiently increase, whereas most 
antioxidants decrease, pointing at increased oxidative stress. In early pregnancy oxidative 
stress is a key factor in placental development. When oxidative stress is poorly regulated, e.g. 
by impaired antioxidant defence, this may lead to placental maladaptation and poor placental 
perfusion, resulting in local as well as maternal oxidative stress and endothelial damage, 
which may lead to preeclampsia.
Part II
The second part of the thesis focuses on the presence of glutathione and related enzymes in 
seminal plasma in relation to male fertility (Chapter 3) and during pregnancy (Chapters 4 & 
5).
In seminal plasma variable amounts of GSTP1-1 and GSTA1-1 are found. The levels of 
glutathione are lower in subfertile males than in fertile males (Chapter 3). Additionally, 
glutathione levels are associated with motility quality and negatively associated with 
abnormal sperm morphology, indicating that glutathione may play a role in male fertility. 
Glutathione and glutathione S-transferases seem to play an important role during foetal 
development, since they are abundantly present in several embryotic and foetal organs 
(Paragraph 4.1). However, the expression of GSTs in some foetal tissues differs from that in 
corresponding adult tissues, indicating that several organs may have other functional 
properties during intra-uterine development. Glutathione and related enzymes, except for 
GSTAlpha, are homogeneously expressed in term placentas (Paragraph 4.2). The high levels 
of GSTTheta suggest that besides GSTPi, GSTTheta is also an important placental GST 
isoform.
In Chapter 5 the assessment of thiol levels in venous and arterial umbilical cord as well as 
corresponding maternal plasma after both vaginal and caesarean deliveries are described. 
Both cysteine and homocysteine are transported either by active transport or driven by a 
concentration gradient from the maternal to the foetal circulation where they are utilised by 
the developing foetus, as seen by the lower arterial levels in comparison to the venous 
umbilical cord levels (Paragraph 5.1). After vaginal delivery glutathione levels in arterial 
umbilical cord are higher as compared with those in the venous umbilical cord, whereas no
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such difference is found in women with caesarean section, suggesting that vaginal delivery is 
associated with higher levels of oxidative stress (Paragraph 5.2).
Part III
In this part of the thesis a study on maternal plasma thiol levels (Chapter 6) and three studies 
on the aminothiol redox status during and after pregnancy in women with severe preeclampsia 
(Chapters 7 -  9) are described.
Women with preeclampsia have higher plasma levels of cysteine and homocysteine than 
normotensive pregnant women, who show lower levels as compared with corresponding 
values in non-pregnant controls (Chapter 6). These differences might be explained by the 
physiological process of hemodilution during pregnancy and the plasma volume reduction in 
preeclampsia. Plasma glutathione levels are lower during pregnancy than in the non-pregnant 
state, whereas these levels are even lower in women with preeclampsia.
In Chapter 7 the redox status for aminothiols is described in women with severe 
preeclampsia. In comparison to controls, women with preeclampsia have a lower free-to- 
oxidised ratio for cysteine, homocysteine, and cysteinylglycine indicating that the redox- 
balance of these thiols has shifted to higher levels of the oxidised thiols. This points at higher 
levels of oxidative stress in women with preeclampsia. The ratios for both cysteine and 
homocysteine are still lower 6 weeks after pregnancy (Chapter 8). In addition, in women 
with normotensive pregnancy as well as in patients with severe preeclampsia the free levels of 
glutathione transiently decrease during pregnancy as compared to corresponding levels 6 
weeks after pregnancy. Therefore, during pregnancy oxidative stress is present, which is even 
more pronounced in women with preeclampsia.
The ratio for homocysteine is lower in women who experienced severe preeclampsia after 
subsequent pregnancies (Chapter 9). Plasma homocysteine levels are elevated in women with 
a history of severe preeclampsia, whereas the antioxidant capacity is higher as compared to 
corresponding values in women with an uncomplicated obstetrical history. These findings 
strongly suggest that the presence of elevated oxidised levels of homocysteine might be an 
underlying factor for the development of preeclampsia. Since hyperhomocysteinemia and 
autooxidation of homocysteine are risk factors for the development of cardiovascular
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diseases, this may explain why women with a history of severe preeclampsia are at higher risk 
for cardiovascular diseases in later life.
Part IV
In the last part of the thesis some studies on genes involved in oxidative stress and their 
contribution to the development of preeclampsia and perinatal mortality are described. 
NAD(P)H oxidase is an enzyme that produces O2- upon activation by angiotensin II (Chapter 
1 0 ). The C242T-polymorphism in the p22phox subunit of this enzyme results in lower 
enzyme activity and subsequent lower O2- production. Therefore this polymorphism could be 
protective against preeclampsia, however, a similar distribution of the three genotypes is 
present in normotensive controls and women with preeclampsia, indicating that this 
polymorphism is not associated with preeclampsia.
In Chapter 11 a study on the contribution of haptoglobin to the development of severe 
preeclampsia and HELLP syndrome is described. Haptoglobin, a glycoprotein with genetic 
heterogenity resulting in three phenotypes with different structural and functional properties, 
could be associated with preeclampsia in two different ways: a) haptoglobin 1 - 1  may prevent 
oxidative stress by capturing free iron, since it has a strong affinity for free haemoglobin; b) 
haptoglobin 2-2 is an angiogenic factor and could be beneficial in placental development. The 
latter function of haptoglobin seems to be most important for the development of the HELLP 
syndrome since the haptoglobin 2 - 2  genotype is found more common in patients with the 
HELLP syndrome.
In Chapter 12 the parental genetic contribution of the detoxification enzyme epoxide 
hydrolase (EPHX) to the development of preeclampsia is described. The rare His1 1 3 /His1 1 3  
genotype in mothers is associated with preeclampsia, whereas no paternal or foetal
113contribution is found. However, the wild-type Tyr allele is more often transmitted to 
offspring than could be expected by chance.
In Chapter 13 the Tyr113His polymorphism in EPHX is identified as a maternal risk factor
113 113for perinatal mortality, since the His /His genotype is more frequently found in women 
who experienced perinatal mortality. A similar distribution is found for the Ile 105Val 
polymorphism of GSTP1 in cases and controls. Furthermore, no paternal contribution in the 
occurrence of perinatal mortality is found for both polymorphisms.
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Conclusions
Summarising, we may conclude that glutathione and related enzymes are correlated with male 
fertility and are important during the physiology of normotensive pregnancy, whereas 
disturbances are seen in preeclampsia and the HELLP syndrome.
Disturbances of thiol levels are associated with preeclampsia. Using the free-to-oxidised ratio 
of thiols we were able to demonstrate the presence of a transient oxidative stress during 
pregnancy, being even more pronounced in preeclampsia and disappearing after delivery. 
However, in women with severe preeclampsia a lower free-to-oxidised ratio for homocysteine 
seems to persist after consecutive pregnancies, following the index-pregnancy. Therefore, the 
free-to-oxidised ratio for homocysteine may be a predictor for preeclampsia or may serve as 
indicator for the development of cardiovascular problems in later life.
Oxidative stress during preeclampsia seems not to be associated with polymorphisms in the 
genes encoding for the p22phox subunit NAD(P)H oxidase or haptoglobin. However, as an 
angiogenic factor, haptoglobin may play a role during placental development.
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Samenvatting en conclusies
Inleiding
Oxidatieve stress speelt waarschijnlijk een belangrijke rol in de pathogenese van pre­
eclampsie. Een verminderde trofoblastinvasie zou kunnen leiden tot een slechte placentaire 
doorbloeding en placentaire oxidatieve stress. Na verloop van tijd zou dit ook in de 
moederlijke circulatie op kunnen treden. In de moederlijke circulatie zijn talrijke exogene 
antioxidanten (bijv. vitamine C en E) of endogene enzymsystemen (bijv. katalase en 
glutathion gerelateerde enzymen) aanwezig die bescherming bieden tegen oxidatieve stress. 
Echter indien de moederlijke antioxidantcapaciteit niet toerijkend is om de grotere 
hoeveelheid oxidanten onschadelijk te maken, dan zou dit kunnen leiden tot het ontstaan van 
pre-eclampsie of het ‘hemolysis, elevated liver enzymes and low platelets’ (HELLP) 
syndroom.
Vanaf 1995 zijn verscheidene onderzoeken uitgevoerd ter opheldering van de hierboven 
beschreven onderwerpen door een samenwerkingsverband tussen de afdelingen Maag-, Darm- 
& Leverziekten en Obstetrie & Gynaecologie van het Universitair Medisch Centrum St. 
Radboud te Nijmegen. In dit proefschrift zijn verschillende studies over glutathion en 
glutathion-gerelateerde enzymen in relatie tot de vruchtbaarheid van de man en de 
embryonale, foetale en placentaire ontwikkeling beschreven (Deel II). Bovendien staan er 
studies beschreven over het redox-evenwicht van glutathion en andere thiolen in pre­
eclampsie (Part III) en over genetische polymorfismen die mogelijk geassocieerd zijn met 
oxidatieve stress in pre-eclampsie (Part IV).
Deel I
In Hoofdstuk 1 zijn de doelen van het proefschrift uiteen gezet. Deze zijn 1) Onderzoek naar 
de betekenis van glutathion en het glutathion gerelateerde biotransformatiesysteem bij de 
vruchtbaarheid van de man en de embryonale, foetale en placentaire ontwikkeling, 2) De rol 
van het redox-evenwicht van aminothiolen bij vrouwen met een ernstige pre-eclampsie en 3) 
Onderzoeken wat de associatie is tussen oxidatieve stress-gerelateerde genen en de 
pathogenese van ernstige pre-eclampsie.
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Hoofdstuk 2 geeft een schematisch overzicht over het concept van ontgifting (Paragraaf 2.1) 
en oxidatieve stress (Paragraaf 2.2), gevolgd door een beschrijving van de veranderingen in 
deze metabole processen bij zowel fysiologische zwangerschappen als die gecompliceerd 
door (ernstige) pre-eclampsie en / of het HELLP syndroom (Paragraaf 2.3). Zowel glutathion 
S-transferasen en glutathion-peroxidasen als hun co-factor glutathion spelen een belangrijke 
rol in het onschadelijk maken van giftige stoffen zoals xenobiotica, carcinogenen, reactieve 
zuurstof radicalen en andere schadelijke (metabole) producten. Oxidatieve stress wordt 
gedefinieerd als een verstoring van het evenwicht tussen oxidanten en antioxidanten in het 
voordeel van de oxidanten. Gedurende een normale zwangerschap neemt de hoeveelheid 
oxidatieve schadeproducten tijdelijk toe, terwijl de hoeveelheid van de meeste antioxidanten 
afneemt, wat op de aanwezigheid van oxidatieve stress wijst. In de vroege zwangerschap 
speelt deze tijdelijke oxidatieve stress een belangrijke rol bij de aanleg van de placenta. Als 
deze oxidatieve stress slecht gereguleerd wordt, bijv. door een verminderde antioxidant- 
capaciteit, kan dit leiden tot een verstoorde placenta aanleg en een verminderde placentaire 
doorbloeding wat kan leiden tot een lokale of zelfs maternale oxidatieve stress en endotheel- 
schade hetgeen tot pre-eclampsie kan leiden.
Deel II
Het tweede gedeelte van het proefschrift richt zich op de aanwezigheid van glutathion en 
gerelateerde enzymen in seminaal plasma in relatie tot mannelijke vruchtbaarheid (Hoofdstuk 
3) en de zwangerschap (Hoofdstuk 4 & 5).
In seminaal plasma zijn variabele concentraties glutathion S-transferase P1-1 en glutathion-S- 
transferase A1-1 aanwezig. Mannen met een verminderde vruchtbaarheid hebben een lagere 
glutathion spiegel in semen dan vruchtbare mannen (Hoofdstuk 3). Verder zijn de glutathion 
concentraties gerelateerd aan de kwaliteit van beweging en negatief gecorreleerd aan een 
abnormale vorm van de spermatozoïden, wat aangeeft dat glutathion mogelijk een rol speelt 
bij de mannelijke vruchtbaarheid.
Glutathion en glutathion-S-transferasen lijken een rol te spelen in de foetale ontwikkeling, 
omdat ze overvloedig tot expressie komen in verscheidene embryonale en foetale organen 
(Paragraaf 4.1). Echter in sommige foetale organen is de expressie van de glutathion-S- 
transferases verschillend van overeenkomstige volwassen organen. Het lijkt erop dat deze
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organen andere functionele eigenschappen hebben gedurende de foetale ontwikkeling. Op 
glutathion-S-transferase A1-1 na, komen glutathion en glutathion-gerelateerde enzymen 
homogeen tot expressie in de placenta (Paragraaf 4.2). De hoge concentratie van glutathion- 
S-transferase T1-1 suggereert dat dit enzym ook een belangrijke rol in de placentaire 
ontgifting speelt net als glutathion S-transferase P1-1.
In (Hoofdstuk 5) worden de bepalingen van de thiolconcentraties, in zowel veneus en 
arterieel navelstrengbloed als overeenkomstig maternaal bloed, na een vaginale bevalling of 
keizersnede beschreven. Cysteine en homocysteine worden beide door actief transport of via 
een concentratie-gradiënt van de maternale naar de foetale bloedsomloop getransporteerd, 
waar ze gebruik worden in de ontwikkeling van de foetus (Paragraaf 5.1). Na een vaginale 
bevalling zijn de glutathionwaarden in arterieel navelstrengbloed hoger in vergelijking met de 
veneuze waarden, terwijl dit verschil niet gevonden wordt na een keizersnede. Dit suggereert 
dat een vaginale bevalling gepaard gaat met meer oxidatieve stress dan een keizersnede 
(Paragraaf 5.2).
Deel III
In dit gedeelte van het proefschrift worden een studie naar de concentraties van thiolen in 
maternaal plasma (Hoofdstuk 6) en drie studies naar het redox-evenwicht van deze thiolen 
tijdens en na de zwangerschap bij vrouwen met een ernstige pre-eclampsie beschreven 
(Hoofdstuk 7 -  9).
Vrouwen met pre-eclampsie hebben hogere plasmaconcentraties van cysteine en 
homocysteine dan normotensieve zwangere vrouwen, die weer lagere waarden laten zien in 
vergelijking met niet zwangere controles (Hoofdstuk 6). Deze verschillen zouden verklaard 
kunnen worden door het fysiologische proces van haemodilutie tijdens de zwangerschap en 
indikking van het maternale bloed tijdens pre-eclampsie. De waarden van glutathion zijn lager 
tijdens de zwangerschap dan in de niet zwangere toestand, terwijl deze waarden nog lager zijn 
in vrouwen met een pre-eclampsie.
In Hoofdstuk 7 wordt het redox evenwicht voor de aminothiolen in vrouwen met een ernstige 
pre-eclampsie beschreven. In vergelijking met controles hebben vrouwen met pre-eclampsie 
een lagere vrij-over-geoxideerd-ratio voor cysteine, homocysteine en cysteinylglycine, wat 
erop wijst dat het redox evenwicht verschoven is naar de aanwezigheid van meer geoxideerde
209
Samenvatting en conclusies
thiolen. Oftewel bij vrouwen met pre-eclampsie is meer oxidatieve stress aanwezig. Voor 
cysteine en homocysteine waren deze ratio' s 6 weken na de zwangerschap nog steeds lager 
(Hoofdstuk 8). Bovendien wordt in dit hoofdstuk beschreven dat tijdens de zwangerschap, 
zowel ongecompliceerd als pre-eclamptisch, de hoeveelheid glutathion tijdelijk afneemt in 
vergelijking met de waarden 6 weken na de zwangerschap. Daarom is het waarschijnlijk dat 
tijdens een normale zwangerschap oxidatieve stress aanwezig is, die in vrouwen met pre­
eclampsie zelfs groter is.
Zelfs na één of meerdere opeenvolgende zwangerschappen na de indexzwangerschap is de 
ratio voor homocysteine is nog steeds lager in vrouwen die een ernstige pre-eclampsie hebben 
gehad (Hoofdstuk 9). Tevens zijn zowel de antioxidantcapaciteit als de homocysteine- 
concentratie in plasma hoger in vergelijking met vrouwen die alleen ongecompliceerde 
zwangerschappen hebben gehad. Deze bevindingen zijn sterke aanwijzingen dat de 
aanwezigheid van verhoogde concentraties van homocysteine in de geoxideerde vorm een 
risicofactor voor pre-eclampsie zou kunnen zijn. Omdat hyperhomocysteïnemie en auto- 
oxidatie van homocysteine tevens risicofactoren zijn voor hart- en vaatziekten, zou dit kunnen 
verklaren waarom vrouwen, die een pre-eclampsie hebben gehad, een verhoogd risico hebben 
op het krijgen van cardiovasculaire aandoeningen.
Deel IV
In het laatste gedeelte van het proefschrift staan een aantal studies beschreven over genen, die 
betrokken zijn bij oxidatieve stress en hun relatie tot pre-eclampsie en perinatale sterfte. 
NAD(P)H oxidase is een enzym dat na stimulatie door angiotensine II zuurstofradicalen 
produceert (Hoofdstuk 10). Het C242T-polymorfisme in p22phox subunit van dit enzym 
resulteert in een verlaging van de enzymactiviteit en daardoor in een verminderde 
zuurstofradicaalproductie. Hierdoor zou dit polymorfisme beschermend kunnen werken voor 
het ontstaan van pre-eclampsie. Echter de drie mogelijke genotypen zijn op dezelfde manier 
verdeeld bij normotensieve controles en vrouwen met pre-eclampsie, wat aangeeft dat dit 
polymorfisme niet geassocieerd is met pre-eclampsie.
In Hoofdstuk 11 staat een studie beschreven naar de rol van haptoglobine in de ontwikkeling 
van pre-eclampsie en het HELLP syndroom. Haptoglobine is een glycoproteine met een 
genetische heterogeniteit, waardoor er drie verschillende fenotypen bestaan, die zowel
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structureel als functioneel verschillend zijn. Haptoglobine kan daarom op twee verschillende 
manieren betrokken zijn bij het ontstaan van pre-eclampsie en het HELLP syndroom: a) 
haptoglobine 1 - 1  kan oxidatieve stress voorkomen door het binden van vrij ijzer, omdat het 
een sterke affiniteit heeft voor de binding van haemoglobine; b) haptoglobine 2 - 2  is een factor 
die betrokken is bij de angiogenese en zou daarom een gunstig effect kunnen hebben op de 
vroege aanleg van de placenta. Deze laatste functie van haptoglobine lijkt belangrijk te zijn in 
de ontwikkeling van het HELLP syndroom, omdat de aanwezigheid van het haptoglobine 2-2 
genotype veel lager is bij vrouwen met het HELLP syndroom.
Hoofdstuk 12 beschrijft een studie naar de genetische bijdrage van de ouders met betrekking 
tot het enzym epoxidehydrolase (EPHX). Moeders met het zeldzame His1 1 3 /His1 1 3  genotype 
hebben een verhoogd risico op pre-eclampsie, terwijl er geen associaties zijn gevonden voor
113het vaderlijke of kinderlijke genotype. Het Tyr allel werd echter vaker doorgeven aan de 
kinderen geboren uit een pre-eclamptische zwangerschap dan kan worden verwacht vanuit 
een normaal overervingpatroon.
Zowel glutathion-S-transferase P1-1 als EPHX zijn betrokken bij het metaboliseren van 
talloze xenobiotica. In Hoofdstuk 13 wordt beschreven dat het Tyr113His polymorfisme in
113 113EPHX bij vrouwen een risicofactor is voor perinatale sterfte, omdat het His /His genotype 
vaker gevonden wordt bij vrouwen die een perinatale sterfte hebben meegemaakt in 
vergelijking met controles, terwijl voor het Ile105Val polymorfisme in glutathion-S- 
transferase P1-1 een gelijke verdeling aanwezig is. Er werd geen vaderlijke bijdrage in beide 
polymorfismen gevonden met betrekking tot het voorkomen van perinatale sterfte.
Conclusie
Samenvattend kunnen we concluderen dat glutathion en glutathion-gerelateerde enzymen zijn 
gecorreleerd met mannelijke vruchtbaarheid en dat ze belangrijk zijn tijdens een fysiologische 
zwangerschap, terwijl verstoringen gezien zijn in pre-eclampsie en het HELLP syndroom. 
Veranderingen in de thiolconcentraties zijn geassocieerd met het ontstaan van pre-eclampsie. 
Door de bepaling van de vrij-over-geoxideerde-ratio van de thiolen hebben we kunnen 
aantonen dat gedurende de zwangerschap er tijdelijk oxidatieve stress aanwezig is, dat deze 
nog hoger is in vrouwen met pre-eclampsie, maar na de zwangerschap weer verdwijnt. Echter 
in vrouwen met een ernstige pre-eclampsie blijft de verlaagde vrij-over-geoxideerde-ratio
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zelfs na opeenvolgende zwangerschappen aanwezig. Daarom zou de vrij-over-geoxideerde- 
ratio voor homocysteine een predictor voor pre-eclampsie kunnen zijn, of zou kunnen dienen 
als indicator voor het ontstaan van hart- en vaatziekten in het latere leven.
Oxidatieve stress tijdens pre-eclampsie lijkt niet geassocieerd te zijn met polymorfismen in de 
genen coderend voor de p22phox subunit van NAD(P)H oxidase of haptoglobine. 
Haptoglobine, als angiogenetische factor, zou een belangrijke rol kunnen spelen bij de aanleg 
van de placenta.
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Dankwoord
Dit proefschrift is natuurlijk niet zomaar tot stand gekomen. In het proces van verzamelen, 
analyseren, discussiëren en publiceren hebben de afgelopen vier jaar verschillende mensen in 
meer of mindere mate een belangrijke bijdrage geleverd aan de totstandkoming van dit 
proefschrift. Het zal niet meevallen om iedereen op de juiste manier te bedanken gezien 
woorden niet altijd uit kunnen drukken wat je wilt zeggen. Alvorens ik me toch ga wagen aan 
een aantal persoonlijke stukjes wil ik iedereen, die op welke manier dan ook heeft bijgedragen 
aan mijn vorming als onderzoeker en/of aan dit proefschrift, graag willen bedanken voor alles 
wat jullie de afgelopen vier jaren voor me gedaan of betekend hebben.
Wilbert, zoveel zou ik over onze samenwerking willen zegen, want in de afgelopen jaren heb 
ik op uiteenlopende gebieden zoveel van je geleerd, dat ik niet weet waar ik zou moeten 
beginnen. Vele pittige / koppige discussies hebben we gevoerd, maar we kwamen er altijd uit. 
Wat echter nooit goed komt zal mijn kaartspel wel wezen, want rikken zal ik altijd op mijn 
manier blijven doen. Daarom een kort maar krachtig besluit: "Wilbert bedankt voor alles!!". 
Eric, het andere gedeelte van de GST-samenwerking, iets op de achtergrond, maar toch 
nadrukkelijk aanwezig, was jij degene die me de "niet-praktische" wetenschap beoefening 
hebt bijgebracht. Mede door inzicht, steun, maar voornamelijk de vele mogelijkheden die je 
me hebt geboden kan ik terugblikken op een zeer leerzame periode.
Beste Prof. Dr. Jansen, hoewel heel het gebeuren van mijn onderzoek niet direct in lijn lag 
met het Maag-, Darm- en Leveronderzoek ben ik blij dat ik me op het Uw afdeling heb mogen 
ontwikkelen en voor alle belangstelling die U de afgelopen jaren getoond heeft.
Prof. Dr. Merkus, Uw betrokkenheid heeft zich alleen de laatste maanden afgespeeld, maar 
tijdens onze korte samenwerking heb ik veel van U rustige en heldere kijk op de wetenschap 
opgestoken.
Natuurlijk mogen mijn medeonderzoekers van de GST-onderzoeken niet ontbreken. De basis 
die door de voorgangers Theo en Maarten zijn gelegd bleken een vruchtbare bodem voor de 
onderzoeken beschreven in dit proefschrift. Erkentelijk ben ik voor het niet aflatende 
enthousiasme, de soms hevige discussies, steun en collegialiteit van mijn mede GST-genoten 
Eva Maria en Petra.
Dankzij de geweldige sfeer die door Hennie, René, Elise, Albert, Annie, Wim, Mariette en de 
vele studenten op het laboratorium, in de koffiekamer of tijden de borrels werden gecreëerd 
kan ik terug kijken op een mooie periode waarvan me vele goede herinneringen bij zullen
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blijven. Niet alleen de sfeer maar ook het feit dat jullie altijd voor alles en nog wat voor me 
klaar stonden is deze periode zeer productief geweest. Zonder jullie was het nooit gelukt.
Geluk heb ik gehad om twee zeer goede studenten onder mijn hoede te mogen hebben. Sophia 
en Geurt het was een hele eer om met jullie samen te werken. Ik prijs jullie toekomstige 
collega' s erg gelukkig met de combinatie van gezelligheid, tomeloze inzet en plezier in jullie 
werk. Succes ga ik jullie niet wensen, want zoals ik altijd zei: "Komt wel goed!”
Ook de buren Lab Interne, met name Magda, die de geweldige HPLC-methode heeft opgezet 
en die altijd een antwoord op mijn HPLC problemen had, maar ook Helga, Heidy, Berry en 
Pierre, stonden altijd klaar om me een helpende hand, suggesties of wat literatuur toe te 
steken. Veel dank ben ik jullie verschuldigd voor al die kleine dingentjes van de afgelopen 
jaren.
Bij zo' n groot project staan altijd een aantal mensen op de achtergrond, zoals Nelleke, Ineke 
en Claudia, die heel wat nuttige hand en span diensten verrichten, maar bovendien zeer 
betrokken en geïnteresseerd waren in het onderzoek.
Iedere donderdag ochtend was het weer raak, het wekelijkse overleg van 9:00. Door de 
bijdragen van vele personen vanuit verschillende disciplines en de vaak zeer informele 
discussies waren deze besprekingen een zeer leerzame aangelegenheid waar zo nu en dan hele 
creatieve samenwerkingen uit zijn voortgevloeid. Daarom zou ik graag in willekeurige 
volgorde Regine, Henk, Chris, Peter, Michael, Iris, Pascal, Tanya Bisseling, Ingrid en de vele 
studenten die hier de revue gepasseerd zijn willen bedanken.
Natuurlijk mag ik de verpleging, de vele artsen en co-assistenten, die iedere keer de GST- 
semafoon hebben gebeld of me hebben bijgestaan bij het bloedprikken, niet vergeten. Daarom 
hartelijk bedankt voor iedereen in de kliniek, die een steentje heeft bijgedragen.
Beste pap en mam, ook al snapten jullie niet altijd waar ik precies mee bezig was genoot ik 
van jullie zichtbare trots als ik weer een artikel gepubliceerd had of een verhaal vertelde over 
een congres. Niet alleen hiervoor, maar ik wil jullie voornamelijk danken voor al jullie steun 
in mijn gehele opleiding, die veel verder terug gaat dan alleen deze promotie, want dankzij 
jullie heb ik mijn eerste jaar Scheikunde overleeft en ben ik geworden wat ik nu ben!!
Lieve Judith, je weet dat ik veel voor je over heb, maar ik kan toch niet nalaten om je als 
laatste te vermelden. Hoewel je zelf vindt dat je bijdrage aan dit boekje zeer gering is ben ik 
erg blij dat je er de laatste maanden geweest bent om keer op keer mijn frustraties aan te 
horen en dat je straks dicht bij me in de buurt zal staan.
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